CN108342363A - It co-expresses anti-MSLN Chimeric antigen receptors and immunologic test point inhibits the transgenosis lymphocyte and application thereof of molecule - Google Patents
It co-expresses anti-MSLN Chimeric antigen receptors and immunologic test point inhibits the transgenosis lymphocyte and application thereof of molecule Download PDFInfo
- Publication number
- CN108342363A CN108342363A CN201710056395.0A CN201710056395A CN108342363A CN 108342363 A CN108342363 A CN 108342363A CN 201710056395 A CN201710056395 A CN 201710056395A CN 108342363 A CN108342363 A CN 108342363A
- Authority
- CN
- China
- Prior art keywords
- lymphocyte
- cell
- seq
- chimeric antigen
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004698 lymphocyte Anatomy 0.000 title claims abstract description 196
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title claims abstract description 121
- 230000001900 immune effect Effects 0.000 title claims description 77
- 238000012360 testing method Methods 0.000 title claims description 72
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 150
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 97
- 230000014509 gene expression Effects 0.000 claims abstract description 75
- 230000003834 intracellular effect Effects 0.000 claims abstract description 71
- 101000576802 Homo sapiens Mesothelin Proteins 0.000 claims abstract description 59
- 102100025096 Mesothelin Human genes 0.000 claims abstract description 59
- 239000000427 antigen Substances 0.000 claims abstract description 38
- 108091007433 antigens Proteins 0.000 claims abstract description 38
- 102000036639 antigens Human genes 0.000 claims abstract description 38
- 230000007969 cellular immunity Effects 0.000 claims abstract description 32
- 230000002147 killing effect Effects 0.000 claims abstract description 31
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 17
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims abstract description 15
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims abstract description 15
- 201000011510 cancer Diseases 0.000 claims abstract description 13
- 210000000170 cell membrane Anatomy 0.000 claims abstract description 4
- 210000004027 cell Anatomy 0.000 claims description 125
- 241000700605 Viruses Species 0.000 claims description 68
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 63
- 150000007523 nucleic acids Chemical class 0.000 claims description 63
- 102000039446 nucleic acids Human genes 0.000 claims description 62
- 108020004707 nucleic acids Proteins 0.000 claims description 62
- 239000004055 small Interfering RNA Substances 0.000 claims description 58
- 230000000694 effects Effects 0.000 claims description 42
- 239000002773 nucleotide Substances 0.000 claims description 40
- 125000003729 nucleotide group Chemical group 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 34
- 230000035755 proliferation Effects 0.000 claims description 33
- 238000000338 in vitro Methods 0.000 claims description 19
- 101150045565 Socs1 gene Proteins 0.000 claims description 17
- 108700027336 Suppressor of Cytokine Signaling 1 Proteins 0.000 claims description 17
- 102100024779 Suppressor of cytokine signaling 1 Human genes 0.000 claims description 17
- 239000013603 viral vector Substances 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 108091092562 ribozyme Proteins 0.000 claims description 12
- 102000053642 Catalytic RNA Human genes 0.000 claims description 10
- 108090000994 Catalytic RNA Proteins 0.000 claims description 10
- 210000002751 lymph Anatomy 0.000 claims description 10
- 206010006187 Breast cancer Diseases 0.000 claims description 8
- 208000026310 Breast neoplasm Diseases 0.000 claims description 8
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims description 8
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 8
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims description 8
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 8
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 8
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 8
- 206010017758 gastric cancer Diseases 0.000 claims description 8
- 201000002313 intestinal cancer Diseases 0.000 claims description 8
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 8
- 230000035772 mutation Effects 0.000 claims description 8
- 201000011549 stomach cancer Diseases 0.000 claims description 8
- 108091033409 CRISPR Proteins 0.000 claims description 7
- 230000000692 anti-sense effect Effects 0.000 claims description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- 230000002062 proliferating effect Effects 0.000 claims description 6
- 102100027207 CD27 antigen Human genes 0.000 claims description 3
- 108010029697 CD40 Ligand Proteins 0.000 claims description 3
- 102100032937 CD40 ligand Human genes 0.000 claims description 3
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 3
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 3
- -1 OX-40 Proteins 0.000 claims description 3
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 3
- 230000001717 pathogenic effect Effects 0.000 claims description 3
- 230000009870 specific binding Effects 0.000 claims description 3
- 241001430294 unidentified retrovirus Species 0.000 claims description 3
- 241000702421 Dependoparvovirus Species 0.000 claims description 2
- 238000002386 leaching Methods 0.000 claims description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 2
- 102100026882 Alpha-synuclein Human genes 0.000 claims 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 1
- 238000010354 CRISPR gene editing Methods 0.000 claims 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 1
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 claims 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims 1
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 1
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 claims 1
- 102100023530 Interleukin-1 receptor-associated kinase 3 Human genes 0.000 claims 1
- 101710199012 Interleukin-1 receptor-associated kinase 3 Proteins 0.000 claims 1
- 102000017578 LAG3 Human genes 0.000 claims 1
- 101150030213 Lag3 gene Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 abstract description 52
- 230000001665 lethal effect Effects 0.000 abstract description 29
- 230000001965 increasing effect Effects 0.000 abstract description 14
- 230000001506 immunosuppresive effect Effects 0.000 abstract description 10
- 238000011282 treatment Methods 0.000 abstract description 6
- 108020004459 Small interfering RNA Proteins 0.000 description 156
- 108020004414 DNA Proteins 0.000 description 155
- 241000282414 Homo sapiens Species 0.000 description 83
- 108090000623 proteins and genes Proteins 0.000 description 72
- 230000004083 survival effect Effects 0.000 description 32
- 102000004169 proteins and genes Human genes 0.000 description 31
- 230000008685 targeting Effects 0.000 description 26
- 102000006940 Interleukin-1 Receptor-Associated Kinases Human genes 0.000 description 23
- 108010072621 Interleukin-1 Receptor-Associated Kinases Proteins 0.000 description 23
- 230000001939 inductive effect Effects 0.000 description 22
- 108020003175 receptors Proteins 0.000 description 22
- 102000005962 receptors Human genes 0.000 description 22
- 230000036039 immunity Effects 0.000 description 21
- 231100000614 poison Toxicity 0.000 description 21
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 20
- 102000057041 human TNF Human genes 0.000 description 20
- 239000002574 poison Substances 0.000 description 20
- 102000004127 Cytokines Human genes 0.000 description 19
- 108090000695 Cytokines Proteins 0.000 description 19
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 19
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 19
- 108020004999 messenger RNA Proteins 0.000 description 19
- 108060003951 Immunoglobulin Proteins 0.000 description 17
- 108010063738 Interleukins Proteins 0.000 description 17
- 102000015696 Interleukins Human genes 0.000 description 17
- 102000001621 Mucoproteins Human genes 0.000 description 17
- 108010093825 Mucoproteins Proteins 0.000 description 17
- 108091000080 Phosphotransferase Proteins 0.000 description 17
- 210000005260 human cell Anatomy 0.000 description 17
- 102000018358 immunoglobulin Human genes 0.000 description 17
- 102000020233 phosphotransferase Human genes 0.000 description 17
- 238000010361 transduction Methods 0.000 description 17
- 230000026683 transduction Effects 0.000 description 17
- 230000002401 inhibitory effect Effects 0.000 description 16
- 108091028043 Nucleic acid sequence Proteins 0.000 description 15
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 13
- 230000003213 activating effect Effects 0.000 description 13
- 239000013612 plasmid Substances 0.000 description 13
- 230000019491 signal transduction Effects 0.000 description 12
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 11
- 102100021984 C-C motif chemokine 4-like Human genes 0.000 description 11
- 101000777471 Homo sapiens C-C motif chemokine 4 Proteins 0.000 description 11
- 101000737602 Homo sapiens Ceramide synthase 1 Proteins 0.000 description 11
- 230000002708 enhancing effect Effects 0.000 description 10
- 230000028327 secretion Effects 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 102000006306 Antigen Receptors Human genes 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 108010083359 Antigen Receptors Proteins 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 230000003321 amplification Effects 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- 230000003828 downregulation Effects 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 238000004806 packaging method and process Methods 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 108020005544 Antisense RNA Proteins 0.000 description 5
- 108010074708 B7-H1 Antigen Proteins 0.000 description 5
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 5
- 206010037549 Purpura Diseases 0.000 description 5
- 241001672981 Purpura Species 0.000 description 5
- 150000001413 amino acids Chemical group 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 239000003184 complementary RNA Substances 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 201000008383 nephritis Diseases 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000003252 repetitive effect Effects 0.000 description 5
- 125000006850 spacer group Chemical group 0.000 description 5
- 108020004491 Antisense DNA Proteins 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 108091029865 Exogenous DNA Proteins 0.000 description 4
- 206010035603 Pleural mesothelioma Diseases 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 239000003816 antisense DNA Substances 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 229910052804 chromium Inorganic materials 0.000 description 4
- 239000011651 chromium Substances 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 239000012894 fetal calf serum Substances 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 210000004907 gland Anatomy 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 230000000527 lymphocytic effect Effects 0.000 description 4
- 210000000822 natural killer cell Anatomy 0.000 description 4
- 230000001613 neoplastic effect Effects 0.000 description 4
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 3
- 241000713666 Lentivirus Species 0.000 description 3
- 102000003735 Mesothelin Human genes 0.000 description 3
- 108090000015 Mesothelin Proteins 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 108091008874 T cell receptors Proteins 0.000 description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 3
- 108091028113 Trans-activating crRNA Proteins 0.000 description 3
- 101710185494 Zinc finger protein Proteins 0.000 description 3
- 102100023597 Zinc finger protein 816 Human genes 0.000 description 3
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000001461 cytolytic effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000013467 fragmentation Methods 0.000 description 3
- 238000006062 fragmentation reaction Methods 0.000 description 3
- 230000009368 gene silencing by RNA Effects 0.000 description 3
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 3
- 108010001064 glycyl-glycyl-glycyl-glycine Proteins 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 210000004224 pleura Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000010008 shearing Methods 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 230000003827 upregulation Effects 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 2
- JREOBWLIZLXRIS-GUBZILKMSA-N Asn-Glu-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O JREOBWLIZLXRIS-GUBZILKMSA-N 0.000 description 2
- QNFRBNZGVVKBNJ-PEFMBERDSA-N Asp-Ile-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)O)N QNFRBNZGVVKBNJ-PEFMBERDSA-N 0.000 description 2
- 102100035273 E3 ubiquitin-protein ligase CBL-B Human genes 0.000 description 2
- 101710141336 E3 ubiquitin-protein ligase CBL-B Proteins 0.000 description 2
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- AIRZWUMAHCDDHR-KKUMJFAQSA-N Lys-Leu-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O AIRZWUMAHCDDHR-KKUMJFAQSA-N 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 102000003661 Ribonuclease III Human genes 0.000 description 2
- 108010057163 Ribonuclease III Proteins 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 201000003433 benign pleural mesothelioma Diseases 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 2
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 208000006178 malignant mesothelioma Diseases 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 210000005033 mesothelial cell Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 201000002513 peritoneal mesothelioma Diseases 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- DWINFPQUSSHSFS-UVBJJODRSA-N Ala-Arg-Trp Chemical compound N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)O DWINFPQUSSHSFS-UVBJJODRSA-N 0.000 description 1
- YIGLXQRFQVWFEY-NRPADANISA-N Ala-Gln-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O YIGLXQRFQVWFEY-NRPADANISA-N 0.000 description 1
- VGPWRRFOPXVGOH-BYPYZUCNSA-N Ala-Gly-Gly Chemical compound C[C@H](N)C(=O)NCC(=O)NCC(O)=O VGPWRRFOPXVGOH-BYPYZUCNSA-N 0.000 description 1
- OBVSBEYOMDWLRJ-BFHQHQDPSA-N Ala-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N OBVSBEYOMDWLRJ-BFHQHQDPSA-N 0.000 description 1
- OYJCVIGKMXUVKB-GARJFASQSA-N Ala-Leu-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N OYJCVIGKMXUVKB-GARJFASQSA-N 0.000 description 1
- UWIQWPWWZUHBAO-ZLIFDBKOSA-N Ala-Leu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](NC(=O)[C@H](C)N)CC(C)C)C(O)=O)=CNC2=C1 UWIQWPWWZUHBAO-ZLIFDBKOSA-N 0.000 description 1
- ZBLQIYPCUWZSRZ-QEJZJMRPSA-N Ala-Phe-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](C)N)CC1=CC=CC=C1 ZBLQIYPCUWZSRZ-QEJZJMRPSA-N 0.000 description 1
- MAZZQZWCCYJQGZ-GUBZILKMSA-N Ala-Pro-Arg Chemical compound [H]N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O MAZZQZWCCYJQGZ-GUBZILKMSA-N 0.000 description 1
- ADSGHMXEAZJJNF-DCAQKATOSA-N Ala-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N ADSGHMXEAZJJNF-DCAQKATOSA-N 0.000 description 1
- XWFWAXPOLRTDFZ-FXQIFTODSA-N Ala-Pro-Ser Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O XWFWAXPOLRTDFZ-FXQIFTODSA-N 0.000 description 1
- FFZJHQODAYHGPO-KZVJFYERSA-N Ala-Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N FFZJHQODAYHGPO-KZVJFYERSA-N 0.000 description 1
- RTZCUEHYUQZIDE-WHFBIAKZSA-N Ala-Ser-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O RTZCUEHYUQZIDE-WHFBIAKZSA-N 0.000 description 1
- DYXOFPBJBAHWFY-JBDRJPRFSA-N Ala-Ser-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)N DYXOFPBJBAHWFY-JBDRJPRFSA-N 0.000 description 1
- PEEYDECOOVQKRZ-DLOVCJGASA-N Ala-Ser-Phe Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O PEEYDECOOVQKRZ-DLOVCJGASA-N 0.000 description 1
- ARHJJAAWNWOACN-FXQIFTODSA-N Ala-Ser-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O ARHJJAAWNWOACN-FXQIFTODSA-N 0.000 description 1
- CREYEAPXISDKSB-FQPOAREZSA-N Ala-Thr-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O CREYEAPXISDKSB-FQPOAREZSA-N 0.000 description 1
- BHFOJPDOQPWJRN-XDTLVQLUSA-N Ala-Tyr-Gln Chemical compound C[C@H](N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCC(N)=O)C(O)=O BHFOJPDOQPWJRN-XDTLVQLUSA-N 0.000 description 1
- QRIYOHQJRDHFKF-UWJYBYFXSA-N Ala-Tyr-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=C(O)C=C1 QRIYOHQJRDHFKF-UWJYBYFXSA-N 0.000 description 1
- CLOMBHBBUKAUBP-LSJOCFKGSA-N Ala-Val-His Chemical compound C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N CLOMBHBBUKAUBP-LSJOCFKGSA-N 0.000 description 1
- GIVATXIGCXFQQA-FXQIFTODSA-N Arg-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N GIVATXIGCXFQQA-FXQIFTODSA-N 0.000 description 1
- UXJCMQFPDWCHKX-DCAQKATOSA-N Arg-Arg-Glu Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(O)=O)C(O)=O UXJCMQFPDWCHKX-DCAQKATOSA-N 0.000 description 1
- IASNWHAGGYTEKX-IUCAKERBSA-N Arg-Arg-Gly Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(O)=O IASNWHAGGYTEKX-IUCAKERBSA-N 0.000 description 1
- HJVGMOYJDDXLMI-AVGNSLFASA-N Arg-Arg-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CCCNC(N)=N HJVGMOYJDDXLMI-AVGNSLFASA-N 0.000 description 1
- MFAMTAVAFBPXDC-LPEHRKFASA-N Arg-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O MFAMTAVAFBPXDC-LPEHRKFASA-N 0.000 description 1
- PHHRSPBBQUFULD-UWVGGRQHSA-N Arg-Gly-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)N PHHRSPBBQUFULD-UWVGGRQHSA-N 0.000 description 1
- AOHKLEBWKMKITA-IHRRRGAJSA-N Arg-Phe-Ser Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N AOHKLEBWKMKITA-IHRRRGAJSA-N 0.000 description 1
- BSYKSCBTTQKOJG-GUBZILKMSA-N Arg-Pro-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O BSYKSCBTTQKOJG-GUBZILKMSA-N 0.000 description 1
- HGKHPCFTRQDHCU-IUCAKERBSA-N Arg-Pro-Gly Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O HGKHPCFTRQDHCU-IUCAKERBSA-N 0.000 description 1
- KXOPYFNQLVUOAQ-FXQIFTODSA-N Arg-Ser-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O KXOPYFNQLVUOAQ-FXQIFTODSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- XQQVCUIBGYFKDC-OLHMAJIHSA-N Asn-Asp-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XQQVCUIBGYFKDC-OLHMAJIHSA-N 0.000 description 1
- WPOLSNAQGVHROR-GUBZILKMSA-N Asn-Gln-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)N WPOLSNAQGVHROR-GUBZILKMSA-N 0.000 description 1
- WIDVAWAQBRAKTI-YUMQZZPRSA-N Asn-Leu-Gly Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O WIDVAWAQBRAKTI-YUMQZZPRSA-N 0.000 description 1
- ALHMNHZJBYBYHS-DCAQKATOSA-N Asn-Lys-Arg Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O ALHMNHZJBYBYHS-DCAQKATOSA-N 0.000 description 1
- MKJBPDLENBUHQU-CIUDSAMLSA-N Asn-Ser-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O MKJBPDLENBUHQU-CIUDSAMLSA-N 0.000 description 1
- DXHINQUXBZNUCF-MELADBBJSA-N Asn-Tyr-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC(=O)N)N)C(=O)O DXHINQUXBZNUCF-MELADBBJSA-N 0.000 description 1
- PBVLJOIPOGUQQP-CIUDSAMLSA-N Asp-Ala-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O PBVLJOIPOGUQQP-CIUDSAMLSA-N 0.000 description 1
- XPGVTUBABLRGHY-BIIVOSGPSA-N Asp-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)O)N XPGVTUBABLRGHY-BIIVOSGPSA-N 0.000 description 1
- XYBJLTKSGFBLCS-QXEWZRGKSA-N Asp-Arg-Val Chemical compound NC(N)=NCCC[C@@H](C(=O)N[C@@H](C(C)C)C(O)=O)NC(=O)[C@@H](N)CC(O)=O XYBJLTKSGFBLCS-QXEWZRGKSA-N 0.000 description 1
- SVFOIXMRMLROHO-SRVKXCTJSA-N Asp-Asp-Phe Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SVFOIXMRMLROHO-SRVKXCTJSA-N 0.000 description 1
- GYWQGGUCMDCUJE-DLOVCJGASA-N Asp-Phe-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(O)=O GYWQGGUCMDCUJE-DLOVCJGASA-N 0.000 description 1
- QJHOOKBAHRJPPX-QWRGUYRKSA-N Asp-Phe-Gly Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=CC=C1 QJHOOKBAHRJPPX-QWRGUYRKSA-N 0.000 description 1
- 108091032955 Bacterial small RNA Proteins 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 101000909256 Caldicellulosiruptor bescii (strain ATCC BAA-1888 / DSM 6725 / Z-1320) DNA polymerase I Proteins 0.000 description 1
- 206010068051 Chimerism Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- SZQCDCKIGWQAQN-FXQIFTODSA-N Cys-Arg-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O SZQCDCKIGWQAQN-FXQIFTODSA-N 0.000 description 1
- WDQXKVCQXRNOSI-GHCJXIJMSA-N Cys-Asp-Ile Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WDQXKVCQXRNOSI-GHCJXIJMSA-N 0.000 description 1
- BCWIFCLVCRAIQK-ZLUOBGJFSA-N Cys-Ser-Cys Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CS)N)O BCWIFCLVCRAIQK-ZLUOBGJFSA-N 0.000 description 1
- 108010090461 DFG peptide Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 101710177611 DNA polymerase II large subunit Proteins 0.000 description 1
- 101710184669 DNA polymerase II small subunit Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- OYTPNWYZORARHL-XHNCKOQMSA-N Gln-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)N)N OYTPNWYZORARHL-XHNCKOQMSA-N 0.000 description 1
- IKFZXRLDMYWNBU-YUMQZZPRSA-N Gln-Gly-Arg Chemical compound NC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N IKFZXRLDMYWNBU-YUMQZZPRSA-N 0.000 description 1
- CLPQUWHBWXFJOX-BQBZGAKWSA-N Gln-Gly-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O CLPQUWHBWXFJOX-BQBZGAKWSA-N 0.000 description 1
- IOFDDSNZJDIGPB-GVXVVHGQSA-N Gln-Leu-Val Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O IOFDDSNZJDIGPB-GVXVVHGQSA-N 0.000 description 1
- TWIAMTNJOMRDAK-GUBZILKMSA-N Gln-Lys-Asp Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O TWIAMTNJOMRDAK-GUBZILKMSA-N 0.000 description 1
- ILKYYKRAULNYMS-JYJNAYRXSA-N Gln-Lys-Phe Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O ILKYYKRAULNYMS-JYJNAYRXSA-N 0.000 description 1
- XQDGOJPVMSWZSO-SRVKXCTJSA-N Gln-Pro-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(=O)N)N XQDGOJPVMSWZSO-SRVKXCTJSA-N 0.000 description 1
- NVHJGTGTUGEWCG-ZVZYQTTQSA-N Gln-Trp-Val Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](C(C)C)C(O)=O NVHJGTGTUGEWCG-ZVZYQTTQSA-N 0.000 description 1
- UBRQJXFDVZNYJP-AVGNSLFASA-N Gln-Tyr-Ser Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCC(=O)N)N)O UBRQJXFDVZNYJP-AVGNSLFASA-N 0.000 description 1
- FITIQFSXXBKFFM-NRPADANISA-N Gln-Val-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O FITIQFSXXBKFFM-NRPADANISA-N 0.000 description 1
- UTKICHUQEQBDGC-ACZMJKKPSA-N Glu-Ala-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCC(=O)O)N UTKICHUQEQBDGC-ACZMJKKPSA-N 0.000 description 1
- WOMUDRVDJMHTCV-DCAQKATOSA-N Glu-Arg-Arg Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O WOMUDRVDJMHTCV-DCAQKATOSA-N 0.000 description 1
- DSPQRJXOIXHOHK-WDSKDSINSA-N Glu-Asp-Gly Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O DSPQRJXOIXHOHK-WDSKDSINSA-N 0.000 description 1
- BUZMZDDKFCSKOT-CIUDSAMLSA-N Glu-Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O BUZMZDDKFCSKOT-CIUDSAMLSA-N 0.000 description 1
- ITBHUUMCJJQUSC-LAEOZQHASA-N Glu-Ile-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(O)=O ITBHUUMCJJQUSC-LAEOZQHASA-N 0.000 description 1
- VSRCAOIHMGCIJK-SRVKXCTJSA-N Glu-Leu-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O VSRCAOIHMGCIJK-SRVKXCTJSA-N 0.000 description 1
- QMOSCLNJVKSHHU-YUMQZZPRSA-N Glu-Met-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)NCC(O)=O QMOSCLNJVKSHHU-YUMQZZPRSA-N 0.000 description 1
- HHSKZJZWQFPSKN-AVGNSLFASA-N Glu-Tyr-Asp Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O HHSKZJZWQFPSKN-AVGNSLFASA-N 0.000 description 1
- ZYRXTRTUCAVNBQ-GVXVVHGQSA-N Glu-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N ZYRXTRTUCAVNBQ-GVXVVHGQSA-N 0.000 description 1
- UGVQELHRNUDMAA-BYPYZUCNSA-N Gly-Ala-Gly Chemical compound [NH3+]CC(=O)N[C@@H](C)C(=O)NCC([O-])=O UGVQELHRNUDMAA-BYPYZUCNSA-N 0.000 description 1
- KFMBRBPXHVMDFN-UWVGGRQHSA-N Gly-Arg-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCNC(N)=N KFMBRBPXHVMDFN-UWVGGRQHSA-N 0.000 description 1
- IDOGEHIWMJMAHT-BYPYZUCNSA-N Gly-Gly-Cys Chemical compound NCC(=O)NCC(=O)N[C@@H](CS)C(O)=O IDOGEHIWMJMAHT-BYPYZUCNSA-N 0.000 description 1
- UQJNXZSSGQIPIQ-FBCQKBJTSA-N Gly-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)CN UQJNXZSSGQIPIQ-FBCQKBJTSA-N 0.000 description 1
- NNCSJUBVFBDDLC-YUMQZZPRSA-N Gly-Leu-Ser Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O NNCSJUBVFBDDLC-YUMQZZPRSA-N 0.000 description 1
- AFWYPMDMDYCKMD-KBPBESRZSA-N Gly-Leu-Tyr Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 AFWYPMDMDYCKMD-KBPBESRZSA-N 0.000 description 1
- WDEHMRNSGHVNOH-VHSXEESVSA-N Gly-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)CN)C(=O)O WDEHMRNSGHVNOH-VHSXEESVSA-N 0.000 description 1
- NVTPVQLIZCOJFK-FOHZUACHSA-N Gly-Thr-Asp Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O NVTPVQLIZCOJFK-FOHZUACHSA-N 0.000 description 1
- ZZWUYQXMIFTIIY-WEDXCCLWSA-N Gly-Thr-Leu Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O ZZWUYQXMIFTIIY-WEDXCCLWSA-N 0.000 description 1
- DNAZKGFYFRGZIH-QWRGUYRKSA-N Gly-Tyr-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=C(O)C=C1 DNAZKGFYFRGZIH-QWRGUYRKSA-N 0.000 description 1
- AFMOTCMSEBITOE-YEPSODPASA-N Gly-Val-Thr Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O AFMOTCMSEBITOE-YEPSODPASA-N 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- LSQHWKPPOFDHHZ-YUMQZZPRSA-N His-Asp-Gly Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)O)N LSQHWKPPOFDHHZ-YUMQZZPRSA-N 0.000 description 1
- NKRWVZQTPXPNRZ-SRVKXCTJSA-N His-Met-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@@H](N)CC1=CN=CN1 NKRWVZQTPXPNRZ-SRVKXCTJSA-N 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 206010048612 Hydrothorax Diseases 0.000 description 1
- HDOYNXLPTRQLAD-JBDRJPRFSA-N Ile-Ala-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)O)N HDOYNXLPTRQLAD-JBDRJPRFSA-N 0.000 description 1
- UKTUOMWSJPXODT-GUDRVLHUSA-N Ile-Asn-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N1CCC[C@@H]1C(=O)O)N UKTUOMWSJPXODT-GUDRVLHUSA-N 0.000 description 1
- NCSIQAFSIPHVAN-IUKAMOBKSA-N Ile-Asn-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N NCSIQAFSIPHVAN-IUKAMOBKSA-N 0.000 description 1
- NZGTYCMLUGYMCV-XUXIUFHCSA-N Ile-Lys-Arg Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N NZGTYCMLUGYMCV-XUXIUFHCSA-N 0.000 description 1
- JSLIXOUMAOUGBN-JUKXBJQTSA-N Ile-Tyr-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N JSLIXOUMAOUGBN-JUKXBJQTSA-N 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- IBMVEYRWAWIOTN-UHFFFAOYSA-N L-Leucyl-L-Arginyl-L-Proline Natural products CC(C)CC(N)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(O)=O IBMVEYRWAWIOTN-UHFFFAOYSA-N 0.000 description 1
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 1
- LHSGPCFBGJHPCY-UHFFFAOYSA-N L-leucine-L-tyrosine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 LHSGPCFBGJHPCY-UHFFFAOYSA-N 0.000 description 1
- LZDNBBYBDGBADK-UHFFFAOYSA-N L-valyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C(C)C)C(O)=O)=CNC2=C1 LZDNBBYBDGBADK-UHFFFAOYSA-N 0.000 description 1
- HXWALXSAVBLTPK-NUTKFTJISA-N Leu-Ala-Trp Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(C)C)N HXWALXSAVBLTPK-NUTKFTJISA-N 0.000 description 1
- MYGQXVYRZMKRDB-SRVKXCTJSA-N Leu-Asp-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN MYGQXVYRZMKRDB-SRVKXCTJSA-N 0.000 description 1
- CQGSYZCULZMEDE-UHFFFAOYSA-N Leu-Gln-Pro Natural products CC(C)CC(N)C(=O)NC(CCC(N)=O)C(=O)N1CCCC1C(O)=O CQGSYZCULZMEDE-UHFFFAOYSA-N 0.000 description 1
- FEHQLKKBVJHSEC-SZMVWBNQSA-N Leu-Glu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 FEHQLKKBVJHSEC-SZMVWBNQSA-N 0.000 description 1
- OMHLATXVNQSALM-FQUUOJAGSA-N Leu-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(C)C)N OMHLATXVNQSALM-FQUUOJAGSA-N 0.000 description 1
- WMIOEVKKYIMVKI-DCAQKATOSA-N Leu-Pro-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O WMIOEVKKYIMVKI-DCAQKATOSA-N 0.000 description 1
- VHTIZYYHIUHMCA-JYJNAYRXSA-N Leu-Tyr-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O VHTIZYYHIUHMCA-JYJNAYRXSA-N 0.000 description 1
- IXHKPDJKKCUKHS-GARJFASQSA-N Lys-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCCN)N IXHKPDJKKCUKHS-GARJFASQSA-N 0.000 description 1
- KWUKZRFFKPLUPE-HJGDQZAQSA-N Lys-Asp-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KWUKZRFFKPLUPE-HJGDQZAQSA-N 0.000 description 1
- MQMIRLVJXQNTRJ-SDDRHHMPSA-N Lys-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)N)C(=O)O MQMIRLVJXQNTRJ-SDDRHHMPSA-N 0.000 description 1
- SKRGVGLIRUGANF-AVGNSLFASA-N Lys-Leu-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O SKRGVGLIRUGANF-AVGNSLFASA-N 0.000 description 1
- URGPVYGVWLIRGT-DCAQKATOSA-N Lys-Met-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(O)=O URGPVYGVWLIRGT-DCAQKATOSA-N 0.000 description 1
- PDIDTSZKKFEDMB-UWVGGRQHSA-N Lys-Pro-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O PDIDTSZKKFEDMB-UWVGGRQHSA-N 0.000 description 1
- LOGFVTREOLYCPF-RHYQMDGZSA-N Lys-Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-RHYQMDGZSA-N 0.000 description 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- ZAJNRWKGHWGPDQ-SDDRHHMPSA-N Met-Arg-Pro Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(=O)O)N ZAJNRWKGHWGPDQ-SDDRHHMPSA-N 0.000 description 1
- FVKRQMQQFGBXHV-QXEWZRGKSA-N Met-Asp-Val Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O FVKRQMQQFGBXHV-QXEWZRGKSA-N 0.000 description 1
- VOOINLQYUZOREH-SRVKXCTJSA-N Met-Gln-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCSC)N VOOINLQYUZOREH-SRVKXCTJSA-N 0.000 description 1
- BMHIFARYXOJDLD-WPRPVWTQSA-N Met-Gly-Val Chemical compound [H]N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O BMHIFARYXOJDLD-WPRPVWTQSA-N 0.000 description 1
- AXHNAGAYRGCDLG-UWVGGRQHSA-N Met-Lys-Gly Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O AXHNAGAYRGCDLG-UWVGGRQHSA-N 0.000 description 1
- SPSSJSICDYYTQN-HJGDQZAQSA-N Met-Thr-Gln Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(N)=O SPSSJSICDYYTQN-HJGDQZAQSA-N 0.000 description 1
- 206010068052 Mosaicism Diseases 0.000 description 1
- 101100219625 Mus musculus Casd1 gene Proteins 0.000 description 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 1
- 108010079364 N-glycylalanine Proteins 0.000 description 1
- 108010066427 N-valyltryptophan Proteins 0.000 description 1
- 102000010648 Natural Killer Cell Receptors Human genes 0.000 description 1
- 108010077854 Natural Killer Cell Receptors Proteins 0.000 description 1
- 206010029719 Nonspecific reaction Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091081548 Palindromic sequence Proteins 0.000 description 1
- QARPMYDMYVLFMW-KKUMJFAQSA-N Phe-Pro-Glu Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C1=CC=CC=C1 QARPMYDMYVLFMW-KKUMJFAQSA-N 0.000 description 1
- KLYYKKGCPOGDPE-OEAJRASXSA-N Phe-Thr-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O KLYYKKGCPOGDPE-OEAJRASXSA-N 0.000 description 1
- 102100037935 Polyubiquitin-C Human genes 0.000 description 1
- UPJGUQPLYWTISV-GUBZILKMSA-N Pro-Gln-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O UPJGUQPLYWTISV-GUBZILKMSA-N 0.000 description 1
- AIOWVDNPESPXRB-YTWAJWBKSA-N Pro-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@@H]2CCCN2)O AIOWVDNPESPXRB-YTWAJWBKSA-N 0.000 description 1
- VDHGTOHMHHQSKG-JYJNAYRXSA-N Pro-Val-Phe Chemical compound CC(C)[C@H](NC(=O)[C@@H]1CCCN1)C(=O)N[C@@H](Cc1ccccc1)C(O)=O VDHGTOHMHHQSKG-JYJNAYRXSA-N 0.000 description 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 1
- 101000902592 Pyrococcus furiosus (strain ATCC 43587 / DSM 3638 / JCM 8422 / Vc1) DNA polymerase Proteins 0.000 description 1
- 108020005093 RNA Precursors Proteins 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 241001068295 Replication defective viruses Species 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- LVVBAKCGXXUHFO-ZLUOBGJFSA-N Ser-Ala-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(O)=O LVVBAKCGXXUHFO-ZLUOBGJFSA-N 0.000 description 1
- YRBGKVIWMNEVCZ-WDSKDSINSA-N Ser-Glu-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O YRBGKVIWMNEVCZ-WDSKDSINSA-N 0.000 description 1
- UQFYNFTYDHUIMI-WHFBIAKZSA-N Ser-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](N)CO UQFYNFTYDHUIMI-WHFBIAKZSA-N 0.000 description 1
- YMTLKLXDFCSCNX-BYPYZUCNSA-N Ser-Gly-Gly Chemical compound OC[C@H](N)C(=O)NCC(=O)NCC(O)=O YMTLKLXDFCSCNX-BYPYZUCNSA-N 0.000 description 1
- UIGMAMGZOJVTDN-WHFBIAKZSA-N Ser-Gly-Ser Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O UIGMAMGZOJVTDN-WHFBIAKZSA-N 0.000 description 1
- QYSFWUIXDFJUDW-DCAQKATOSA-N Ser-Leu-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QYSFWUIXDFJUDW-DCAQKATOSA-N 0.000 description 1
- GJFYFGOEWLDQGW-GUBZILKMSA-N Ser-Leu-Gln Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CO)N GJFYFGOEWLDQGW-GUBZILKMSA-N 0.000 description 1
- AZWNCEBQZXELEZ-FXQIFTODSA-N Ser-Pro-Ser Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O AZWNCEBQZXELEZ-FXQIFTODSA-N 0.000 description 1
- BMKNXTJLHFIAAH-CIUDSAMLSA-N Ser-Ser-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O BMKNXTJLHFIAAH-CIUDSAMLSA-N 0.000 description 1
- SQHKXWODKJDZRC-LKXGYXEUSA-N Ser-Thr-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O SQHKXWODKJDZRC-LKXGYXEUSA-N 0.000 description 1
- PIQRHJQWEPWFJG-UWJYBYFXSA-N Ser-Tyr-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(O)=O PIQRHJQWEPWFJG-UWJYBYFXSA-N 0.000 description 1
- 241000713311 Simian immunodeficiency virus Species 0.000 description 1
- 101150014221 Son gene Proteins 0.000 description 1
- 108091027544 Subgenomic mRNA Proteins 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- CAJFZCICSVBOJK-SHGPDSBTSA-N Thr-Ala-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CAJFZCICSVBOJK-SHGPDSBTSA-N 0.000 description 1
- XSLXHSYIVPGEER-KZVJFYERSA-N Thr-Ala-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O XSLXHSYIVPGEER-KZVJFYERSA-N 0.000 description 1
- TWLMXDWFVNEFFK-FJXKBIBVSA-N Thr-Arg-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O TWLMXDWFVNEFFK-FJXKBIBVSA-N 0.000 description 1
- VUVCRYXYUUPGSB-GLLZPBPUSA-N Thr-Gln-Glu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N)O VUVCRYXYUUPGSB-GLLZPBPUSA-N 0.000 description 1
- FQPDRTDDEZXCEC-SVSWQMSJSA-N Thr-Ile-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O FQPDRTDDEZXCEC-SVSWQMSJSA-N 0.000 description 1
- GXUWHVZYDAHFSV-FLBSBUHZSA-N Thr-Ile-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GXUWHVZYDAHFSV-FLBSBUHZSA-N 0.000 description 1
- YOOAQCZYZHGUAZ-KATARQTJSA-N Thr-Leu-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YOOAQCZYZHGUAZ-KATARQTJSA-N 0.000 description 1
- BIBYEFRASCNLAA-CDMKHQONSA-N Thr-Phe-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=CC=C1 BIBYEFRASCNLAA-CDMKHQONSA-N 0.000 description 1
- ZESGVALRVJIVLZ-VFCFLDTKSA-N Thr-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@@H]1C(=O)O)N)O ZESGVALRVJIVLZ-VFCFLDTKSA-N 0.000 description 1
- BPGDJSUFQKWUBK-KJEVXHAQSA-N Thr-Val-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 BPGDJSUFQKWUBK-KJEVXHAQSA-N 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 102000006612 Transducin Human genes 0.000 description 1
- 108010087042 Transducin Proteins 0.000 description 1
- WLBZWXXGSOLJBA-HOCLYGCPSA-N Trp-Gly-Lys Chemical compound C1=CC=C2C(C[C@H](N)C(=O)NCC(=O)N[C@@H](CCCCN)C(O)=O)=CNC2=C1 WLBZWXXGSOLJBA-HOCLYGCPSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- QOIKZODVIPOPDD-AVGNSLFASA-N Tyr-Cys-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(O)=O QOIKZODVIPOPDD-AVGNSLFASA-N 0.000 description 1
- QUILOGWWLXMSAT-IHRRRGAJSA-N Tyr-Gln-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O QUILOGWWLXMSAT-IHRRRGAJSA-N 0.000 description 1
- AZZLDIDWPZLCCW-ZEWNOJEFSA-N Tyr-Ile-Phe Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O AZZLDIDWPZLCCW-ZEWNOJEFSA-N 0.000 description 1
- LQGDFDYGDQEMGA-PXDAIIFMSA-N Tyr-Ile-Trp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)N LQGDFDYGDQEMGA-PXDAIIFMSA-N 0.000 description 1
- JAGGEZACYAAMIL-CQDKDKBSSA-N Tyr-Lys-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC1=CC=C(C=C1)O)N JAGGEZACYAAMIL-CQDKDKBSSA-N 0.000 description 1
- ANHVRCNNGJMJNG-BZSNNMDCSA-N Tyr-Tyr-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CS)C(=O)O)N)O ANHVRCNNGJMJNG-BZSNNMDCSA-N 0.000 description 1
- BUPRFDPUIJNOLS-UFYCRDLUSA-N Tyr-Tyr-Met Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCSC)C(O)=O BUPRFDPUIJNOLS-UFYCRDLUSA-N 0.000 description 1
- 108010056354 Ubiquitin C Proteins 0.000 description 1
- NYTKXWLZSNRILS-IFFSRLJSSA-N Val-Gln-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)N)O NYTKXWLZSNRILS-IFFSRLJSSA-N 0.000 description 1
- HPANGHISDXDUQY-ULQDDVLXSA-N Val-Lys-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N HPANGHISDXDUQY-ULQDDVLXSA-N 0.000 description 1
- LCHZBEUVGAVMKS-RHYQMDGZSA-N Val-Thr-Leu Chemical compound CC(C)C[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(O)=O LCHZBEUVGAVMKS-RHYQMDGZSA-N 0.000 description 1
- HTONZBWRYUKUKC-RCWTZXSCSA-N Val-Thr-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O HTONZBWRYUKUKC-RCWTZXSCSA-N 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 108010076324 alanyl-glycyl-glycine Proteins 0.000 description 1
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 1
- 108010041407 alanylaspartic acid Proteins 0.000 description 1
- 108010005233 alanylglutamic acid Proteins 0.000 description 1
- 108010044940 alanylglutamine Proteins 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 230000003092 anti-cytokine Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 108010060035 arginylproline Proteins 0.000 description 1
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000011942 biocatalyst Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 101150055766 cat gene Proteins 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000004715 cellular signal transduction Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 108700004025 env Genes Proteins 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- 108700004026 gag Genes Proteins 0.000 description 1
- 108010006664 gamma-glutamyl-glycyl-glycine Proteins 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 108010078144 glutaminyl-glycine Proteins 0.000 description 1
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 1
- 108010050475 glycyl-leucyl-tyrosine Proteins 0.000 description 1
- 108010050848 glycylleucine Proteins 0.000 description 1
- 108010015792 glycyllysine Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 108010044374 isoleucyl-tyrosine Proteins 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 108010073472 leucyl-prolyl-proline Proteins 0.000 description 1
- 108010012058 leucyltyrosine Proteins 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000001589 lymphoproliferative effect Effects 0.000 description 1
- 201000005282 malignant pleural mesothelioma Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 101710135378 pH 6 antigen Proteins 0.000 description 1
- 238000009116 palliative therapy Methods 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 210000003245 peritoneal mesothelial cell Anatomy 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 108010070409 phenylalanyl-glycyl-glycine Proteins 0.000 description 1
- 108010051242 phenylalanylserine Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 108700004029 pol Genes Proteins 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 108010004914 prolylarginine Proteins 0.000 description 1
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 108091035233 repetitive DNA sequence Proteins 0.000 description 1
- 102000053632 repetitive DNA sequence Human genes 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 108010056030 retronectin Proteins 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000009938 salting Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000003335 steric effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 108010038745 tryptophylglycine Proteins 0.000 description 1
- 108010044292 tryptophyltyrosine Proteins 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 108010003137 tyrosyltyrosine Proteins 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 108010009962 valyltyrosine Proteins 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 108010000998 wheylin-2 peptide Proteins 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464466—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
- A61K39/464468—Mesothelin [MSLN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/867—Retroviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention proposes a kind of transgenosis lymphocyte, a kind of construct and a kind of therapeutic combination for the treatment of cancer, the cellular immunity checkpoint of the transgenosis lymphocyte and is silenced and expresses Chimeric antigen receptor.Wherein, the Chimeric antigen receptor includes:Extracellular region, the extracellular region include the heavy chain variable region and light chain variable region of single-chain antibody, the single-chain antibody specific recognition antigen MSLN;Transmembrane region, the transmembrane region are connected with the extracellular region, and are embedded into the cell membrane of the T lymphocytes;Intracellular region, the intracellular region are connected with the transmembrane region, and the intracellular region includes the intracellular section and CD3 ζ chains of CD28.The transgenosis lymphocyte, which has, resists the immunosuppressive characteristic that tumour cell mediates, and is significantly increased to the killing ability of tumour cell, and the tumour of especially high expression MSLN has significant orientation lethal effect.
Description
Technical field
The present invention relates to biomedicine fields, in particular it relates to a kind of T lymphocytes, a kind of slow virus, one kind
Transgenosis lymphocyte, a kind of construct, a kind of therapeutic combination for treating cancer and a kind of raising lymphocyte activity
Method.
Background technology
Between quality (mesothelin, MSLN) be a kind of differentiation antigen, it is only limitted in the expression of human normal tissues
The mesothelial cell of pleura, pericardium and peritonaeum lining.However, the quality but high expression in a variety of human cancer tissues, including
Almost all of celiothelioma and cancer of pancreas and about 70% oophoroma and about 50% adenocarcinoma of lung and other cancers, such as bile duct
Cancer, gastric cancer, intestinal cancer, the cancer of the esophagus, breast cancer.Interstitial plain gene encodes the precursor protein of 71KDa, and precursor protein is then processed to
Fall off segment and the protein fragments of 40KDa of 31KDa, the segment that falls off of 31KDa are referred to as megakaryocyte-potentiating factor (MPF),
And the protein fragments of 40KDa are referred to as a quality, quality passes through glycosyl-phosphatidyl inositol (glycosyl-
Phosphatidylinositol, GPI) anchoring effect be fixed on cell membrane.
By taking celiothelioma as an example, it is that pleura is primary that celiothelioma, which is divided into mesothelioma of pleura and peritoneal mesothelioma, mesothelioma of pleura,
Tumour is divided into topical type (mostly benign) and diffuses type (being all pernicious), wherein it is chest prognosis to diffuse type malignant mesothelioma
One of the worst tumour.Peritoneal mesothelioma refers to the tumour for being primary in Peritoneal Mesothelial Cells.Clinical manifestation does not have characteristic, often
The sings and symptoms seen have:Abdominal pain, ascites, abdominal distension and abdominal mass etc..The treatment of malignant pleural mesothelioma, does not still have at present
Effective radical cure method.In therapy, there are palliative therapy, surgical intervention, chemotherapy and radiotherapy etc., it is considered that
For the I phase patients of the opposite limitation of tumour, opinion does the pleuropulmonary resection effected a radical cure.For II, III, IV phase patient, radical-ability
Operation is nonsensical, only implements palliative operation.In fact, when most patients clarify a diagnosis to disease, it has been in
II is more than the phase.The hydrothorax increased rapidly often results in the serious expiratory dyspnea of patient, and palliative operation can only temporarily improve these evenings
The quality of life of phase patient, and can not effect a radical cure.
It can be seen that exploitation be directed between quality height expression tumour therapy it is particularly urgent.
Invention content
The application is made to the discovery of following facts and problem and understanding based on inventor:
Between the quality but high expression in a variety of human cancer tissues, including almost all of celiothelioma and cancer of pancreas peace treaty
70% oophoroma and about 50% adenocarcinoma of lung and other cancers, such as cholangiocarcinoma, gastric cancer, intestinal cancer, the cancer of the esophagus, breast cancer.
Therefore, quality represents a target spot for having huge attraction in immunotherapy of tumors field.
Based on above-mentioned discovery, inventors herein proposes a kind of nucleic acid molecules carrying silenced cell immunologic test point and encode embedding
The transgenosis lymphocyte formed after the construct of the nucleic acid molecules of conjunction antigen receptor and a kind of importing with this construct, coding
Chimeric antigen receptor molecule of the antigen binding MSLN.Therefore, construct and transgenosis lymphocyte proposed by the present invention is available
In tumour, especially between quality positive tumor adoptive T cell immunization therapy;Transgenosis lymphocyte pair proposed by the invention
The specific killing ability of quality tumour is strong between height expression, has weaker killing to the mesothelial cell of normal MSLN expressions.
In the first aspect of the present invention, the present invention proposes a kind of T lymphocytes.According to an embodiment of the invention, the T
The cellular immunity checkpoint of lymphocyte is silenced;And expression Chimeric antigen receptor, wherein the Chimeric antigen receptor packet
It includes:Extracellular region, the extracellular region include the heavy chain variable region and light chain variable region of single-chain antibody, and the single-chain antibody specificity is known
Other antigen MSLN;Transmembrane region, the transmembrane region are connected with the extracellular region, and are embedded into the cell membrane of the T lymphocytes
In;Intracellular region, the intracellular region are connected with the transmembrane region, and the intracellular region includes the intracellular section and CD3 ζ of CD28
Chain.Wherein, cellular immunity checkpoint includes cell surface or at least one intracellular immunologic test point.Reality according to the present invention
Example is applied, the T lymphocytes of the embodiment of the present invention, which have, resists the immunosuppressive characteristic that tumour cell mediates, proliferation in vitro
Ability, the proliferation in tumour patient body and survival ability significantly improve, and are significantly increased to the killing ability of tumour cell, especially
There is significant orientation lethal effect to the tumour cell of high expression MSLN.
In the second aspect of the present invention, the present invention proposes a kind of slow virus.According to an embodiment of the invention, the slow disease
Poison carries following nucleic acid molecules:The nucleic acid molecules of encoding chimeric antigen receptor, the Chimeric antigen receptor have SEQ ID NO:1
Shown in amino acid sequence, the nucleic acid molecules of the encoding chimeric antigen receptor have SEQ ID NO:Nucleotides sequence shown in 2
Row;And the nucleic acid molecules of silenced cell immunologic test point, the nucleotide of the nucleic acid molecules of the silenced cell immunologic test point
Sequence is selected from SEQ ID NO:At least one of 3~135.
MVLLVTSLLLCELPHPAFLLIPDIQAQVQLVQSGAEVKRPGASVQVSCRASGYSINTYYMQWVRQAPGAGLEWMGVI
NPSGVTSYAQKFQGRVTLTNDTSTNTVYMQLNSLTSADTAVYYCARWALWGDFGMDVWGKGTLVTVSSGGGGSGGGG
SGGGGSDIQMTQSPSTLSASIGDRVTITCRASEGIYHWLAWYQQKPGKAPKLLIYKASSLASGAPSRFSGSGSGTDF
TLTISSLQPDDFATYYCQQYSNYPLTFGGGTKLEIKRASFVPVFLPAKPTTTPAPRPPTPAPTIASQPLSLRPEACR
PAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCNHRNKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRF
PEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKM
AEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR(SEQ ID NO:1).
ATGGTTCTGCTGGTGACATCTCTCCTGCTCTGTGAACTGCCTCATCCCGCTTTTCTGCTCATTCCCGACATTCAGGC
TCAAGTCCAACTGGTCCAAAGTGGTGCTGAAGTCAAACGCCCGGGTGCCTCCGTCCAAGTCTCCTGCCGTGCCTCTG
GCTACTCGATTAACACCTATTACATGCAGTGGGTCCGTCAAGCACCGGGTGCAGGTCTGGAATGGATGGGTGTCATC
AATCCGTCCGGCGTGACCTCATATGCGCAGAAATTTCAAGGTCGCGTTACCCTGACGAACGATACCAGCACGAATAC
CGTCTACATGCAGCTGAACTCTCTGACGAGTGCAGACACCGCGGTGTATTACTGCGCACGTTGGGCACTGTGGGGCG
ATTTCGGCATGGATGTTTGGGGCAAAGGTACGCTGGTGACCGTTAGCTCTGGTGGTGGTGGTTCTGGTGGTGGTGGT
AGTGGCGGTGGCGGTTCTGATATTCAGATGACGCAAAGCCCGTCTACCCTGAGTGCCTCCATTGGTGACCGTGTTAC
GATCACCTGTCGCGCATCCGAAGGCATCTATCATTGGCTGGCTTGGTACCAGCAAAAACCGGGTAAAGCGCCGAAAC
TGCTGATCTATAAAGCAAGTTCCCTGGCATCGGGTGCTCCGAGCCGCTTTTCAGGTTCGGGTAGCGGCACCGATTTC
ACGCTGACCATCTCATCGCTGCAGCCGGACGATTTCGCTACCTACTACTGCCAACAATACTCAAACTACCCGCTGAC
CTTCGGTGGAGGGACCAAGCTGGAGATCAAACGTGCTAGCTTCGTGCCGGTCTTCCTGCCAGCGAAGCCCACCACGA
CGCCAGCGCCGCGACCACCAACACCGGCGCCCACCATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGG
CCAGCGGCGGGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGATATCTACATCTGGGCGCCCTTGGCCGG
GACTTGTGGGGTCCTTCTCCTGTCACTGGTTATCACCCTTTACTGCAACCACAGGAACAAACGGGGCAGAAAGAAAC
TCCTGTATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGATGGCTGTAGCTGCCGATTT
CCAGAAGAAGAAGAAGGAGGATGTGAACTGAGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACCAGCAGGG
CCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGTTTTGGACAAGAGACGTGGCCGGG
ACCCTGAGATGGGGGGAAAGCCGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAATGAACTGCAGAAAGATAAGATG
GCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGATGGCCTTTACCAGGGTCT
CAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAGGCCCTGCCCCCTCGCTAA(SEQ ID NO:2).
GGCCAGGATGGTTCTTAGACT(SEQ ID NO:3).
GGATTTCCAGTGGCGAGAGAA(SEQ ID NO:4).
GCCUGUGUUCUCUGUGGACUAUG(SEQ ID NO:5).
GGUGCUGCUAGUCUGGGUCCUGG(SEQ ID NO:6).
GACAGAGAGAAGGGCAGAAGUGC(SEQ ID NO:7).
CAGCUUCUCCAACACAUCGGAGA(SEQ ID NO:8).
CCGUGUCACACAACUGCCCAACG(SEQ ID NO:9).
UAUGCCACCAUUGUCUUUCCUAG(SEQ ID NO:10).
UGCUAAACUGGUACCGCAUGAGC(SEQ ID NO:11).
GUGACAGAGAGAAGGGCAGAAGU(SEQ ID NO:12).
CUGAGGAUGGACACUGCUCUUGG(SEQ ID NO:13).
AUCGGAGAGCUUCGUGCUAAACU(SEQ ID NO:14).
GGCAACGGAACCCAGATTTAT(SEQ ID NO:15).
GGAACCCAAATTACGTGTACT(SEQ ID NO:16).
GAACCCAAATTACGTGTACTA(SEQ ID NO:17).
GGGAGAAGACTATATTGTACA(SEQ ID NO:18).
GACGTTTATAGCCGAAATGAT(SEQ ID NO:19).
GACACTAATACACCAGGTAGA(SEQ ID NO:20).
ACCUCACUAUCCAAGGACUGAGG(SEQ ID NO:21).
AUGAGUUGACCUUCCUAGAUGAU(SEQ ID NO:22).
GGGGAAUGAGUUGACCUUCCUAG(SEQ ID NO:23).
CUCUGGAUCCUUGCAGCAGUUAG(SEQ ID NO:24).
CUCCUCUGGAUCCUUGCAGCAGU(SEQ ID NO:25).
UUUGUGUGUGAGUAUGCAUCUCC(SEQ ID NO:26).
CACCUCCAGUGGAAAUCAAGUGA(SEQ ID NO:27).
CACGGGACUCUACAUCUGCAAGG(SEQ ID NO:28).
UUCUGACUUCCUCCUCUGGAUCC(SEQ ID NO:29).
AAGUCUGUGCGGCAACCUACAUG(SEQ ID NO:30).
GGTCGGTCAGAATGCCTATCT(SEQ ID NO:31).
GCCAATGACTTACGGGACTCT(SEQ ID NO:32).
GCAGAGGGAATTCGCTCAGAA(SEQ ID NO:33).
GGAAATTCGGGCACATCATAT(SEQ ID NO:34).
GATTAAGAGATGACTGGACTA(SEQ ID NO:35).
GAGATGACTGGACTAGGTCTA(SEQ ID NO:36).
AGGAAAUUCGGGCACAUCAUAUG(SEQ ID NO:37).
GACUGAUGAAAGGGAUGUGAAUU(SEQ ID NO:38).
GCCACUGAUUUUCAAAGAGAUCU(SEQ ID NO:39).
AGCAGAGUUUUCCCAUUUUCAGA(SEQ ID NO:40).
AACUUAAACAGGCAUGUCAUUGC(SEQ ID NO:41).
UUCAGAAGAUAAUGACUCACAUG(SEQ ID NO:42).
GCCUCUGUAUUUAAGCCAACAGA(SEQ ID NO:43).
UGCUCAUGUGAUUGUGGAGUAGA(SEQ ID NO:44).
AUGUUUUCACAUCUUCCCUUUGA(SEQ ID NO:45).
GAGAGACUUCACUGCAGCCUUUC(SEQ ID NO:46).
GATTGCCTCTACTCATCACTA(SEQ ID NO:47).
UCCUAAUGACAAUGGGUCAUACC(SEQ ID NO:48).
AAGACAUUGCCUGCCAUGCUUGG(SEQ ID NO:49).
GUCAUACCGCUGUUCUGCAAAUU(SEQ ID NO:50).
CUCCUGUAUAGUUUACUUCCUUU(SEQ ID NO:51).
UACCGCUGUUCUGCAAAUUUUCA(SEQ ID NO:52).
AAAACAAACCAGGCAUUGUUUAU(SEQ ID NO:53).
AACUAGAAUGCCCUGUGAAAUAC(SEQ ID NO:54).
GUGACUUGGUGCAAGCUCAAUGG(SEQ ID NO:55).
AUCCAUGGGAAAGAAUCAUGUGA(SEQ ID NO:56).
UGGUGCAAGCUCAAUGGAACAAC(SEQ ID NO:57).
GCTGCTCACCCTTATGAACCT(SEQ ID NO:58).
AGGACAUGGUGGUGGACGAGUGC(SEQ ID NO:59).
UGCUCUUCCUGCACGAUAUCAGU(SEQ ID NO:60).
ACCUCUACUGGUUCCUGUACAUC(SEQ ID NO:61).
CCCUCCAACUCUGCUCCUCUAGG(SEQ ID NO:62).
CCCUGAGUGGACAGUCGUCUUCG(SEQ ID NO:63).
CUGCUCCAGGGAAGCUUCUAUGG(SEQ ID NO:64).
CGCUCAAGGUCCUGUAUGCCACC(SEQ ID NO:65).
GAGUUCACCAAGCUCAACAUUUA(SEQ ID NO:66).
UGCUGCUGCUCACCCUUAUGAAC(SEQ ID NO:67).
CCCAUCUCCGUGCUCUUCUUUGA(SEQ ID NO:68).
GGGACATCGTCGAGCTATTCA(SEQ ID NO:69).
GGACATCGTCGAGCTATTCAT(SEQ ID NO:70).
GCCAATGTCACCGTGGATAAT(SEQ ID NO:71).
GTCATCTGTGGCAGTATATCA(SEQ ID NO:72).
GGATGTAGAGTAGTGTTAGAT(SEQ ID NO:73).
GGCAAAGTTAAGACCATCAAT(SEQ ID NO:74).
GACCAAATCCACGCTCAATTA(SEQ ID NO:75).
UACUGCUUAAAUCUUCCAUCAGC(SEQ ID NO:76).
GACUGAGAAGUUCUGUCUGAUUU(SEQ ID NO:77).
CUGUUUCAUCACCCAAACAUACU(SEQ ID NO:78).
GAAGAUCCUCCCACAUCACUAAA(SEQ ID NO:79).
UAGACCAAGGUAAAAGUGGAACA(SEQ ID NO:80).
AAGAGGUUUUUAUCUGAGCUUGA(SEQ ID NO:81).
UACCUGCACAACGUUCAACCAUG(SEQ ID NO:82).
GCCUGGAUUCAUGUCUCUCAUUU(SEQ ID NO:83).
CCCUCGGAAUUUCUCUGCCAAGC(SEQ ID NO:84).
UGCUGAAGAUCCUCCCACAUCAC(SEQ ID NO:85).
GCACCTCCTACCTCTTCATGT(SEQ ID NO:86).
CGCACUUCCGCACAUUCCGUUCG(SEQ ID NO:87).
GGGGAGGGUCUCUGGCUUUAUUU(SEQ ID NO:88).
CAGCAUUAACUGGGAUGCCGUGU(SEQ ID NO:89).
CCAGGACCUGAACUCGCACCUCC(SEQ ID NO:90).
UACAUAUACCCAGUAUCUUUGCA(SEQ ID NO:91).
GCCGACAAUGCAGUCUCCACAGC(SEQ ID NO:92).
CCCCUGGUUGUUGUAGCAGCUUA(SEQ ID NO:93).
CUGCUGUGCAGAAUCCUAUUUUA(SEQ ID NO:94).
UGGGAUGCCGUGUUAUUUUGUUA(SEQ ID NO:95).
UCGCACCUCCUACCUCUUCAUGU(SEQ ID NO:96).
GCGGAAAGCTGTGAAGATACG(SEQ ID NO:97).
ACAAAGCCCTCATCGACAGAA(SEQ ID NO:98).
ATGCCACTTCTCAGTACATGT(SEQ ID NO:99).
GTGGACTTCAGTACAACTCAC(SEQ ID NO:100).
GTGGAATTTACTTGCCTCTCC(SEQ ID NO:101).
GTTGGATGAAGCTAACTTACC(SEQ ID NO:102).
ACTGGGAAGACGTGTAACTCT(SEQ ID NO:103).
AAGGAATTGCATCCAAGGTAT(SEQ ID NO:104).
GGAATTGCATCCAAGGTATAC(SEQ ID NO:105).
GGATGAGACTGGCAATGGTCA(SEQ ID NO:106).
UCCUCAGUUUCGGGAGAUCAUCC(SEQ ID NO:107).
GAGUCUCUCAAAUCUCAGGAAUU(SEQ ID NO:108).
AGCUCUAGUCCUUUUUGUGUAAU(SEQ ID NO:109).
CACUGGAAAUGUUCAGAACUUGC(SEQ ID NO:110).
AUGAUGAAUGGGACAAUCUUAUC(SEQ ID NO:111).
CACACUGUGUUUCAUCGAGUACA(SEQ ID NO:112).
GCAGAACCAUCCAUGGACUGUGA(SEQ ID NO:113).
AAAGAUGUGGCCUUUUGUGAUGG(SEQ ID NO:114).
UUCAGAACUUGCCAGUUUUGUCC(SEQ ID NO:115).
AUGAGACUGGCAAUGGUCACAGG(SEQ ID NO:116).
GTCAATTCCAGGGAGATAACT(SEQ ID NO:117).
GCCTGGAAGCAATGGCTCTAA(SEQ ID NO:118).
GCACCAAACCCGGAAGCTATA(SEQ ID NO:119).
GTTGCACTCGATTGGGACAGT(SEQ ID NO:120).
GGATTATGTGAACCTACACCT(SEQ ID NO:121).
GGAATCACAGCGAGTTCAAAT(SEQ ID NO:122).
GCAAGGCATAGTCTCATTGAA(SEQ ID NO:123).
GGTGAAGAGAGCCTTAGAGAT(SEQ ID NO:124).
GTGAAGAGAGCCTTAGAGATA(SEQ ID NO:125).
AGGAGCUAAGGUCUUUUCCAAUG(SEQ ID NO:126).
AUGUCGAUGCAAAAAUUGCAAAA(SEQ ID NO:127).
GUCACAUGCUGGCAGAAAUCAAA(SEQ ID NO:128).
UCCAGGUUACAUGGCAUUUCUCA(SEQ ID NO:129).
UUGAACUUUGAACCUGUGAAAUG(SEQ ID NO:130).
UCCACAUCAACAGCUAAAUCAUU(SEQ ID NO:131).
AUGCUGGCAGAAAUCAAAGCAAU(SEQ ID NO:132).
UGCAGAGAAUGACAAAGAUGUCA(SEQ ID NO:133).
GGCAGAACUCACCAGUCACAUCA(SEQ ID NO:134).
UCGGUCCUGUGAUAAUGGUCACU(SEQ ID NO:135).
According to an embodiment of the invention, the slow virus of the present invention is imported into the transgenosis lymphocyte obtained by lymphocyte,
It, which has, resists the immunosuppressive characteristic that tumour cell mediates, proliferative capacity in vitro, the proliferation in tumour patient body
It is significantly increased with survival ability, the killing ability of tumour cell is significantly increased, especially had to the tumour cell of high expression MSLN
There is significant orientation lethal effect.
In the third aspect of the present invention, the present invention proposes a kind of slow virus.According to an embodiment of the invention, the slow disease
Poison, which carries, contains SEQ ID NO:136, nucleotide sequence shown in 137,138,139,140 or 141.
ATGGTTCTGCTGGTGACATCTCTCCTGCTCTGTGAACTGCCTCATCCCGCTTTTCTGCTCATTCCCGACATTCAGGC
TCAAGTCCAACTGGTCCAAAGTGGTGCTGAAGTCAAACGCCCGGGTGCCTCCGTCCAAGTCTCCTGCCGTGCCTCTG
GCTACTCGATTAACACCTATTACATGCAGTGGGTCCGTCAAGCACCGGGTGCAGGTCTGGAATGGATGGGTGTCATC
AATCCGTCCGGCGTGACCTCATATGCGCAGAAATTTCAAGGTCGCGTTACCCTGACGAACGATACCAGCACGAATAC
CGTCTACATGCAGCTGAACTCTCTGACGAGTGCAGACACCGCGGTGTATTACTGCGCACGTTGGGCACTGTGGGGCG
ATTTCGGCATGGATGTTTGGGGCAAAGGTACGCTGGTGACCGTTAGCTCTGGTGGTGGTGGTTCTGGTGGTGGTGGT
AGTGGCGGTGGCGGTTCTGATATTCAGATGACGCAAAGCCCGTCTACCCTGAGTGCCTCCATTGGTGACCGTGTTAC
GATCACCTGTCGCGCATCCGAAGGCATCTATCATTGGCTGGCTTGGTACCAGCAAAAACCGGGTAAAGCGCCGAAAC
TGCTGATCTATAAAGCAAGTTCCCTGGCATCGGGTGCTCCGAGCCGCTTTTCAGGTTCGGGTAGCGGCACCGATTTC
ACGCTGACCATCTCATCGCTGCAGCCGGACGATTTCGCTACCTACTACTGCCAACAATACTCAAACTACCCGCTGAC
CTTCGGTGGAGGGACCAAGCTGGAGATCAAACGTGCTAGCACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTC
CTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGG
GGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCTCTGGCTGGTACTTGCGGGGTCCTGCTGCTTTCACTCGT
GATCACTCTTTACTGTAAGCGCGGTCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGA
CTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAAGGCGGCTGCGAACTGCGCGTGAAATTC
AGCCGCAGCGCAGATGCTCCAGCCTACCAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGA
GGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAGAATCCCCAAG
AGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGA
AGAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCACATGCA
GGCCCTGCCGCCTCGGTAATCCTACTGCgtcgaGCGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTC
CCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATT
GTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGC
AGGCATGCTGGGGATGCGGTGGGCTCTATGGGTCGACCAAGGTCGGGCAGGAAGAGGGCCTATTTCCCATGATTCCT
TCATATTTGCATATACGATACAAGGCTGTTAGAGAGATAATTAGAATTAATTTGACTGTAAACACAAAGATATTAGT
ACAAAATACGTGACGTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTTTAAAATTATGTTTTAAAATGGACTATC
ATATGCTTACCGTAACTTGAAAGTATTTCGATTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCTCCCCA
GGCGCAGATCAAAGAGAGTTCAAGAGACTCTCTTTGATCTGCGCCTTTTTT(SEQ ID NO:136).
ATGGTTCTGCTGGTGACATCTCTCCTGCTCTGTGAACTGCCTCATCCCGCTTTTCTGCTCATTCCCGACATTCAGGC
TCAAGTCCAACTGGTCCAAAGTGGTGCTGAAGTCAAACGCCCGGGTGCCTCCGTCCAAGTCTCCTGCCGTGCCTCTG
GCTACTCGATTAACACCTATTACATGCAGTGGGTCCGTCAAGCACCGGGTGCAGGTCTGGAATGGATGGGTGTCATC
AATCCGTCCGGCGTGACCTCATATGCGCAGAAATTTCAAGGTCGCGTTACCCTGACGAACGATACCAGCACGAATAC
CGTCTACATGCAGCTGAACTCTCTGACGAGTGCAGACACCGCGGTGTATTACTGCGCACGTTGGGCACTGTGGGGCG
ATTTCGGCATGGATGTTTGGGGCAAAGGTACGCTGGTGACCGTTAGCTCTGGTGGTGGTGGTTCTGGTGGTGGTGGT
AGTGGCGGTGGCGGTTCTGATATTCAGATGACGCAAAGCCCGTCTACCCTGAGTGCCTCCATTGGTGACCGTGTTAC
GATCACCTGTCGCGCATCCGAAGGCATCTATCATTGGCTGGCTTGGTACCAGCAAAAACCGGGTAAAGCGCCGAAAC
TGCTGATCTATAAAGCAAGTTCCCTGGCATCGGGTGCTCCGAGCCGCTTTTCAGGTTCGGGTAGCGGCACCGATTTC
ACGCTGACCATCTCATCGCTGCAGCCGGACGATTTCGCTACCTACTACTGCCAACAATACTCAAACTACCCGCTGAC
CTTCGGTGGAGGGACCAAGCTGGAGATCAAACGTGCTAGCACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTC
CTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGG
GGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCTCTGGCTGGTACTTGCGGGGTCCTGCTGCTTTCACTCGT
GATCACTCTTTACTGTAAGCGCGGTCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGA
CTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAAGGCGGCTGCGAACTGCGCGTGAAATTC
AGCCGCAGCGCAGATGCTCCAGCCTACCAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGA
GGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAGAATCCCCAAG
AGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGA
AGAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCACATGCA
GGCCCTGCCGCCTCGGTAATCCTACTGCgtcgaGCGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTC
CCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATT
GTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGC
AGGCATGCTGGGGATGCGGTGGGCTCTATGGGTCGACCAAGGTCGGGCAGGAAGAGGGCCTATTTCCCATGATTCCT
TCATATTTGCATATACGATACAAGGCTGTTAGAGAGATAATTAGAATTAATTTGACTGTAAACACAAAGATATTAGT
ACAAAATACGTGACGTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTTTAAAATTATGTTTTAAAATGGACTATC
ATATGCTTACCGTAACTTGAAAGTATTTCGATTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCTCCCCA
ACACAGACGCCATGATTTGCTTCAAGAGAGCAAATCATGGCGTCTGTGTTTTTTT(SEQ ID NO:137).
ATGGTTCTGCTGGTGACATCTCTCCTGCTCTGTGAACTGCCTCATCCCGCTTTTCTGCTCATTCCCGACATTCAGGC
TCAAGTCCAACTGGTCCAAAGTGGTGCTGAAGTCAAACGCCCGGGTGCCTCCGTCCAAGTCTCCTGCCGTGCCTCTG
GCTACTCGATTAACACCTATTACATGCAGTGGGTCCGTCAAGCACCGGGTGCAGGTCTGGAATGGATGGGTGTCATC
AATCCGTCCGGCGTGACCTCATATGCGCAGAAATTTCAAGGTCGCGTTACCCTGACGAACGATACCAGCACGAATAC
CGTCTACATGCAGCTGAACTCTCTGACGAGTGCAGACACCGCGGTGTATTACTGCGCACGTTGGGCACTGTGGGGCG
ATTTCGGCATGGATGTTTGGGGCAAAGGTACGCTGGTGACCGTTAGCTCTGGTGGTGGTGGTTCTGGTGGTGGTGGT
AGTGGCGGTGGCGGTTCTGATATTCAGATGACGCAAAGCCCGTCTACCCTGAGTGCCTCCATTGGTGACCGTGTTAC
GATCACCTGTCGCGCATCCGAAGGCATCTATCATTGGCTGGCTTGGTACCAGCAAAAACCGGGTAAAGCGCCGAAAC
TGCTGATCTATAAAGCAAGTTCCCTGGCATCGGGTGCTCCGAGCCGCTTTTCAGGTTCGGGTAGCGGCACCGATTTC
ACGCTGACCATCTCATCGCTGCAGCCGGACGATTTCGCTACCTACTACTGCCAACAATACTCAAACTACCCGCTGAC
CTTCGGTGGAGGGACCAAGCTGGAGATCAAACGTGCTAGCACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTC
CTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGG
GGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCTCTGGCTGGTACTTGCGGGGTCCTGCTGCTTTCACTCGT
GATCACTCTTTACTGTAAGCGCGGTCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGA
CTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAAGGCGGCTGCGAACTGCGCGTGAAATTC
AGCCGCAGCGCAGATGCTCCAGCCTACCAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGA
GGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAGAATCCCCAAG
AGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGA
AGAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCACATGCA
GGCCCTGCCGCCTCGGTAATCCTACTGCgtcgaGCGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTC
CCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATT
GTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGC
AGGCATGCTGGGGATGCGGTGGGCTCTATGGGTCGACCAAGGTCGGGCAGGAAGAGGGCCTATTTCCCATGATTCCT
TCATATTTGCATATACGATACAAGGCTGTTAGAGAGATAATTAGAATTAATTTGACTGTAAACACAAAGATATTAGT
ACAAAATACGTGACGTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTTTAAAATTATGTTTTAAAATGGACTATC
ATATGCTTACCGTAACTTGAAAGTATTTCGATTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCTCCCCG
CATCACTTGGGATTAATATTCAAGAGATATTAATCCCAAGTGATGCTTTTT(SEQ ID NO:138).
ATGGTTCTGCTGGTGACATCTCTCCTGCTCTGTGAACTGCCTCATCCCGCTTTTCTGCTCATTCCCGACATTCAGGC
TCAAGTCCAACTGGTCCAAAGTGGTGCTGAAGTCAAACGCCCGGGTGCCTCCGTCCAAGTCTCCTGCCGTGCCTCTG
GCTACTCGATTAACACCTATTACATGCAGTGGGTCCGTCAAGCACCGGGTGCAGGTCTGGAATGGATGGGTGTCATC
AATCCGTCCGGCGTGACCTCATATGCGCAGAAATTTCAAGGTCGCGTTACCCTGACGAACGATACCAGCACGAATAC
CGTCTACATGCAGCTGAACTCTCTGACGAGTGCAGACACCGCGGTGTATTACTGCGCACGTTGGGCACTGTGGGGCG
ATTTCGGCATGGATGTTTGGGGCAAAGGTACGCTGGTGACCGTTAGCTCTGGTGGTGGTGGTTCTGGTGGTGGTGGT
AGTGGCGGTGGCGGTTCTGATATTCAGATGACGCAAAGCCCGTCTACCCTGAGTGCCTCCATTGGTGACCGTGTTAC
GATCACCTGTCGCGCATCCGAAGGCATCTATCATTGGCTGGCTTGGTACCAGCAAAAACCGGGTAAAGCGCCGAAAC
TGCTGATCTATAAAGCAAGTTCCCTGGCATCGGGTGCTCCGAGCCGCTTTTCAGGTTCGGGTAGCGGCACCGATTTC
ACGCTGACCATCTCATCGCTGCAGCCGGACGATTTCGCTACCTACTACTGCCAACAATACTCAAACTACCCGCTGAC
CTTCGGTGGAGGGACCAAGCTGGAGATCAAACGTGCTAGCACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTC
CTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGG
GGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCTCTGGCTGGTACTTGCGGGGTCCTGCTGCTTTCACTCGT
GATCACTCTTTACTGTAAGCGCGGTCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGA
CTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAAGGCGGCTGCGAACTGCGCGTGAAATTC
AGCCGCAGCGCAGATGCTCCAGCCTACCAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGA
GGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAGAATCCCCAAG
AGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGA
AGAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCACATGCA
GGCCCTGCCGCCTCGGTAATCCTACTGCgtcgaGCGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTC
CCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATT
GTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGC
AGGCATGCTGGGGATGCGGTGGGCTCTATGGGTCGACCAAGGTCGGGCAGGAAGAGGGCCTATTTCCCATGATTCCT
TCATATTTGCATATACGATACAAGGCTGTTAGAGAGATAATTAGAATTAATTTGACTGTAAACACAAAGATATTAGT
ACAAAATACGTGACGTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTTTAAAATTATGTTTTAAAATGGACTATC
ATATGCTTACCGTAACTTGAAAGTATTTCGATTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCTCCCCA
GGCGCAGATCAAAGAGAGTTCAAGAGACTCTCTTTGATCTGCGCCTTTTTTAGCTATCGATAGCTAAAAAAACACAG
ACGCCATGATTTGCTCTCTTGAAGCAAATCATGGCGTCTGTGTTGGGGAAGATCTGTGGTCTCATACAGAACTTATA
AGATTCCCAAATCCAAAGACATTTCACGTTTATGGTGATTTCCCAGAACACATAGCGACATGCAAATATTGCAGGGC
GCCACTCCCCTGTCCCTCACAGCCATCTTCCTGCCAGGGCGCACGCGCGCTGGGTGTTCCCGCCTAGTGACACTGGG
CCCGCGATTCCTTGGAGCGGGTTGATGACGTCAGCGTTCGAATTGTCGAC(SEQ ID NO:139).
ATGGTTCTGCTGGTGACATCTCTCCTGCTCTGTGAACTGCCTCATCCCGCTTTTCTGCTCATTCCCGACATTCAGGC
TCAAGTCCAACTGGTCCAAAGTGGTGCTGAAGTCAAACGCCCGGGTGCCTCCGTCCAAGTCTCCTGCCGTGCCTCTG
GCTACTCGATTAACACCTATTACATGCAGTGGGTCCGTCAAGCACCGGGTGCAGGTCTGGAATGGATGGGTGTCATC
AATCCGTCCGGCGTGACCTCATATGCGCAGAAATTTCAAGGTCGCGTTACCCTGACGAACGATACCAGCACGAATAC
CGTCTACATGCAGCTGAACTCTCTGACGAGTGCAGACACCGCGGTGTATTACTGCGCACGTTGGGCACTGTGGGGCG
ATTTCGGCATGGATGTTTGGGGCAAAGGTACGCTGGTGACCGTTAGCTCTGGTGGTGGTGGTTCTGGTGGTGGTGGT
AGTGGCGGTGGCGGTTCTGATATTCAGATGACGCAAAGCCCGTCTACCCTGAGTGCCTCCATTGGTGACCGTGTTAC
GATCACCTGTCGCGCATCCGAAGGCATCTATCATTGGCTGGCTTGGTACCAGCAAAAACCGGGTAAAGCGCCGAAAC
TGCTGATCTATAAAGCAAGTTCCCTGGCATCGGGTGCTCCGAGCCGCTTTTCAGGTTCGGGTAGCGGCACCGATTTC
ACGCTGACCATCTCATCGCTGCAGCCGGACGATTTCGCTACCTACTACTGCCAACAATACTCAAACTACCCGCTGAC
CTTCGGTGGAGGGACCAAGCTGGAGATCAAACGTGCTAGCACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTC
CTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGG
GGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCTCTGGCTGGTACTTGCGGGGTCCTGCTGCTTTCACTCGT
GATCACTCTTTACTGTAAGCGCGGTCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGA
CTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAAGGCGGCTGCGAACTGCGCGTGAAATTC
AGCCGCAGCGCAGATGCTCCAGCCTACCAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGA
GGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAGAATCCCCAAG
AGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGA
AGAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCACATGCA
GGCCCTGCCGCCTCGGTAATCCTACTGCgtcgaGCGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTC
CCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATT
GTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGC
AGGCATGCTGGGGATGCGGTGGGCTCTATGGGTCGACCAAGGTCGGGCAGGAAGAGGGCCTATTTCCCATGATTCCT
TCATATTTGCATATACGATACAAGGCTGTTAGAGAGATAATTAGAATTAATTTGACTGTAAACACAAAGATATTAGT
ACAAAATACGTGACGTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTTTAAAATTATGTTTTAAAATGGACTATC
ATATGCTTACCGTAACTTGAAAGTATTTCGATTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCTCCCCA
GGCGCAGATCAAAGAGAGTTCAAGAGACTCTCTTTGATCTGCGCCTTTTTTAGCTATCGATAGCTAAAAAGCATCAC
TTGGGATTAATATCTCTTGAATATTAATCCCAAGTGATGCGGGGAAGATCTGTGGTCTCATACAGAACTTATAAGAT
TCCCAAATCCAAAGACATTTCACGTTTATGGTGATTTCCCAGAACACATAGCGACATGCAAATATTGCAGGGCGCCA
CTCCCCTGTCCCTCACAGCCATCTTCCTGCCAGGGCGCACGCGCGCTGGGTGTTCCCGCCTAGTGACACTGGGCCCG
CGATTCCTTGGAGCGGGTTGATGACGTCAGCGTTCGAATTGTCGAC(SEQ ID NO:140).
ATGGTTCTGCTGGTGACATCTCTCCTGCTCTGTGAACTGCCTCATCCCGCTTTTCTGCTCATTCCCGACATTCAGGC
TCAAGTCCAACTGGTCCAAAGTGGTGCTGAAGTCAAACGCCCGGGTGCCTCCGTCCAAGTCTCCTGCCGTGCCTCTG
GCTACTCGATTAACACCTATTACATGCAGTGGGTCCGTCAAGCACCGGGTGCAGGTCTGGAATGGATGGGTGTCATC
AATCCGTCCGGCGTGACCTCATATGCGCAGAAATTTCAAGGTCGCGTTACCCTGACGAACGATACCAGCACGAATAC
CGTCTACATGCAGCTGAACTCTCTGACGAGTGCAGACACCGCGGTGTATTACTGCGCACGTTGGGCACTGTGGGGCG
ATTTCGGCATGGATGTTTGGGGCAAAGGTACGCTGGTGACCGTTAGCTCTGGTGGTGGTGGTTCTGGTGGTGGTGGT
AGTGGCGGTGGCGGTTCTGATATTCAGATGACGCAAAGCCCGTCTACCCTGAGTGCCTCCATTGGTGACCGTGTTAC
GATCACCTGTCGCGCATCCGAAGGCATCTATCATTGGCTGGCTTGGTACCAGCAAAAACCGGGTAAAGCGCCGAAAC
TGCTGATCTATAAAGCAAGTTCCCTGGCATCGGGTGCTCCGAGCCGCTTTTCAGGTTCGGGTAGCGGCACCGATTTC
ACGCTGACCATCTCATCGCTGCAGCCGGACGATTTCGCTACCTACTACTGCCAACAATACTCAAACTACCCGCTGAC
CTTCGGTGGAGGGACCAAGCTGGAGATCAAACGTGCTAGCACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTC
CTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGG
GGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCTCTGGCTGGTACTTGCGGGGTCCTGCTGCTTTCACTCGT
GATCACTCTTTACTGTAAGCGCGGTCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGA
CTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAAGGCGGCTGCGAACTGCGCGTGAAATTC
AGCCGCAGCGCAGATGCTCCAGCCTACCAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGA
GGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAGAATCCCCAAG
AGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGA
AGAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCACATGCA
GGCCCTGCCGCCTCGGTAATCCTACTGCGTCGAGCGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTC
CCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATT
GTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGC
AGGCATGCTGGGGATGCGGTGGGCTCTATGGGTCGACCAAGGTCGGGCAGGAAGAGGGCCTATTTCCCATGATTCCT
TCATATTTGCATATACGATACAAGGCTGTTAGAGAGATAATTAGAATTAATTTGACTGTAAACACAAAGATATTAGT
ACAAAATACGTGACGTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTTTAAAATTATGTTTTAAAATGGACTATC
ATATGCTTACCGTAACTTGAAAGTATTTCGATTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCTCCCCA
GGCGCAGATCAAAGAGAGTTCAAGAGACTCTCTTTGATCTGCGCCTTTTTTAGCTATCGATAGCTAAAAAGCCTAGA
GAAGTTTCAGGGAATCTCTTGAATTCCCTGAAACTTCTCTAGGCGGGGAAGATCTGTGGTCTCATACAGAACTTATA
AGATTCCCAAATCCAAAGACATTTCACGTTTATGGTGATTTCCCAGAACACATAGCGACATGCAAATATTGCAGGGC
GCCACTCCCCTGTCCCTCACAGCCATCTTCCTGCCAGGGCGCACGCGCGCTGGGTGTTCCCGCCTAGTGACACTGGG
CCCGCGATTCCTTGGAGCGGGTTGATGACGTCAGCGTTCGAATTGTCGAC(SEQ ID NO:141).
According to an embodiment of the invention, the slow virus of the present invention is imported into the transgenosis lymphocyte obtained by lymphocyte,
It, which has, resists the immunosuppressive characteristic that tumour cell mediates, proliferative capacity in vitro, the proliferation in tumour patient body
It is significantly increased with survival ability, the killing ability of tumour cell is significantly increased, especially had to the tumour cell of high expression MSLN
There is significant orientation lethal effect.
In the fourth aspect of the present invention, the present invention proposes a kind of transgenosis lymphocyte.According to an embodiment of the invention,
The lymphocyte cell immunologic test point is silenced;And expression Chimeric antigen receptor, the Chimeric antigen receptor include:Born of the same parents
Outskirt, the extracellular region include the heavy chain variable region and light chain variable region of antibody, and the antibody can be with specific for tumour antigen
In conjunction with;Transmembrane region;And intracellular region, the intracellular region include co-stimulators intracellular section, wherein the antibody is single-stranded
Antibody, the tumour antigen are MSLN.Inventor has surprisingly found that cellular immunity checkpoint is silenced and expresses the embedding of anti-MSLN
Close in-vitro multiplication ability, the proliferation in tumour patient body and the survival ability of the lymphocyte of antigen receptor and in neoplastic disease
The specific killing ability to tumour cell in human body greatly improves, and especially has to the tumour cell of high expression MSLN notable
Orientation lethal effect.
According to an embodiment of the invention, above-mentioned transgenosis lymphocyte can also have following additional technical feature at least it
One:
According to an embodiment of the invention, the lymphocyte cell immunologic test point independently selected from CTLA4, PD1,
At least one of TIM3, BTLA, LAG-3, IRAK-M, SOCS1, A20, CBL-B.Wherein, CTLA4, PD1, TIM3, BTLA,
LAG-3 is cell surface immunologic test point, and IRAK-M, SOCS1, A20, CBL-B are intracellular immunity checkpoint.The present invention is implemented
The immunologic test point of example has the function of negative regulation and weakens cellullar immunologic response, is matched by corresponding on tumour cell
The specific bond of body, the downward for causing T lymphoproliferatives to react, the secretion of cell factor reduce and the incapability of T cell or
Apoptosis.According to an embodiment of the invention, the successful silence of the cell surface of the embodiment of the present invention or intracellular immunity checkpoint, into
One step improves the effect of transgenosis lymphocyte resists the immunosupress that tumour mediates, and transgenosis lymphocyte expands in vitro
And proliferation in tumour patient body and survival ability, the orientation lethal effect of tumour cell is further strengthened.
According to an embodiment of the invention, it is by shRNA, instead that immunologic test point in the lymphocyte cell surface, which is silenced,
What at least one phosphorothioate odn, ribozyme, dominant negative mutations, CRISPR and Zinc finger nuclease were realized.According to an embodiment of the invention, originally
The successful silence of the cellular immunity checkpoint of inventive embodiments, the lymphocyte for being remarkably improved the embodiment of the present invention resist tumour
The immunosuppressive characteristic mediated, further improves orientation lethal effect of the transgenosis lymphocyte to tumour cell.
According to an embodiment of the invention, the co-stimulators intracellular section independently selected from 4-1BB, OX-40,
At least one of CD40L, CD27, CD30, CD28 and their derivative.The co-stimulators born of the same parents of the embodiment of the present invention
The expression of inner segment and the silence joint of cellular immunity checkpoint have the function of positive regulation and enhancing cellullar immunologic response, make
The transgenosis lymphopoiesis for obtaining the embodiment of the present invention is more notable to the orientation lethal effect effect of tumour;The present invention is implemented
The joint of the expression of the co-stimulators intracellular section of example and the silence of cellular immunity checkpoint so that the embodiment of the present invention
The proliferative capacity of transgenosis lymphocyte and more notable to the orientation lethal effect of tumour.
According to an embodiment of the invention, the lymphocyte cell immunologic test point is CTLA4, PD1, CBL-B.Wherein,
CTLA4, PD1 are cell surface immunologic test points, and CBL-B is intracellular immunity checkpoint.According to an embodiment of the invention, this hair
The lymphocyte cell surface immunologic test point CTLA4 or PD1 of bright embodiment be silenced or lymphocyte cell in immunologic test
Point is that CBL-B is silenced, and prevents PD1 or CTLA4 developed by molecule and its respective ligand PD-L1 and PD-L2 or CD80 and CD86
Combination, to effectively inhibit incapability or apoptosis to T lymphocytes, or pass through CBL-B silences, enhancing T cell receptor letter
Number conduction so that proliferation and survival ability of the transgenosis lymphocyte in tumour patient body are further enhanced, to tumour
Orientation lethal effect effect it is more notable.
According to an embodiment of the invention, immunologic test point, which is silenced, in the lymphocyte cell is realized by shRNA
's.According to an embodiment of the invention, the shRNA of the embodiment of the present invention carry specific silenced cell surface or it is intracellular at least it
The shRNA of the shRNA of 1 immunologic test point, the embodiment of the present invention have silenced cell surface or intracellular efficiently, specific
At least one immunologic test point effect, the successful silence of cellular immunity checkpoint, i.e. cell surface or intracellular immunity inspection
The successful silence of point, prevents the specific binding of immunologic test point and respective ligand, to effectively inhibit immunologic test point
The negative regulation mechanism of or apoptosis incompetent to T lymphocytes etc., so that the transgenosis lymphocyte of the embodiment of the present invention is swollen
Tumor proliferation in patient body and survival ability are further enhanced, and coordinate the antigen targeting of Chimeric antigen receptor so that this
The transgenosis lymphocyte of inventive embodiments is more notable to the orientation lethal effect effect of tumour.
According to an embodiment of the invention, the co-stimulators intracellular section is the intracellular section of 4-1BB or CD28.This hair
The co-stimulators intracellular section of the Chimeric antigen receptor of transgenosis lymphocyte in bright is the intracellular of CD28 or 4-1BB
Section.According to an embodiment of the invention, co-stimulators intracellular section is the intracellular section of CD28 or 4-1BB, is further enhanced
The orientation lethal effect of the transgenosis lymphocyte of the embodiment of the present invention.
According to an embodiment of the invention, the lymphocyte is CD3+T lymphocytes or natural killer cells are killed naturally
Hinder T cell.The cellular immunity checkpoint of the above-mentioned lymphocyte of the embodiment of the present invention is silenced, while expressing antigentic specificity
Chimeric antigen receptor, such as the Chimeric antigen receptor of the MSLN antigentic specificities of the embodiment of the present invention, above-mentioned lymphocyte it is thin
The targeting of born of the same parents' immunologic cytotoxicity effect is stronger, and proliferation and survival ability in tumour patient body are further enhanced, to swollen
The orientation lethal effect effect of tumor is more notable.
In the ninth aspect of the present invention, the present invention proposes a kind of construct.According to an embodiment of the invention, the structure
Body includes:First nucleic acid molecules, the first nucleic acid molecule encoding Chimeric antigen receptor;And second nucleic acid molecules, described
2 nucleic acid molecules silenced cell immunologic test points.Wherein, for example preceding institute of the cellular immunity checkpoint, the Chimeric antigen receptor
It states.It according to an embodiment of the invention, can after the construct of the embodiment of the present invention successfully imports the lymphocyte of the embodiment of the present invention
The Chimeric antigen receptor of effective reticence cell surface or at least one intracellular immunologic test point and expression antigentic specificity, to
The lymphocyte of the embodiment of the present invention is to tumour cell, and the orientation lethal effect of the tumour cell of especially high expression MSLN is more
Significantly.
According to an embodiment of the invention, above-mentioned construct can further include following additional technical feature at least it
One:
According to an embodiment of the invention, it is characterised in that first nucleic acid molecules are set with second nucleic acid molecules
Silenced cell immunologic test point and the expression Chimeric antigen receptor in the lymphocyte in front.Reality according to the present invention
Example is applied, the lymphocyte of above-mentioned first nucleic acid molecules and the second nucleic acid molecules, the cell table of lymphocyte are successfully provided with
Face or at least one intracellular immunologic test point are by success silence, while in lymphocytic cell surface successful expression antigen-specific
Sex-mosaicism antigen receptor, it is stronger and special with lethality such as the Chimeric antigen receptor of the MSLN specificity of the embodiment of the present invention
Anisotropic stronger tumor-killing effect.
According to an embodiment of the invention, the construct further comprises:First promoter, first promoter and institute
The first nucleic acid molecules are stated to be operably connected;And second promoter, second promoter can with second nucleic acid molecules
It is operatively connected.According to an embodiment of the invention, the introducing of the first promoter and the second promoter so that the first nucleic acid molecules
And the second nucleic acid molecules expression independently, be effectively ensured Chimeric antigen receptor antigen targeting biological action and
With effective reticence cellular immunity checkpoint so that the targeting of the lymphocyte of the embodiment of the present invention is stronger, to tumour
Lethal effect, it is especially more notable to the orientation killing of the tumour cell of high expression MSLN.
According to an embodiment of the invention, first promoter, second promoter are separately selected from U6, H1,
CMV, EF-1, LTR, RSV promoter.According to an embodiment of the invention, the above-mentioned promoter of the embodiment of the present invention has to start and imitate
The characteristics of rate height, high specificity, to ensure that the efficient silence of cellular immunity checkpoint and the efficient table of Chimeric antigen receptor
It reaches, it is big to the in-vitro multiplication ability, the proliferation in tumour patient body and survival ability of the lymphocyte of the embodiment of the present invention
It is big to improve, it is more notable to the orientation fragmentation effect of tumour.
According to an embodiment of the invention, the carrier of the construct is non-pathogenic virus carrier.Non-pathogenic virus carries
Body is introduced into the duplication and amplification efficiency for substantially increasing construct in lymphocyte, to substantially increase cellular immunity inspection
High efficient expression of the silence and Chimeric antigen receptor made an inventory of in lymphocyte so that Lymphocyte Proliferation in Vitro ability is swelling
Tumor proliferation in patient body and survival ability greatly improve, and the targeting of lymphocyte further enhances, to tumour cell
Lethal effect is more notable.
According to an embodiment of the invention, the viral vectors includes being selected from retrovirus vector, slow virus carrier or gland
At least one of viral related viral vectors.The carrier of the virus of the embodiment of the present invention is in virus packaging and course of infection, disease
Malicious infection scope is extensive, can not only infect terminally differentiated cells, but also can infect the cell in division stage, genome can both be integrated
It to host chromosome, and can be free in except host chromosome, so that wide spectrum can be realized and efficient efficiency of infection, cellular immunity
High efficient expression of the checkpoint by efficient silence and Chimeric antigen receptor in lymphocyte so that the lymph of the embodiment of the present invention is thin
In-vitro multiplication ability, the proliferation in tumour patient body and the survival ability of born of the same parents greatly improves, the targeting of lymphocyte into
One step enhances, especially more notable to the orientation lethal effect of the tumour cell of high expression MSLN to tumour cell.
In the tenth aspect of the present invention, the present invention, which proposes, a kind of preparing foregoing T lymphocytes or transgenosis
The method of lymphocyte.According to an embodiment of the invention, the method includes:By foregoing construct or noted earlier
Slow virus be introduced into lymphocyte or T lymphocytes.The construct or slow virus are successfully introduced into above-mentioned lymphocyte
Or in T lymphocytes, the cellular immunity inspection for realizing lymphocyte is silenced expression with Chimeric antigen receptor, to this
Transgenosis lymphocyte or T lymphocytes prepared by the preparation methods of the inventive embodiments proliferation internal and external in tumour patient
And survival ability greatly improves in tumour patient body, transgenosis lymphocyte or T lymphocytes are to tumour cell, especially to height
The targeting killing effect for expressing the tumour cell of MSLN is stronger.
In the eleventh aspect of the present invention, the present invention proposes a kind of therapeutic combination for treating cancer.According to this
The embodiment of invention, the therapeutic combination include:Above-mentioned construct, slow virus, T lymphocytes or transgenosis lymph are thin
Born of the same parents.The composition of any one of the above therapeutic combination can be achieved transgenosis lymphocyte or T lymphocytes cell surface or
High efficient expression of the silence and Chimeric antigen receptor of intracellular immunity checkpoint in transgenosis lymphocyte or T lymphocytes,
So that gained transgenosis lymphocyte or T lymphocytes have the significant immunosupress resisted tumour cell and mediated,
Survival ability greatly improves in the proliferation and tumour patient body of tumour patient in vitro and in vivo, transgenosis lymphocyte or T lymphs
The targeting killing effect of cells against tumor cells is stronger, and the therapeutic combination of the treating cancer of the embodiment of the present invention is to tumour cell
Targeting killing effect significantly increase, especially the targeting killing effect of the tumour cell of high expression MSLN is significantly increased.
According to an embodiment of the invention, above-mentioned therapeutic combination can further include following additional technical feature at least
One of:
According to an embodiment of the invention, the cancer includes being selected from celiothelioma, cancer of pancreas, oophoroma, cholangiocarcinoma, lung cancer,
Gastric cancer, intestinal cancer, at least one of the cancer of the esophagus and breast cancer.Above-mentioned tumour cell has the specificity overexpression of MSLN, the present invention
The therapeutic combination of embodiment can make the silence and high efficient expression antigen on lymphocyte cell surface or intracellular immunity checkpoint
Specific chimeric antigen receptor, such as the antigen-specific chimerics the MSLN antigen receptor of the embodiment of the present invention, gained lymphocyte or T
Lymphocyte has the significant immunosuppressive characteristic resisted tumour cell and mediated, the survival ability in the microenvironment of tumour
It greatly improves, gained lymphocyte or T lymphocytes are stronger to the targeting killing effect of the tumour cell of high expression MSLN.
In the twelveth aspect of the present invention, the present invention proposes a kind of method improving lymphocyte activity, the lymph
Cell carries Chimeric antigen receptor, according to an embodiment of the invention, the method includes:Make the cellular immunity of the lymphocyte
Checkpoint is silenced.The cellular immunity checkpoint, the lymphocyte and the Chimeric antigen receptor be as defined above,
The lymphocyte activity include the Lymphocyte Proliferation in Vitro ability, the proliferation in tumour patient body and survival ability with
And at least one of orientation killing ability of the lymphocyte in tumour patient body.According to an embodiment of the invention, this hair
The cell surface of the lymphocyte of bright embodiment or intracellular immunity checkpoint are silenced, and lymphocyte is activated, is Hypertrophic anti-
It should raise, cytokine secretion increases, anti-tune dies ability enhancing so that the lymphocyte of the embodiment of the present invention expands in vitro,
Survival ability greatly improves in proliferation and tumour patient body in tumour patient body, above-mentioned lymphocyte cell immunologic test point
Silence cooperation lymphocyte Chimeric antigen receptor antigentic specificity effect, to realize be effective against tumour cell mediate
Immunosupress, the targeting killing effect of the tumour cell of high expression MSLN is significantly increased.
According to an embodiment of the invention, the method for above-mentioned raising lymphocyte activity can further include following additional
At least one technical characteristic:
According to an embodiment of the invention, the tumour includes being selected from celiothelioma, cancer of pancreas, oophoroma, cholangiocarcinoma, lung cancer,
Gastric cancer, intestinal cancer, at least one of the cancer of the esophagus and breast cancer.Above-mentioned tumor cell specific height expresses MSLN.The embodiment of the present invention
Raising lymphocyte activity method, make the Chimeric antigen receptor of Expressions In Lymphocytes MSLN antigentic specificities, while making leaching
The immunologic test point of bar cell is silenced, and the method for the raising lymphocyte activity of the embodiment of the present invention is further improved to height
Express MSLN tumour cell orientation kill ability, such as above-mentioned celiothelioma, cancer of pancreas, oophoroma, cholangiocarcinoma, lung cancer, gastric cancer,
Intestinal cancer, the cancer of the esophagus or breast cancer cell.
It should be noted that the term " cellular immunity checkpoint " used in the present invention includes cell surface immunologic test
Point and intracellular immunity checkpoint, " cell surface immunologic test point " is a kind of memebrane protein of lymphocytic cell surface, with tumour
The ligand interaction expressed on cell, can inhibit antitumor lymphocyte reaction." intracellular immunity checkpoint " is a kind of
A kind of intracellular protein, the cellular signal transduction mechanism albumen of negative regulation of such cellular immunity checkpoint albumen, can inhibit anti-
Tumor lympha cell effect.
Description of the drawings
Fig. 1 is that the Chimeric antigen receptor according to the ... of the embodiment of the present invention for co-expressing MSLN antigentic specificities and the silence mankind are thin
The structural schematic diagram of the slow virus carrier of born of the same parents' immunologic test point;
Fig. 2 is the Chimeric antigen receptor and silence PD1 of coexpression MSLN antigentic specificities according to the ... of the embodiment of the present invention
Lymphocyte, the result figure of proliferative capacity enhancing;
Fig. 3 is the Chimeric antigen receptor and silence PD1 of coexpression MSLN antigentic specificities according to the ... of the embodiment of the present invention
Lymphocyte, interferon-γ secrete the result figure increased;And
Fig. 4 is the Chimeric antigen receptor and silence PD1 of coexpression MSLN antigentic specificities according to the ... of the embodiment of the present invention
Lymphocyte, the result figure of killing tumor cell ability enhancing.
Specific implementation mode
The embodiment of the present invention is described below in detail, the embodiments described below is exemplary, it is intended to for explaining this
Invention, and be not considered as limiting the invention.
T lymphocytes or transgenosis lymphocyte
In one aspect of the invention, the present invention proposes a kind of T lymphocytes or transgenosis lymphocyte.According to the present invention
Embodiment, the cellular immunity checkpoint of the T lymphocytes of the embodiment of the present invention is silenced;And expression Chimeric antigen receptor,
Wherein, Chimeric antigen receptor includes:Extracellular region, extracellular region includes the heavy chain variable region and light chain variable region of single-chain antibody, single-stranded
Antibody specificity identifies antigen MSLN;Transmembrane region, transmembrane region are connected with extracellular region, and are embedded into the cell of institute's T lymphocytes
In film;Intracellular region, intracellular region are connected with transmembrane region, and intracellular region includes the intracellular section and CD3 ζ chains of CD28 or 4-1BB.Its
In, cellular immunity checkpoint includes cell surface or intracellular immunologic test point.The T lymphocytes of the embodiment of the present invention turn
Gene lymphocyte cell immunologic test point is silenced the Chimeric antigen receptor of Combined expression MSLN antigentic specificities, and the present invention is real
Apply example T lymphocytes or transgenosis lymphocyte in the internal and external proliferation of tumour patient and survival ability and in tumour
The killing ability to specific tumor cell in patient body significantly increases, especially the spy to the tumour cell of high efficient expression MSLN
Anisotropic fragmentation effect greatly improves.
Tumour can close lymphocyte to it to avoid immunosurveillance by stimulating the expression of its inhibitive ability of immunity receptor
Immunologic cytotoxicity reaction;As immune negative regulator mechanism, the cytotoxic T lymphocyte (CTLs) of activation also expresses negative regulation
Regulatory agency, i.e. cell surface or intracellular immunologic test point molecule.As the embodiment of the present invention apoptosis 1 by
Body (PD1) expression interacts on activation CTLs with the programmed death ligand 1 (PD-L1) expressed on tumour cell, can
To inhibit antitumor t cell responses.Many tumours express PD-L1, and the combination of PD-L1 and its ligand PD-1 lead to CTLs hyperplasia
Property reaction downward, cell factor secretion reduce and T cell incapability or apoptosis.The cytotoxic T of the embodiment of the present invention drenches
Bar cellular antigens 4 (CTLA4) are the key that the negative regulatory factors of another T cell, can inhibit T cell activation, by with
It expresses the interaction of ligand B7.1, B7.2 (CD80 and CD86) on antigen presenting cell and inhibits the activation of T cell.This
CBL-B (E3 ubiquitin protein ligase CBL-B) in the cytotoxic T lymphocyte of inventive embodiments is intracellular another
Crucial negative regulatory factor, by inhibiting T cell receptor (TCR) signal transduction, to inhibit the activity of T cell.Therefore, this hair
The T lymphocytes of bright embodiment or the immunologic test point of transgenosis lymphocyte are silenced, and T lymphocytes or transgenosis lymph are thin
The proliferation in tumour patient body and survival ability of born of the same parents significantly improves.
In addition, according to an embodiment of the invention, the antibody of above-mentioned Chimeric antigen receptor extracellular region is single-chain antibody.Inventor
It was found that single-chain antibody can remove the competitive surface protein of nonspecific reaction, while single-chain antibody is more easy to infiltration tumor tissues
Increase drug concentration levels.The Chimeric antigen receptor of the transgenosis Expressions In Lymphocytes single-chain antibody of the embodiment of the present invention, significantly
Improve orientation lethal effect of the transgenosis lymphocyte to targets neoplastic cells.
The combination antigen of other embodiment according to the present invention, above-mentioned antibody is MSLN.Therefore the embodiment of the present invention
Transgenosis lymphocyte there is directionality lethal effect, the specific binding of antigen-antibody for the cell of expression antigen MSLN
Act on stronger, the transgenosis lymphocyte for substantially increasing the embodiment of the present invention kills the orientation of MSLN antigen presentation tumour cells
Wound acts on.
The cellular immunity checkpoint of other embodiment according to the present invention, lymphocyte includes cell surface and cell
Interior immunologic test point, the lymphocyte cell surface immunologic test point of the embodiment of the present invention independently selected from CTLA4, PD1,
At least one TIM3, BTLA, LAG-3, in lymphocyte cell immunologic test point independently selected from IRAK-M, SOCS1, A20,
At least one of CBL-B.Above-mentioned molecule can be combined with the antigentic specificity of tumor cells expression, inhibit the work of lymphocyte
Change, promote the incapability or apoptosis of lymphocyte, to negative regulation and weakens cellullar immunologic response.Implementation according to the present invention
The successful silence of example, above-mentioned cell surface or intracellular immunity checkpoint, further improves transgenosis lymphocyte in tumour
Proliferation in patient body and survival ability further strengthen the orientation lethal effect of tumour cell.
Other embodiment according to the present invention, the lymphocyte cell surface immunologic test point quilt of the embodiment of the present invention
Silence is realized by least one shRNA, antisense nucleic acid, ribozyme, dominant negative mutations, Zinc finger nuclease and CRISPR.
Children purpura nephritis or short hairpin RNA (shRNA) are the importing forms of siRNA (siRNA), and siRNA is a kind of small
RNA molecule (is made of) 21~25 nucleotide, (is made with specific cleavage to double-stranded RNA in III families of RNAase by Dicer
Enzyme) it is process;SiRNA plays central role in RNA silence accesses, degrades to specific mRNA (mRNA), is
Regulate and control after transcriptional level.
Antisense nucleic acid includes antisense RNA and antisense DNA, and antisense RNA refers to can be with one section of small molecule of mRNA complete complementaries
RNA or oligonucleotide fragment, antisense DNA refer to can be combined with the sense strand complementation in gene DNA double-strand short and small DNA points
Son, antisense RNA and antisense DNA are mainly played a role by the translation of mRNA and the transcription of gene DNA;Antisense nucleic acid one
Aspect to form space steric effect by being combined with said target mrna, and ribosomes is prevented to be combined with mRNA, and on the other hand it is tied with mRNA
Endogenous RNA enzyme or ribozyme are activated after conjunction, and then the mRNA that degrades;The control region specific bond of antisense DNA and gene DNA double helix
DNA tripolymers are formed, or are combined with DNA encoding area, the extension for the mRNA chains transcribed is terminated;Antisense nucleic acid, which may also suppress, to be turned
The processing modification of mRNA after record, such as the ends 5' cap, the ends 3' tailing, intermediate montage and internal base methylate, and prevent maturation
MRNA is transported from nucleus into cytoplasm, and therefore, antisense RNA is a kind of technology of effective silence target gene.
Ribozyme is the RNA molecule for having catalysis, is biocatalyst, degradable special mRNA sequence, and ribozyme is logical
It crosses catalysis and turns phosphate and phosphodiester bond hydrolysis participation RNA itself shearings, process, with general antisense RNA phase
There is relatively stable space structure than, ribozyme, be not easily susceptible to the attack of RNA enzyme, it is often more important that, ribozyme after cutting off mRNA,
It can be escaped from hybridization chain again, recombine and cut others mRNA molecules.
Dominant negative mutation refers to not only own reactive energy after the mutation of certain signal transducers, moreover it is possible to inhibit or block same
The effect of one intracellular wild type signal transducer, it is mainly real by way of forming dimer with wild-type protein
Existing, this mutation toxic effect is big, can significantly inhibit or block the effect of intracellular echo signal transducin.
Zinc finger nuclease identifies that domain and a non-specific nucleic acid restriction endonuclease are constituted by a DNA, and DNA identifies that domain is by one
Serial Cys2-His2 zinc finger proteins are composed in series (general 3~4), and each zinc finger protein identifies and combines one special three
Conjuncted base, zinc finger protein form alpha-beta-β secondary structures, and it is special to determine that the DNA of zinc finger is combined for wherein 16 amino acid residues of α spirals
The opposite sex, skeleton structure is conservative, is tied to determining that the change of the amino acid calling sequence of DNA binding specificities can obtain new DNA
Specificity is closed, so as to design different amino acid calling sequences for different target gene, realizes different target gene
Specific silence.
CRISPR (Clustered regularly interspaced short palindromic repeats, rule
The short palindrome in cluster interval repeats), it is a kind of gene editing device, is bacterium to protect themselves against a system of virus.It
The target gene of other organisms can be used for deleting, adding, activating or inhibiting, these target genes include the mesh in people's cell
Mark gene.
CRISPR clusters are a special repetitive dna sequence families being widely present in bacterium and Archimycetes genome,
Sequence is by a leader (Leader), multiple short and highly conserved repetitive sequences (Repeat) and multiple spacer regions
(Spacer) it forms.Leader is normally at CRISPR clusters upstream, is considered rich in the region that AT length is 300~500bp
It may be the promoter sequence of CRISPR clusters.Repetitive sequence section length is 21~48bp can form hair fastener knot containing palindromic sequence
Structure.It is separated by the spacer region that length is 26~72bp between repetitive sequence.The regions Spacer are made of the exogenous DNA captured, when
It when exogenous DNA containing same sequence is invaded, can be identified by bacterium body, and carry out shearing and be allowed to expression silencing, reach protection
The purpose of inherently safe.By being found to the flanking sequence analysis of CRISPR clusters, there is a polymorphism family base in its vicinity
Cause.The protein of family coding, which contains the functional domain that can be had an effect with nucleic acid, (has nuclease, unwindase, integrase
With polymerase isoreactivity), and play a role jointly with the regions CRISPR, therefore it is named as CRISPR association bases (CRISPR
Associated), it is abbreviated as Cas.Presently found Cas includes the multiple types such as Cas1~Cas10.Cas genes and CRISPR
Common evolutionary collectively forms a highly conserved system.When bacterium resists the invasion of the exogenous DNAs such as bacteriophage, in leader
Regulation and control under, CRISPR is transcribed into long RNA precursors (Pre RISPR RNA, pre-crRNA), is subsequently processed into a series of
The short ripe crRNA containing conservative repetitive sequence and spacer region, finally identifies and is attached to the exogenous DNA array being complementary to
Upper performance shear action.The processing of pre-crRNA is participated in by the Cas9 in Cas families.Cas9 contains the RuvC in amino terminal
With HNH2 unique active sites in the middle part of protein, play a role in crRNA maturations and double-stranded DNA shearing.pre-
While crRNA is transcribed, with the trans-activation crRNA of its repetitive sequence complementation (Trans-activating crRNA,
TracrRNA) also transcription comes out, and Cas9 and double-stranded RNA specificity RNase III nucleases is excited to carry out pre-crRNA
Processing.After processing is ripe, crRNA, tracrRNA and Cas9 form complex, identify and be incorporated into the sequence of crRNA complementations, so
After unlock DNA double chain, form R-loop, so that crRNA and complementary strand thereof, another chain is kept free single-chain state, then
The complementary dna chain of crRNA is sheared by the HNH active sites in Cas9, RuvC active sites are sheared incomplementarity chain, are eventually introduced
DNA double chain is broken (DSB).By engineer RNA, sgRNA (the short guide to be formed with guiding function can be transformed
RNA), to guide Cas9 to cut the pinpoint target gene of DNA.
In conclusion shRNA, antisense nucleic acid, ribozyme, dominant negative mutations, CRISPR, Zinc finger nuclease are specific silence
The means of the effective means of target gene, cryptiogene are not particularly limited, and those skilled in the art can be according to specific experiment
Purpose and condition selection, shRNA, antisense nucleic acid, ribozyme, dominant negative mutations as used by the embodiment of the present invention, CRISPR or
At least one of Zinc finger nuclease realizes the specific silence of target gene.
According to an embodiment of the invention, lymphocyte cell surface or intracellular immunity checkpoint are silenced and preferably use
ShRNA is realized.SiRNA molecule entrained by ShRNA is typically the dual zone of base-pair of the length between 10 and 30.
PD1 or CTLA4 or the CBL-B siRNA of the embodiment of the present invention are designed to the volume for being derived from PD1 or CTLA4 or CBL-B mRNA
Code region, by the degradation of mRNA come inhibition of gene expression.SiRNA, which is associated with, to be referred to as inducing RNA silencing complex (RISC)
Multiplexed protein compound, positive-sense strand is by enzymatic lysis during this period.It is based on sequence homology in the RISC being activated, guides RISC
To corresponding mRNA;Identical nucleic acid cleavage targets PD1 or CTLA4 or CBL-B mRNA, generate specific gene PD1 or
CTLA4 or CBL-B silences inhibit the expression of specific gene PD1 or CTLA4 or CBL-B.SiRNA is imported carefully in the form of shRNA
(shRNA includes the nucleotide siRNA sequence of about 18-23, the nucleotide ring and a siRNA of one 9-15 length of heel to born of the same parents
The reversed supplement of sequence), the design of shRNA preferably avoids the match point in 3 ' UTR cytogenes;It ensures appropriate
Chain selects.One single siRNA molecule can be repeated the division applied to more targeting mRNA molecules.RNAi (RNA interference) can lead to
The mode for crossing introducing synthesis siRNA is induced.According to an embodiment of the invention, the shRNA of the embodiment of the present invention is constantly originated from carefully
Intracellular, therefore its effect is more lasting, to extend the shRNA periods, shRNA used in the embodiment of the present invention has efficient, special
The success of the effect on anisotropic silenced cell surface or intracellular immunity checkpoint, cell surface or intracellular immunity checkpoint is heavy
It is silent so that transgenosis lymphocyte has the significant immunosuppressive characteristic resisted tumour and mediated, in tumour patient body
Proliferation and survival ability are further enhanced, more notable to the orientation lethal effect effect of tumour.
In addition, according to an embodiment of the invention, the co-stimulators intracellular section is independently selected from 4-1BB, OX-
40, at least one of CD40L, CD27, CD30, CD28 and their derivative.The expression of co-stimulators intracellular section
There is positive regulation and enhancing cellullar immunologic response with the silence joint of cell surface or at least one intracellular immunologic test point
Effect so that transgenosis lymphocyte has the significant immunosuppressive characteristic resisted tumour and mediated, in neoplastic disease human body
Interior proliferation and survival ability is further enhanced, more aobvious to the orientation lethal effect effect of the tumour of high expression MSLN
It writes.
Other embodiment according to the present invention, the lymphocyte cell surface preferred CTLA4 or PD1 of immunologic test point,
The preferred CBL-B of immunologic test point in lymphocyte.According to an embodiment of the invention, lymphocyte cell surface immunologic test point
CTLA4 or PD1 is silenced or intracellular immunity checkpoint CBL-B is silenced so that transgenosis lymphocyte has more significantly
Resistance tumour mediate immunosuppressive characteristic, proliferation and survival ability in tumour patient body are further carried
Height, it is more notable to the orientation lethal effect effect of tumour.
According to an embodiment of the invention, the lymphocyte of the embodiment of the present invention is CD3+Lymphocyte or natural killer cells
Or natural killer T cells.CD3+Lymphocyte is total T cell, and natural killer cells is one kind of immunocyte, and non-specificity is known
Other target cell, natural killer T cells are that have T cell and the T cell subgroup of Natural Killer Cell Receptors.In above-mentioned lymphocyte
Immunologic test point is silenced and expresses Chimeric antigen receptor so that the target killing of the cellular immunity of above-mentioned lymphocyte is more
By force, more notable to the lethal effect effect of tumour cell.
Slow virus or construct
In another aspect of this invention, the present invention proposes a kind of slow virus or construct.According to an embodiment of the invention,
Slow virus or construct carry following nucleic acid molecules:The nucleic acid molecules of encoding chimeric antigen receptor, Chimeric antigen receptor have SEQ
ID NO:The nucleic acid molecules of amino acid sequence shown in 1, encoding chimeric antigen receptor have SEQ ID NO:Nucleotide shown in 2
Sequence;And the nucleic acid molecules on silenced cell surface or intracellular immunity checkpoint, the core of silenced cell surface immunologic test point
The nucleotides sequence of acid molecule is classified as selected from SEQ ID NO:At least one of 3~68, the nucleic acid of immunologic test point in silenced cell
The nucleotides sequence of molecule is classified as selected from SEQ ID NO:At least one of 69~135.Wherein, SEQ ID NO:3~14 be the mankind
Programmed death receptor 1 (PD1) siRNA nucleotide sequences, SEQ ID NO:15~30 be that human cell poison T lymphocytes are related
Antigen 4 (CTLA4) siRNA sequence, SEQ ID NO:31~46 be human T cells immunoglobulin mucoprotein molecule 3 (TIM3)
SiRNA sequence, SEQ ID NO:47~57 be human T-lymphocyte decay factor (BTLA) siRNA sequence, SEQ ID NO:58
~68 be 3 albumen of Human Lymphocytes activating gene (LAG-3) siRNA sequence, SEQ ID NO:69~85 be mankind IRAK-M
(interleukin 1 receptor associated kinase 3) siRNA nucleotide sequences, SEQ ID NO:86~96 be mankind SOCS1 (cell because
Subsignal transduction inhibiting factor 1) siRNA sequence, SEQ ID NO:97~116 be that (tumor necrosis factor-alpha induces egg to mankind A20
White A20) siRNA sequence, SEQ ID NO:117~135 be mankind CBL-B (E3 ubiquitin protein ligase CBL-B) siRNA sequences
The slow virus of the embodiment of the present invention or construct are imported the transgenosis obtained by lymphocyte by row according to an embodiment of the invention
In lymphocyte, immunologic test point PD1, CTLA4, TIM3, BTLA, LAG-3 of cell surface or intracellular immunity checkpoint
IRAK-M, SOCS1, A20, CBL-B are by specific silence and inhibit to express, while expressing the chimeric of anti-MSLN in its cell surface
Antigen receptor, to which the transgenosis lymphocyte of the embodiment of the present invention is provided with the immunosuppressive of significant resistance tumour mediation
Effect, anti-tune dies ability and proliferative capacity enhancing, orientation killing ability significantly improve, and the transgenosis lymph of the embodiment of the present invention is thin
Born of the same parents greatly improve in the internal and external proliferation of tumour patient and survival ability and the killing ability in tumour patient body, especially
It is especially pronounced to the tumor cell specific fragmentation effect of high expression MSLN.
According to ground of the invention embodiment, the slow virus of the embodiment of the present invention or construct carry and contain SEQ ID NO:136、
137, nucleotide sequence shown in 138,139,140 or 141.Wherein, SEQ ID NO:136 be the anti-MSLN chimeric antigens of coexpression
The nucleic acid molecules (MSLN-CAR/iPD1) of receptor and silenced cell immunologic test point PD-1, SEQ ID NO:137 be that coexpression is anti-
The nucleic acid molecules (MSLN-CAR/iCBL-B) of MSLN Chimeric antigen receptors and silenced cell immunologic test point CBL-B, SEQ ID
NO:138 be the nucleic acid molecules (MSLN-CAR/ for co-expressing anti-MSLN Chimeric antigen receptors and silenced cell immunologic test point CTLA4
ICTLA4), SEQ ID NO:139 be that the anti-MSLN Chimeric antigen receptors of coexpression, silenced cell immunologic test point PD1 and silence are another
The nucleic acid molecules (MSLN-CAR/iPD1-CBL-B) of one cellular immunity checkpoint CBL-B, SEQ ID NO:140 be coexpression
The nucleic acid of anti-MSLN Chimeric antigen receptors, silenced cell immunologic test point PD1 and another cellular immunity checkpoint of silence CTLA4
Molecule (MSLN-CAR/iPD1-CTLA4), SEQ ID NO:141 be that the anti-MSLN Chimeric antigen receptors of coexpression, the first silence are thin
Nucleic acid molecules (the MSLN-CAR/iPD1- of the nucleic acid molecules of born of the same parents' immunologic test point PD1 and the second silenced cell immunologic test point PD1
PD1).According to an embodiment of the invention, the transgenosis lymph obtained by the slow virus of implementation column of the present invention importing lymphocyte is thin
Born of the same parents, the immunologic test point PD1 or CTLA4 or CBL-B of cell is by specific silence and the Chimeric antigen receptor table of anti-MSLN
It reaches so that transgenosis lymphocyte has effects that ability and increasing are died in the immunosupress that significantly resistance tumour mediates, anti-tune
Grow ability enhancing, orientation killing ability significantly improve so that transgenosis lymphocyte is in tumour patient in vitro and in vivo
Proliferation and survival ability and the killing ability in tumour patient body greatly improve, especially the tumour cell to high expression MSLN
Specific killing effect it is especially pronounced.
According to an embodiment of the invention, inventor is to realize above-mentioned cell chimerism antigen receptor and table in the following way
What face or intracellular immunity checkpoint shRNA were separately expressed, wherein it should be noted that expression herein both refers to egg
White expression refers to rna transcription again.
Promoter:First promoter, the first promoter are operably connected with the nucleic acid molecules of encoding chimeric antigen receptor;
And second promoter, the second promoter are operably connected with the nucleic acid molecules of silenced cell immunologic test point.According to this hair
Bright embodiment, used first promoter, the second promoter are separately selected from U6, CMV, H1, EF-1, LTR, RSV
Promoter, the introducing of the first and second promoter so that the nucleic acid molecules and silenced cell of encoding chimeric antigen receptor are immune
The expression of the nucleic acid molecules of checkpoint independently, to effective reticence cell surface or intracellular immunity checkpoint, and
It ensure that the high efficient expression of Chimeric antigen receptor so that survival rate of the lymphocyte in tumor environment greatly improves, and lymph is thin
The targeting of born of the same parents is stronger, more notable to the specific killing action of tumour.
According to an embodiment of the invention, can also be further introduced into third promoter, third promoter independently selected from U6,
The nucleic acid minute of the immunologic test point of at least one of CMV, H1, EF-1, LTR, RSV promoter, third promoter and silenced cell
The operable connection of son, the nucleic acid molecules of the immunologic test for the silenced cell that third promoter and the second promoter are connected are not
Together, the shRNA of silence difference immunologic test point is respectively started in third promoter and the second promoter.
Pass through the introducing of above-mentioned first, second promoter or further third promoter so that cell surface is intracellular
Immunologic test point is efficiently expressed the transgenosis Lymphocyte Membrane in the embodiment of the present invention by efficient silence and Chimeric antigen receptor
On, to efficiently inhibit the immune negative regulation of immunologic test point and ensure that the biological action of Chimeric antigen receptor, to
So that survival rate of the lymphocyte in tumor environment greatly improves, the targeting killing effect of lymphocyte is more notable.
In addition, according to an embodiment of the invention, the carrier of the construct of the embodiment of the present invention is non-pathogenic virus carrier.
Non-pathogenic virus carrier substantially increases duplication and amplification efficiency of the construct in lymphocyte, and then the embodiment of the present invention
Proliferation and survival ability of the lymphocyte in tumour patient body greatly improve, the targeting of lymphocyte further increases
By force, more notable to the lethal effect of tumour cell.
According to an embodiment of the invention, the viral vectors of the construct of the embodiment of the present invention be selected from retrovirus vector,
At least one of slow virus carrier, adenovirus vector or adenoassociated virus carrier.According to an embodiment of the invention, of the invention
The carrier of the virus of embodiment is in virus packaging and course of infection, and virus-infected area is extensive, and it is thin both to have infected terminal differentiation
Born of the same parents, and the cell in division stage can be infected, it can be not only integrated into host chromosome, but also can be free in except host chromosome, it is real
Existing wide spectrum and efficient efficiency of infection, to which cell surface or intracellular immunity checkpoint are by efficient silence and Chimeric antigen receptor
The high efficient expression in lymphocyte, the proliferation in tumour patient body and survival ability of the lymphocyte of the embodiment of the present invention are big
Big to improve, the targeting of lymphocyte further enhances, more notable to the lethal effect of tumour cell.
According to a particular embodiment of the invention, for building a slow virus carrier, inventor is slow in order to build one
Purpose nucleic acid is inserted into viral genome by viral vectors in the position of certain virus sequences, to generate replication defective
Virus.In order to generate virion, it (comprising gag, pol and env genes, but does not include LTR that inventor builds package cell line in turn
With packaging ingredient).Recombinant plasmid containing target gene is concomitantly introduced into packet by inventor together with slow virus LTR and packaging sequence
It fills in cell line.Packaging sequence allows recombinant plasmid rna transcription product to be wrapped into virion, is then secreted into culture
In base.And then inventor collects the matrix for including recombinant slow virus, selectively concentrates, and it is used for gene transfer.Slow carrier
Various kinds of cell type can be infected, including can dividing cell and can not dividing cell.
In addition, according to an embodiment of the invention, the slow virus of the embodiment of the present invention is compound slow virus, in addition to common slow
Viral gene gag, pol and env also include other genes of regulation and control and structure function.Slow virus carrier is art technology
Known to personnel, slow virus includes:Human immunodeficiency virus HIV -1, HIV -2 and simian immunodeficiency virus SIV.Slow disease
Poisonous carrier is generated by Multiple decrements AIDS virus Disease-causing gene, such as all deletes gene env, vif, vpr, vpu and nef,
Slow virus carrier is set to form biological safe type carrier.Recombined lentivirus vector can infect non-dividing cell, while can be used for body
The transfer of interior and outer-gene and nucleic acid sequence expression.Such as:In suitable host cell, and with packaging function (gag,
Pol, env, rev and tat) two or more carriers together, non-dividing cell can be infected.The targeting of recombinant virus,
It is to be realized by antibody or particular ligand (targeting particular cell types receptor) and the combination of memebrane protein.Meanwhile recombinating disease
The targeting of poison is encoded specific by being inserted into an ordered sequence (including regulatory region) to viral vectors together with another
The gene of the ligand of receptor on target cell makes carrier be provided with specific targeting.Various useful slow virus carriers, and it is each
The carrier of the generations such as kind method and operation, for changing the expression of cell.According to an embodiment of the invention, the embodiment of the present invention
Slow virus carrier effectively can transport and co-express shRNA (transport form of siRNA), the small shRNA can effectively inhibit PD1 or
The expression of CTLA4 or CBL-B.
According to an embodiment of the invention, the gland association viral vectors (AAV) of the embodiment of the present invention can be used one or more
The DNA structures of known serum type gland association viral vectors.Those skilled in the art build a suitable gland association
Viral vectors carries with this and co-expresses children purpura nephritis, which can inhibit PD1 or CTLA4 or CBL-B genes
Expression.
In addition, according to an embodiment of the invention, the embodiment of the present invention also includes micro- gene.Micro- gene means with combination
(selected nucleotide sequence and operable necessary relevant connection sequence) come instruct conversion, transcription and/or gene outcome exist
Expression in vivo or in vitro host cell.It is controlled using the expression that " operable connection " sequence includes continuous target gene
Sequence, and act on trans- or far distance controlled target gene expression control sequence.
In addition, the carrier of the embodiment of the present invention further includes conventional control element, in the cell transfecting with plasmid vector together
Or/and in the cell infection of viral vectors together, these elements allow transcription, conversion and/or the expression of children purpura nephritis.Largely
Expression control sequence (including natural, can induce and/or promoter of specific organization) be likely to be used.It is according to the present invention
Embodiment, the promoter for expressing shRNA are RNA polymerase promoter.Meanwhile according to an embodiment of the invention, promoter is choosing
From U6, H1, the RAN polymerase promoters of pol I, pol II and pol III.According to an embodiment of the invention, promoter is
Tissue-specific promoter.According to an embodiment of the invention, promoter is inducible promoter.According to an embodiment of the invention,
Promoter is selected from the promoter based on selected carrier.According to an embodiment of the invention, when selecting slow virus carrier, promoter
For U6, H1, CMV IE genes, EF-1 α, ubiquitin C or phosphoglycerokinase (PGK) promoter.Other conventional expression control sequences
Including optional label or reporter gene, including encoding geneticin, hygromycin, ampicillin or Puromycine resistance etc.
Nucleotide sequence.The other assemblies of carrier include replication orgin.
What the technology of carrier construction was well known to those skilled in the art, these technologies include conventional cloning techniques, such as
Nucleotide sequence needed for used shRNA, polymerase chain reaction and any offer appropriate in embodiments of the present invention
Method.
According to an embodiment of the invention, inventor constructs coexpression children purpura nephritis (shRNA) (for inhibiting immune inspection
Make an inventory of) and Chimeric antigen receptor (CAR) viral vectors.The transport silence PD1 or CTLA4 or CBL-B of the embodiment of the present invention
SiRNA children purpura nephritis and expression Chimeric antigen receptor (CAR) viral vectors or plasmid be it is compound, this virus carry
Body or plasmid increase its stability in combination with polymer or other materials, or assist its targeting movement.
The method of prepare transgenosis lymphocyte
In another aspect of this invention, the present invention, which proposes, a kind of preparing foregoing T lymphocytes or transgenosis
The method of lymphocyte.According to an embodiment of the invention, this method includes:By foregoing construct or foregoing
Slow virus is introduced into lymphocyte or T lymphocytes.Incorporation way can be selected from electricity turn or virus infects host cell
Mode introduces.The construct of the embodiment of the present invention or slow virus are successfully introduced into above-mentioned lymphocyte or T lymphocytes, realize
The expression of Chimeric antigen receptor and the cell surface of lymphocyte or intracellular immunity checkpoint for antigen MSLN are sunk
It is silent, so that gained lymphocyte or T lymphocytes have effects that significantly to resist the immunosupress that tumour mediates, swollen
Tumor is greatly improved with survival ability in external proliferation and tumour patient body in patient body, and lymphocyte or T lymphocytes are to swollen
Oncocyte, it is especially stronger to the targeting killing effect of the tumour cell of high expression MSLN.
The therapeutic combination for the treatment of cancer
In another aspect of this invention, of the invention to propose a kind of therapeutic combination for treating cancer.According to this
The embodiment of invention, the therapeutic combination include:Above-mentioned construct, above-mentioned slow virus, above-mentioned T lymphocytes above-mentioned turn base
Because of lymphocyte.The composition of any one of the above therapeutic combination can be achieved turning base for antigen MSLN Chimeric antigen receptors
Because in lymphocyte or T lymphocytes high efficient expression and transgenosis lymphocyte or T lymphocyte cells surface or intracellular
The silence of immunologic test point, so that gained transgenosis lymphocyte or T lymphocytes expand, in vitro in neoplastic disease human body
Survival ability greatly improves in interior proliferation and tumour patient body, and transgenosis lymphocyte or T lymphocytes express MSLN to height
Tumour cell targeting killing effect it is stronger.
According to an embodiment of the invention, it is supplied to the therapeutic combination of the embodiment of the present invention of patient, is preferably applied to
Bio-compatible solution or acceptable pharmacy delivery vehicle.Various therapeutic combinations as preparation are suspended or are dissolved in medicine
Upper or physiologically acceptable carrier, such as physiological saline;Isotonic salting liquid or other people's being proficient in the knowledge of is obvious
In formula.Carrier appropriate depends greatly on administration route.Other have water and anhydrous isotonic sterile injection liquid and
There are water and anhydrous sterile suspensions, is pharmaceutically acceptable carrier.
According to an embodiment of the invention, sufficient amount of viral vectors is transduceed in targeting T-cells, and is provided sufficiently strong
The transgenosis of degree, silence PD1 or CTLA4 or CBL-B and the distinctive anti-MSLN Chimeric antigen receptors of expression.The dosage of therapeutic reagent
Depend primarily on treatment situation, age, weight, the health degree of patient, so as to cause the variability of patient.
Silence PD1 or CTLA4 or CBL-B and distinctive these methods for antigen MSLN Chimeric antigen receptors of expression
It is a part for combination therapy.These viral vectors and antitumor T cell for adoptive immunotherapy, can be by individually or knot
The method for closing other treatment cancer executes together.Under suitable conditions, therapy includes using one or more
Medicinal treatment.
According to an embodiment of the invention, the cancer includes being selected from celiothelioma, cancer of pancreas, oophoroma, cholangiocarcinoma, lung cancer,
Gastric cancer, intestinal cancer, at least one of the cancer of the esophagus and breast cancer.Following biological effect:The silence of cellular immunity checkpoint, joint are chimeric
High efficient expression of the antigen receptor in transgenosis lymphocyte or T lymphocytes so that gained lymphocyte or T lymphocytes exist
Survival ability in the microenvironment of above-mentioned tumour greatly improves, the target killing of lymphocyte or T lymphocytes to tumour cell
Act on it is stronger, it is especially more notable to the lethal effect of the above-mentioned tumour cell of high expression MSLN.
The method for improving lymphocyte activity
In another aspect of this invention, the present invention proposes a kind of method improving lymphocyte activity, and the present invention is implemented
The lymphocyte of example carries Chimeric antigen receptor, and according to an embodiment of the invention, this method includes:Make the thin of the lymphocyte
Born of the same parents' immunologic test point is silenced, and cellular immunity checkpoint, lymphocyte, Chimeric antigen receptor are as defined above.According to this
The lymphocyte activity of the embodiment of invention, the embodiment of the present invention includes Lymphocyte Proliferation in Vitro ability, in neoplastic disease human body
At least one of killing ability of the interior proliferation and survival ability and lymphocyte in tumour patient body.It is according to the present invention
The cellular immunity checkpoint of embodiment, the lymphocyte of the embodiment of the present invention is silenced, and lymphocyte is activated, productive reaction
Up-regulation, cytokine secretion increase, anti-tune dies ability enhancing.The lymphocyte of the embodiment of the present invention expands and be proliferated in vitro,
The targeting killing effect of tumour cell is significantly increased.
The solution of the present invention is explained below in conjunction with embodiment.
It will be understood to those of skill in the art that the following examples are merely to illustrate the present invention, and it should not be regarded as limiting this
The range of invention.Particular technique or condition are not specified in embodiment, according to technology or item described in document in the art
Part (such as with reference to works such as J. Pehanorm Brookers, what Huang Peitang etc. was translated《Molecular Cloning:A Laboratory guide》, the third edition, Science Press)
Or it is carried out according to product description.Reagents or instruments used without specified manufacturer, being can be by acquisition purchased in market
Conventional products.
Embodiment 1
Used cell line and basic experiment technology are as described below in the embodiment of the present invention:
The generation of slow virus and the transduction of human T lymphocyte
The slow virus carrier of replication defective is generated, and the transduction for human T lymphocyte is collected by centrifugation in slow virus carrier.
The experimentation of generation, the collection of slow virus carrier is briefly described below:It is 150- squares li that 293T cells, which are layered on floor space,
In the Tissue Culture Dish of rice, and according to specification, (Open Biosystems/Thermo are purchased from using Express-In
Scientific, Waltham, MA) viral transduction is carried out to 293T cells.Often the slow virus transgenosis of 15 micrograms is added in disk cell
PCMVR8.74 plasmids (the Gag/Pol/Tat/Rev tables of plasmid, the pVSV-G (VSV P-glycoprotein expressions plasmid) of 5 micrograms, 10 micrograms
Up to plasmid) and 174 microlitres of Express-In (a concentration of 1 microgram/microlitre).Supernatant was collected respectively at 24 hours and 48 hours,
And using ultracentrifuge 28,000rpm (centrifuge rotor be Beckman SW 32Ti, be purchased from Beckman Coulter,
Brea, CA) under conditions of centrifuge 2 hours.Weight finally is carried out to virus particle precipitation with the RPMI-1640 culture mediums of 0.75ml
It is outstanding.
The primary T lymphocytes of people are detached from healthy volunteer's donor.Human T lymphocyte's culture is cultivated in RPMI-1640
It is stimulated in base and using the coated pearl of monoclonal antibody (being purchased from Invitrogen, Carlsbad, CA) of AntiCD3 McAb and CD28
Activation.It 18~24 hours after human T lymphocyte's activation, is transduceed, is turned to T lymphocytes using the method for spin-inoculation
It is as described below to lead process:In 24- orifice plates, 0.5 × 10 is covered with per hole6T lymphocytes are added 0.75ml's into every hole cell
The viral supernatants and Polybrene (a concentration of 8 micrograms/ml) of above-mentioned resuspension.The mixed liquor of cell and virus particle it is desk-top from
Scheming (is purchased from Sorvall ST 40;Thermo Scientific) in centrifugation, centrifugal condition is room temperature, 2500rpm, and the time is
90 minutes.People's recombination leukocyte mesonium-2 (IL-2;Purchased from Novartis, Basel, Switzerland) every 2~3 days addition T
In lymphocyte culture medium, the final concentration of 100-IU/ml of IL-2 keeps the density of cell in T lymphocyte incubations
It is 0.5 × 106~1 × 106/ml.Once suspend mode occur in the T lymphocytes transduceed, such as vitro growth rates are slack-off and cell
Become smaller, wherein vitro growth rates and size be by Coulter Counter (being purchased from Beckman Coulter) assessment,
Or the T lymphocytes transduceed, on the time point that some is planned, T lymphocytes can be used to do work and can analyze.
Flow cytometer used in embodiments herein is that BD FACSCanto II (are purchased from BD
Biosciences), and flow cytometric analysis data using FlowJo version 7.2.5 softwares (be purchased from Tree Star,
Ashland, OR) it is analyzed.
Measure the secretion of cell factor
2-7 days after plasmid transduction, (number of cells was 1 for non-transduction or the T cell of Chimeric antigen receptor plasmid of having transduceed
×106/ hole) and people's pleural mesothelium oncocyte, human pleural mesothelioma cells (coming from ATCC) co-cultivation,
Change different effect target rations in experimentation.Using specific enzyme-linked immunosorbent assay, (cell factor is enzyme-linked to be exempted from
Epidemic disease adsorb test agent box, be purchased from R&D Systems, Inc., Minneapolis, MN, USA) detection cell supernatant in cell because
The yield of son.Above-mentioned cell supernatant is derived from the supernatant for having cultivated the cell after 24 hours, 48 hours and 72 hours, measures knot
Fruit is used for weighing the yield of representational cell factor (interferon-γ) (IFN γ).
Brief continuous mode is as follows:The cell factor as series of standards control in 100 microlitres/hole is added in ELISA Plate
Dilute solution (such as IFN γ) or cell conditioned medium solution to be measured, and ELISA Plate is placed at room temperature 2 hours.It is inhaled after 2 hours and abandons enzyme
Solution and the washing lotion rinse ELISA Plate with 400 microlitres, rinse four times in target.After rinse, 200 are added into each hole of ELISA Plate
Microlitre enzyme-linked anti-cytokine antibodies.Continue to place 2 hours at room temperature, it is backward per hole in 200 microlitres of bottom is added
Object solution.After substrate solution is added, ELISA Plate is placed at room temperature 30 minutes, later, 50 microlitres of end is added into every hole
Only reaction solution.Optical density of the ELISA Plate per hole is measured in 30 minutes.Microplate reader is arranged in 450nm.
Chromium release experiment
In embodiment anti-MSLN Chimeric antigen receptors T cell (anti-MSLN is assessed using the analysis of 4-hours, 51 chromium method for releasing
CAR T lymphocytes) cytotoxic activity.It is as follows:The label 1 under 37 degrees Celsius is small with 51Cr for target detection cell
When.After label, with the RPMI culture medium rinse cells containing 10% fetal calf serum (FCS).After rinse, cell is resuspended in identical
Culture medium in, the concentration that cell is resuspended is 1 × 105/ml.T cell is with different target effect cell ratio (T after transduction:E it) is added
It it is 200 microlitres per pore volume in target detection cell suspending liquid, and by cell kind in the holes 96-.By cell in 37 degree of incubators
Middle culture 4 hours.After 4 hours, 30 microlitres of supernatant is taken out from every hole be put in the 96- microwell plates of counter and count point
Analysis.Analytical instrument is the micro- scintillation counters of top counting NXT (being purchased from Packard Bioscience).Effect in all counting holes
The number of cell is calculated based on T cell sum.Labeled target detection cell is MSLN+MSTO-211H (people's pleuras
Mesothelioma cell, human pleural mesothelioma cells (coming from ATCC)).
The carrier of the structure coexpression of embodiment 2 silenced cell immunologic test point shRNA and anti-MSLN Chimeric antigen receptors
In the present embodiment, coding is had sequence, 4-1BB intracellulars section and the T cell of the single-chain antibody of anti-human MSLN by inventor
ζ-chain-ordering of receptor combination is cloned on the slow virus carrier containing EF-1 promoters (lentiviral vector), clone
In the process, the restricted digestion of selection is XbaI and NotI double digestions and NotI and XhoI double digestions, by digestion, connection,
The amplification of screening and purpose plasmid generates the slow virus plasmid (LV-MSLN CAR) for expressing anti-MSLN Chimeric antigen receptors.Including
The sequence quilt of U6 promoters and people PD1 shRNA (iPD1) or CBL-B shRNA (iCBL-B) or CTLA4 shRNA (iCTLA4)
It clones into LV-MSLN CAR vector plasmids, is built into LV-MSLN CAR/iPD1 or LV-MSLN CAR/iCBL or LV-MSLN
CAR/i CTLA4.Fig. 1 is the schematic diagram of slow virus carrier, includes the sequence of the anti-MSLN Chimeric antigen receptors of coding, U6 or H1 are opened
Promoter sequences, PD1 shRNA or CBL-B shRNA or CTLA4 shRNA sequences.The sequence of anti-MSLN Chimeric antigen receptors is opening
Under the startup regulation and control of mover EF-1, CTLA4, PD1 CBL-B shRNA sequences are under the startup regulation and control of promoter U6 or H1.
Embodiment 3, which co-expresses PD1 shRNA and the T lymphocytes of anti-MSLN Chimeric antigen receptors, has ability of cell proliferation
The characteristics of higher
In the present embodiment, peripheral blood lymphocytes is derived from blank blood donor.Peripheral blood lymphocytes by gradient from
The heart is detached, Gradient Centrifuge Ficoll-Hypaque.It (is purchased from T lymphocyte activating factor magnetic beads CD3/CD28
Invitrogen, Carlsbad, CA) in the presence of, the T lymphocytes being activated are by slow virus carrier transduction, amplification in vitro training
It supports, method is as described in Example 1.2-7 days after slow virus carrier transduction, (number of cells was 1 × 10 to the T cell of transduction6/
Hole) and MSLN+MSTO-211H is co-cultured, and after 4 days, is detected by streaming instrument before cell number.Experimental result is as shown in Figure 2.Fig. 2
The result shows that T of the T lymphocytes for the LV-MSLN CAR/iPD1 that transduceed than transduceed LV-MSLN CAR or zero load LV-GFP
The cell number of lymphocyte dramatically increases.Mark represents the average value ± SD in every 3 holes.(P<0.05;LV-MSLN CAR/
iPD1vs.LV-MSLN CAR).
Embodiment 4, which co-expresses PD1 shRNA and the T lymphocytes of anti-MSLN Chimeric antigen receptors, has cytokine secretion
More features
In the presence of T lymphocyte activating factor magnetic bead CD3/CD28, the T lymphocytes being activated pass through slow virus carrier
Transduction, amplification in vitro culture, method are as described in Example 1.2-7 days after slow virus carrier transduction, the T cell of transduction was (thin
Born of the same parents' number is 1 × 106/ hole) and MSLN+MSTO-211H cells co-culture, and after 4 days, point of cell factor is detected by ELISA
It secretes.Experimental result is as shown in Figure 3.Fig. 3 the result shows that, the T lymphocyte ratios of the LV-MSLN CAR/iPD1 that transduceed have been transduceed LV-
More IFN γ (the P of T lymphocytic emiocytosis of MSLN CAR or zero load LV-GFP<0.05;LV-MSLN CAR/iPD1 vs.LV-
MSLN CAR).T lymphocyte of the T lymphocytes of this LV-MSLN CAR/iPD1 that illustrate to have transduceed than the LV-MSLN CAR that transduce
Generation Cytokines significantly improve.
Embodiment 5 co-expresses the T lymphocytic tumours cytolytic abilities of PD1 shRNA and anti-MSLN Chimeric antigen receptors
Enhancing.
In the present embodiment, peripheral blood lymphocytes is derived from blank blood donor.Peripheral blood lymphocytes by gradient from
The heart is detached, Gradient Centrifuge Ficoll-Hypaque.T lymphocytes and t cell activation factor magnetic bead CD3/CD28 (purchases
From Invitrogen, Carlsbad, CA) in 5%CO2, be incubated culture 72 hours under 37 degrees Celsius, culture medium is added with 2mmol/
L glutamine, the mould of fetal calf serum (FCS) (being purchased from Sigma-Aldrich Co.) and 100U/ml of 10% high-temperature inactivation
The dual anti-RPMI culture mediums 1640 of element/streptomysin (are purchased from Invitrogen Gibco Cat.no.12633-012).Activation culture
After 72 hours, with washing lotion rinse cell, magnetic bead is washed away.T cell kind is being covered with recombination fibronectin fragment (FNch-296;
Retronectin) on Tissue Culture Dish, lentiviruses transduction is used in combination, transduction slow virus is respectively LV-MSLN CAR/iPD1, LV-
MSLN CAR or zero load (LV-GFP) transductive process are as described in Example 1.T cell culture after transduction is cultivated in RPMI-1640
In base and with the recombinant human IL-2 factors (100ng/ml;Purchased from R&D Systems) carry out induced amplification 7-10 days, then carry out
Functional test is tested.Inventor's measurement transduceed different slow virus T cell (effector cell) to MSLN+MSTO-211H targets are thin
The lethal effect of born of the same parents, it is 1 that target, which imitates cell proportion,:25 or 1:5, measurement method uses 4-hour of standard51Chromium method for releasing, 4-hours51
Chromium method for releasing is as described in Example 1.The results are shown in Figure 4.As shown in figure 4, co-expressing anti-MSLN Chimeric antigen receptors and PD1
The T lymphocytes of the T lymphocytes MSLN Chimeric antigen receptors more anti-than single expression of shRNA (iPD1), more efficiently can be killed
Dead MSLN+MSTO-211H target cells.The T lymphocytes (control LV-GFP T lymphocytes) of unloaded lentiviruses transduction are to MSLN+
MSTO-211H cells are without apparent lethal effect.Statistical data represents the average value ± SEM in three holes.
Embodiment 6 co-expresses the T cell of CBL-B shRNA and anti-MSLN Chimeric antigen receptors, coexpression CTLA4 shRNA
With the T cell of anti-MSLN Chimeric antigen receptors, PD1 shRNA, CBL-B shRNA and anti-MSLN Chimeric antigen receptors are co-expressed
T cell, co-expresses the cell of the T cell of PD1 shRNA, CTLA4 shRNA and anti-MSLN Chimeric antigen receptors, and solvability increases
By force and have the characteristics that cytokine secretion is more and cell Proliferation is stronger.
In the present embodiment, inventor has also investigated coexpression CBL-B shRNA and the T of anti-MSLN Chimeric antigen receptors is thin
Born of the same parents, the T cell for co-expressing CTLA4 shRNA and anti-MSLN Chimeric antigen receptors, co-express 2 shRNA (PD1 shRNA and
CBL-B shRNA or PD1 shRNA and CTLA4 shRNA or 2 PD1 shRNAs for the different regions PD1) and anti-MSLN
Tumor lysis ability, cytokine secretion ability and the ability of cell proliferation of the T cell of Chimeric antigen receptor.Experimentation and reality
It is identical to apply example 3,4 and 5.The cytolytic ability of the T cell of above-mentioned T cell MSLN Chimeric antigen receptors more anti-than single expression increases
By force, cytokine secretion is more and cell Proliferation is stronger.Co-express 2 shRNA (PD1 shRNA and CTLA4 shRNA or PD1
ShRNA and CBL-B shRNA or 2 PD1 shRNAs for the different regions PD1) and the T of anti-MSLN Chimeric antigen receptors it is thin
Born of the same parents are than 1 shRNA (PD1 shRNA or CBL-B shRNA or CTLA4 shRNA) of coexpression and anti-MSLN Chimeric antigen receptors
The cytolytic ability of T cell is stronger, and cytokine secretion is more and cell Proliferation is stronger.
In the description of this specification, reference term " one embodiment ", " some embodiments ", " example ", " specifically show
The description of example " or " some examples " etc. means specific features, structure, material or spy described in conjunction with this embodiment or example
Point is included at least one embodiment or example of the invention.In the present specification, schematic expression of the above terms are not
It must be directed to identical embodiment or example.Moreover, particular features, structures, materials, or characteristics described can be in office
It can be combined in any suitable manner in one or more embodiments or example.In addition, without conflicting with each other, the skill of this field
Art personnel can tie the feature of different embodiments or examples described in this specification and different embodiments or examples
It closes and combines.
Although the embodiments of the present invention has been shown and described above, it is to be understood that above-described embodiment is example
Property, it is not considered as limiting the invention, those skilled in the art within the scope of the invention can be to above-mentioned
Embodiment is changed, changes, replacing and modification.
SEQUENCE LISTING
<110>Beijing horsepower bio tech ltd
<120>It co-expresses anti-MSLN Chimeric antigen receptors and immunologic test point inhibits molecule
<130> PIDC1153486
<160> 141
<170> PatentIn version 3.3
<210> 1
<211> 507
<212> PRT
<213> Artificial
<220>
<223>The amino acid sequence of Chimeric antigen receptor
<400> 1
Met Val Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro
1 5 10 15
Ala Phe Leu Leu Ile Pro Asp Ile Gln Ala Gln Val Gln Leu Val Gln
20 25 30
Ser Gly Ala Glu Val Lys Arg Pro Gly Ala Ser Val Gln Val Ser Cys
35 40 45
Arg Ala Ser Gly Tyr Ser Ile Asn Thr Tyr Tyr Met Gln Trp Val Arg
50 55 60
Gln Ala Pro Gly Ala Gly Leu Glu Trp Met Gly Val Ile Asn Pro Ser
65 70 75 80
Gly Val Thr Ser Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Leu Thr
85 90 95
Asn Asp Thr Ser Thr Asn Thr Val Tyr Met Gln Leu Asn Ser Leu Thr
100 105 110
Ser Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Trp Ala Leu Trp Gly
115 120 125
Asp Phe Gly Met Asp Val Trp Gly Lys Gly Thr Leu Val Thr Val Ser
130 135 140
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
145 150 155 160
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Ile Gly
165 170 175
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu Gly Ile Tyr His Trp
180 185 190
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
195 200 205
Tyr Lys Ala Ser Ser Leu Ala Ser Gly Ala Pro Ser Arg Phe Ser Gly
210 215 220
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
225 230 235 240
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Asn Tyr Pro Leu
245 250 255
Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Ser Phe Val
260 265 270
Pro Val Phe Leu Pro Ala Lys Pro Thr Thr Thr Pro Ala Pro Arg Pro
275 280 285
Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro
290 295 300
Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu
305 310 315 320
Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys
325 330 335
Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Asn His Arg
340 345 350
Asn Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe
355 360 365
Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg
370 375 380
Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser
385 390 395 400
Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr
405 410 415
Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys
420 425 430
Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn
435 440 445
Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu
450 455 460
Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly
465 470 475 480
His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr
485 490 495
Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
500 505
<210> 2
<211> 1524
<212> DNA
<213> Artificial
<220>
<223>The nucleotide sequence of the nucleic acid molecules of encoding chimeric antigen receptor
<400> 2
atggttctgc tggtgacatc tctcctgctc tgtgaactgc ctcatcccgc ttttctgctc 60
attcccgaca ttcaggctca agtccaactg gtccaaagtg gtgctgaagt caaacgcccg 120
ggtgcctccg tccaagtctc ctgccgtgcc tctggctact cgattaacac ctattacatg 180
cagtgggtcc gtcaagcacc gggtgcaggt ctggaatgga tgggtgtcat caatccgtcc 240
ggcgtgacct catatgcgca gaaatttcaa ggtcgcgtta ccctgacgaa cgataccagc 300
acgaataccg tctacatgca gctgaactct ctgacgagtg cagacaccgc ggtgtattac 360
tgcgcacgtt gggcactgtg gggcgatttc ggcatggatg tttggggcaa aggtacgctg 420
gtgaccgtta gctctggtgg tggtggttct ggtggtggtg gtagtggcgg tggcggttct 480
gatattcaga tgacgcaaag cccgtctacc ctgagtgcct ccattggtga ccgtgttacg 540
atcacctgtc gcgcatccga aggcatctat cattggctgg cttggtacca gcaaaaaccg 600
ggtaaagcgc cgaaactgct gatctataaa gcaagttccc tggcatcggg tgctccgagc 660
cgcttttcag gttcgggtag cggcaccgat ttcacgctga ccatctcatc gctgcagccg 720
gacgatttcg ctacctacta ctgccaacaa tactcaaact acccgctgac cttcggtgga 780
gggaccaagc tggagatcaa acgtgctagc ttcgtgccgg tcttcctgcc agcgaagccc 840
accacgacgc cagcgccgcg accaccaaca ccggcgccca ccatcgcgtc gcagcccctg 900
tccctgcgcc cagaggcgtg ccggccagcg gcggggggcg cagtgcacac gagggggctg 960
gacttcgcct gtgatatcta catctgggcg cccttggccg ggacttgtgg ggtccttctc 1020
ctgtcactgg ttatcaccct ttactgcaac cacaggaaca aacggggcag aaagaaactc 1080
ctgtatatat tcaaacaacc atttatgaga ccagtacaaa ctactcaaga ggaagatggc 1140
tgtagctgcc gatttccaga agaagaagaa ggaggatgtg aactgagagt gaagttcagc 1200
aggagcgcag acgcccccgc gtaccagcag ggccagaacc agctctataa cgagctcaat 1260
ctaggacgaa gagaggagta cgatgttttg gacaagagac gtggccggga ccctgagatg 1320
gggggaaagc cgagaaggaa gaaccctcag gaaggcctgt acaatgaact gcagaaagat 1380
aagatggcgg aggcctacag tgagattggg atgaaaggcg agcgccggag gggcaagggg 1440
cacgatggcc tttaccaggg tctcagtaca gccaccaagg acacctacga cgcccttcac 1500
atgcaggccc tgccccctcg ctaa 1524
<210> 3
<211> 21
<212> DNA
<213> Artificial
<220>
<223>Mankind's programmed death receptor 1(PD1)SiRNA nucleotide sequences
<400> 3
ggccaggatg gttcttagac t 21
<210> 4
<211> 21
<212> DNA
<213> Artificial
<220>
<223>Mankind's programmed death receptor 1(PD1)SiRNA nucleotide sequences
<400> 4
ggatttccag tggcgagaga a 21
<210> 5
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Mankind's programmed death receptor 1(PD1)SiRNA nucleotide sequences
<400> 5
gccuguguuc ucuguggacu aug 23
<210> 6
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Mankind's programmed death receptor 1(PD1)SiRNA nucleotide sequences
<400> 6
ggugcugcua gucugggucc ugg 23
<210> 7
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Mankind's programmed death receptor 1(PD1)SiRNA nucleotide sequences
<400> 7
gacagagaga agggcagaag ugc 23
<210> 8
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Mankind's programmed death receptor 1(PD1)SiRNA nucleotide sequences
<400> 8
cagcuucucc aacacaucgg aga 23
<210> 9
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Mankind's programmed death receptor 1(PD1)SiRNA nucleotide sequences
<400> 9
ccgugucaca caacugccca acg 23
<210> 10
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Mankind's programmed death receptor 1(PD1)SiRNA nucleotide sequences
<400> 10
uaugccacca uugucuuucc uag 23
<210> 11
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Mankind's programmed death receptor 1(PD1)SiRNA nucleotide sequences
<400> 11
ugcuaaacug guaccgcaug agc 23
<210> 12
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Mankind's programmed death receptor 1(PD1)SiRNA nucleotide sequences
<400> 12
gugacagaga gaagggcaga agu 23
<210> 13
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Mankind's programmed death receptor 1(PD1)SiRNA nucleotide sequences
<400> 13
cugaggaugg acacugcucu ugg 23
<210> 14
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Mankind's programmed death receptor 1(PD1)SiRNA nucleotide sequences
<400> 14
aucggagagc uucgugcuaa acu 23
<210> 15
<211> 21
<212> DNA
<213> Artificial
<220>
<223>Human cell's poison T lymphocyte-associated antigen 4s(CTLA4)SiRNA sequence
<400> 15
ggcaacggaa cccagattta t 21
<210> 16
<211> 21
<212> DNA
<213> Artificial
<220>
<223>Human cell's poison T lymphocyte-associated antigen 4s(CTLA4)SiRNA sequence
<400> 16
ggaacccaaa ttacgtgtac t 21
<210> 17
<211> 21
<212> DNA
<213> Artificial
<220>
<223>Human cell's poison T lymphocyte-associated antigen 4s(CTLA4)SiRNA sequence
<400> 17
gaacccaaat tacgtgtact a 21
<210> 18
<211> 21
<212> DNA
<213> Artificial
<220>
<223>Human cell's poison T lymphocyte-associated antigen 4s(CTLA4)SiRNA sequence
<400> 18
gggagaagac tatattgtac a 21
<210> 19
<211> 21
<212> DNA
<213> Artificial
<220>
<223>Human cell's poison T lymphocyte-associated antigen 4s(CTLA4)SiRNA sequence
<400> 19
gacgtttata gccgaaatga t 21
<210> 20
<211> 21
<212> DNA
<213> Artificial
<220>
<223>Human cell's poison T lymphocyte-associated antigen 4s(CTLA4)SiRNA sequence
<400> 20
gacactaata caccaggtag a 21
<210> 21
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Human cell's poison T lymphocyte-associated antigen 4s(CTLA4)SiRNA sequence
<400> 21
accucacuau ccaaggacug agg 23
<210> 22
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Human cell's poison T lymphocyte-associated antigen 4s(CTLA4)SiRNA sequence
<400> 22
augaguugac cuuccuagau gau 23
<210> 23
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Human cell's poison T lymphocyte-associated antigen 4s(CTLA4)SiRNA sequence
<400> 23
ggggaaugag uugaccuucc uag 23
<210> 24
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Human cell's poison T lymphocyte-associated antigen 4s(CTLA4)SiRNA sequence
<400> 24
cucuggaucc uugcagcagu uag 23
<210> 25
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Human cell's poison T lymphocyte-associated antigen 4s(CTLA4)SiRNA sequence
<400> 25
cuccucugga uccuugcagc agu 23
<210> 26
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Human cell's poison T lymphocyte-associated antigen 4s(CTLA4)SiRNA sequence
<400> 26
uuugugugug aguaugcauc ucc 23
<210> 27
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Human cell's poison T lymphocyte-associated antigen 4s(CTLA4)SiRNA sequence
<400> 27
caccuccagu ggaaaucaag uga 23
<210> 28
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Human cell's poison T lymphocyte-associated antigen 4s(CTLA4)SiRNA sequence
<400> 28
cacgggacuc uacaucugca agg 23
<210> 29
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Human cell's poison T lymphocyte-associated antigen 4s(CTLA4)SiRNA sequence
<400> 29
uucugacuuc cuccucugga ucc 23
<210> 30
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Human cell's poison T lymphocyte-associated antigen 4s(CTLA4)SiRNA sequence
<400> 30
aagucugugc ggcaaccuac aug 23
<210> 31
<211> 21
<212> DNA
<213> Artificial
<220>
<223>Human T cells immunoglobulin mucoprotein molecule 3(TIM3 )SiRNA sequence
<400> 31
ggtcggtcag aatgcctatc t 21
<210> 32
<211> 21
<212> DNA
<213> Artificial
<220>
<223>Human T cells immunoglobulin mucoprotein molecule 3(TIM3 )SiRNA sequence
<400> 32
gccaatgact tacgggactc t 21
<210> 33
<211> 21
<212> DNA
<213> Artificial
<220>
<223>Human T cells immunoglobulin mucoprotein molecule 3(TIM3 )SiRNA sequence
<400> 33
gcagagggaa ttcgctcaga a 21
<210> 34
<211> 21
<212> DNA
<213> Artificial
<220>
<223>Human T cells immunoglobulin mucoprotein molecule 3(TIM3 )SiRNA sequence
<400> 34
ggaaattcgg gcacatcata t 21
<210> 35
<211> 21
<212> DNA
<213> Artificial
<220>
<223>Human T cells immunoglobulin mucoprotein molecule 3(TIM3 )SiRNA sequence
<400> 35
gattaagaga tgactggact a 21
<210> 36
<211> 21
<212> DNA
<213> Artificial
<220>
<223>Human T cells immunoglobulin mucoprotein molecule 3(TIM3 )SiRNA sequence
<400> 36
gagatgactg gactaggtct a 21
<210> 37
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Human T cells immunoglobulin mucoprotein molecule 3(TIM3 )SiRNA sequence
<400> 37
aggaaauucg ggcacaucau aug 23
<210> 38
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Human T cells immunoglobulin mucoprotein molecule 3(TIM3 )SiRNA sequence
<400> 38
gacugaugaa agggauguga auu 23
<210> 39
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Human T cells immunoglobulin mucoprotein molecule 3(TIM3 )SiRNA sequence
<400> 39
gccacugauu uucaaagaga ucu 23
<210> 40
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Human T cells immunoglobulin mucoprotein molecule 3(TIM3 )SiRNA sequence
<400> 40
agcagaguuu ucccauuuuc aga 23
<210> 41
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Human T cells immunoglobulin mucoprotein molecule 3(TIM3 )SiRNA sequence
<400> 41
aacuuaaaca ggcaugucau ugc 23
<210> 42
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Human T cells immunoglobulin mucoprotein molecule 3(TIM3 )SiRNA sequence
<400> 42
uucagaagau aaugacucac aug 23
<210> 43
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Human T cells immunoglobulin mucoprotein molecule 3(TIM3 )SiRNA sequence
<400> 43
gccucuguau uuaagccaac aga 23
<210> 44
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Human T cells immunoglobulin mucoprotein molecule 3(TIM3 )SiRNA sequence
<400> 44
ugcucaugug auuguggagu aga 23
<210> 45
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Human T cells immunoglobulin mucoprotein molecule 3(TIM3 )SiRNA sequence
<400> 45
auguuuucac aucuucccuu uga 23
<210> 46
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Human T cells immunoglobulin mucoprotein molecule 3(TIM3 )SiRNA sequence
<400> 46
gagagacuuc acugcagccu uuc 23
<210> 47
<211> 21
<212> DNA
<213> Artificial
<220>
<223>Human T-lymphocyte decay factor(BTLA)SiRNA sequence
<400> 47
gattgcctct actcatcact a 21
<210> 48
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Human T-lymphocyte decay factor(BTLA)SiRNA sequence
<400> 48
uccuaaugac aaugggucau acc 23
<210> 49
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Human T-lymphocyte decay factor(BTLA)SiRNA sequence
<400> 49
aagacauugc cugccaugcu ugg 23
<210> 50
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Human T-lymphocyte decay factor(BTLA)SiRNA sequence
<400> 50
gucauaccgc uguucugcaa auu 23
<210> 51
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Human T-lymphocyte decay factor(BTLA)SiRNA sequence
<400> 51
cuccuguaua guuuacuucc uuu 23
<210> 52
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Human T-lymphocyte decay factor(BTLA)SiRNA sequence
<400> 52
uaccgcuguu cugcaaauuu uca 23
<210> 53
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Human T-lymphocyte decay factor(BTLA)SiRNA sequence
<400> 53
aaaacaaacc aggcauuguu uau 23
<210> 54
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Human T-lymphocyte decay factor(BTLA)SiRNA sequence
<400> 54
aacuagaaug cccugugaaa uac 23
<210> 55
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Human T-lymphocyte decay factor(BTLA)SiRNA sequence
<400> 55
gugacuuggu gcaagcucaa ugg 23
<210> 56
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Human T-lymphocyte decay factor(BTLA)SiRNA sequence
<400> 56
auccauggga aagaaucaug uga 23
<210> 57
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Human T-lymphocyte decay factor(BTLA)SiRNA sequence
<400> 57
uggugcaagc ucaauggaac aac 23
<210> 58
<211> 21
<212> DNA
<213> Artificial
<220>
<223>3 albumen of Human Lymphocytes activating gene(LAG1)SiRNA sequence
<400> 58
gctgctcacc cttatgaacc t 21
<210> 59
<211> 23
<212> DNA
<213> Artificial
<220>
<223>3 albumen of Human Lymphocytes activating gene(LAG1)SiRNA sequence
<400> 59
aggacauggu gguggacgag ugc 23
<210> 60
<211> 23
<212> DNA
<213> Artificial
<220>
<223>3 albumen of Human Lymphocytes activating gene(LAG1)SiRNA sequence
<400> 60
ugcucuuccu gcacgauauc agu 23
<210> 61
<211> 23
<212> DNA
<213> Artificial
<220>
<223>3 albumen of Human Lymphocytes activating gene(LAG1)SiRNA sequence
<400> 61
accucuacug guuccuguac auc 23
<210> 62
<211> 23
<212> DNA
<213> Artificial
<220>
<223>3 albumen of Human Lymphocytes activating gene(LAG1)SiRNA sequence
<400> 62
cccuccaacu cugcuccucu agg 23
<210> 63
<211> 23
<212> DNA
<213> Artificial
<220>
<223>3 albumen of Human Lymphocytes activating gene(LAG1)SiRNA sequence
<400> 63
cccugagugg acagucgucu ucg 23
<210> 64
<211> 23
<212> DNA
<213> Artificial
<220>
<223>3 albumen of Human Lymphocytes activating gene(LAG1)SiRNA sequence
<400> 64
cugcuccagg gaagcuucua ugg 23
<210> 65
<211> 23
<212> DNA
<213> Artificial
<220>
<223>3 albumen of Human Lymphocytes activating gene(LAG1)SiRNA sequence
<400> 65
cgcucaaggu ccuguaugcc acc 23
<210> 66
<211> 23
<212> DNA
<213> Artificial
<220>
<223>3 albumen of Human Lymphocytes activating gene(LAG1)SiRNA sequence
<400> 66
gaguucacca agcucaacau uua 23
<210> 67
<211> 23
<212> DNA
<213> Artificial
<220>
<223>3 albumen of Human Lymphocytes activating gene(LAG1)SiRNA sequence
<400> 67
ugcugcugcu cacccuuaug aac 23
<210> 68
<211> 23
<212> DNA
<213> Artificial
<220>
<223>3 albumen of Human Lymphocytes activating gene(LAG1)SiRNA sequence
<400> 68
cccaucuccg ugcucuucuu uga 23
<210> 69
<211> 21
<212> DNA
<213> Artificial
<220>
<223>Mankind IRAK-M siRNA (- 1 receptor-associated kinase 3 of human interleukin) nucleotide sequence
<400> 69
gggacatcgt cgagctattc a 21
<210> 70
<211> 21
<212> DNA
<213> Artificial
<220>
<223>Mankind IRAK-M siRNA (- 1 receptor-associated kinase 3 of human interleukin) nucleotide sequence
<400> 70
ggacatcgtc gagctattca t 21
<210> 71
<211> 21
<212> DNA
<213> Artificial
<220>
<223>Mankind IRAK-M siRNA (- 1 receptor-associated kinase 3 of human interleukin) nucleotide sequence
<400> 71
gccaatgtca ccgtggataa t 21
<210> 72
<211> 21
<212> DNA
<213> Artificial
<220>
<223>Mankind IRAK-M siRNA (- 1 receptor-associated kinase 3 of human interleukin) nucleotide sequence
<400> 72
gtcatctgtg gcagtatatc a 21
<210> 73
<211> 21
<212> DNA
<213> Artificial
<220>
<223>Mankind IRAK-M siRNA (- 1 receptor-associated kinase 3 of human interleukin) nucleotide sequence
<400> 73
ggatgtagag tagtgttaga t 21
<210> 74
<211> 21
<212> DNA
<213> Artificial
<220>
<223>Mankind IRAK-M siRNA (- 1 receptor-associated kinase 3 of human interleukin) nucleotide sequence
<400> 74
ggcaaagtta agaccatcaa t 21
<210> 75
<211> 21
<212> DNA
<213> Artificial
<220>
<223>Mankind IRAK-M siRNA (- 1 receptor-associated kinase 3 of human interleukin) nucleotide sequence
<400> 75
gaccaaatcc acgctcaatt a 21
<210> 76
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Mankind IRAK-M siRNA (- 1 receptor-associated kinase 3 of human interleukin) nucleotide sequence
<400> 76
uacugcuuaa aucuuccauc agc 23
<210> 77
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Mankind IRAK-M siRNA (- 1 receptor-associated kinase 3 of human interleukin) nucleotide sequence
<400> 77
gacugagaag uucugucuga uuu 23
<210> 78
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Mankind IRAK-M siRNA (- 1 receptor-associated kinase 3 of human interleukin) nucleotide sequence
<400> 78
cuguuucauc acccaaacau acu 23
<210> 79
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Mankind IRAK-M siRNA (- 1 receptor-associated kinase 3 of human interleukin) nucleotide sequence
<400> 79
gaagauccuc ccacaucacu aaa 23
<210> 80
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Mankind IRAK-M siRNA (- 1 receptor-associated kinase 3 of human interleukin) nucleotide sequence
<400> 80
uagaccaagg uaaaagugga aca 23
<210> 81
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Mankind IRAK-M siRNA (- 1 receptor-associated kinase 3 of human interleukin) nucleotide sequence
<400> 81
aagagguuuu uaucugagcu uga 23
<210> 82
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Mankind IRAK-M siRNA (- 1 receptor-associated kinase 3 of human interleukin) nucleotide sequence
<400> 82
uaccugcaca acguucaacc aug 23
<210> 83
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Mankind IRAK-M siRNA (- 1 receptor-associated kinase 3 of human interleukin) nucleotide sequence
<400> 83
gccuggauuc augucucuca uuu 23
<210> 84
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Mankind IRAK-M siRNA (- 1 receptor-associated kinase 3 of human interleukin) nucleotide sequence
<400> 84
cccucggaau uucucugcca agc 23
<210> 85
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Mankind IRAK-M siRNA (- 1 receptor-associated kinase 3 of human interleukin) nucleotide sequence
<400> 85
ugcugaagau ccucccacau cac 23
<210> 86
<211> 21
<212> DNA
<213> Artificial
<220>
<223>Mankind SOCS1 siRNA(Human cytokine's signal transduction inhibiting factor 1)Sequence
<400> 86
gcacctccta cctcttcatg t 21
<210> 87
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Mankind SOCS1 siRNA(Human cytokine's signal transduction inhibiting factor 1)Sequence
<400> 87
cgcacuuccg cacauuccgu ucg 23
<210> 88
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Mankind SOCS1 siRNA(Human cytokine's signal transduction inhibiting factor 1)Sequence
<400> 88
ggggaggguc ucuggcuuua uuu 23
<210> 89
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Mankind SOCS1 siRNA(Human cytokine's signal transduction inhibiting factor 1)Sequence
<400> 89
cagcauuaac ugggaugccg ugu 23
<210> 90
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Mankind SOCS1 siRNA(Human cytokine's signal transduction inhibiting factor 1)Sequence
<400> 90
ccaggaccug aacucgcacc ucc 23
<210> 91
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Mankind SOCS1 siRNA(Human cytokine's signal transduction inhibiting factor 1)Sequence
<400> 91
uacauauacc caguaucuuu gca 23
<210> 92
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Mankind SOCS1 siRNA(Human cytokine's signal transduction inhibiting factor 1)Sequence
<400> 92
gccgacaaug cagucuccac agc 23
<210> 93
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Mankind SOCS1 siRNA(Human cytokine's signal transduction inhibiting factor 1)Sequence
<400> 93
ccccugguug uuguagcagc uua 23
<210> 94
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Mankind SOCS1 siRNA(Human cytokine's signal transduction inhibiting factor 1)Sequence
<400> 94
cugcugugca gaauccuauu uua 23
<210> 95
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Mankind SOCS1 siRNA(Human cytokine's signal transduction inhibiting factor 1)Sequence
<400> 95
ugggaugccg uguuauuuug uua 23
<210> 96
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Mankind SOCS1 siRNA(Human cytokine's signal transduction inhibiting factor 1)Sequence
<400> 96
ucgcaccucc uaccucuuca ugu 23
<210> 97
<211> 21
<212> DNA
<213> Artificial
<220>
<223>Mankind A20 siRNA (human tnf-α inducible protein A20) sequence
<400> 97
gcggaaagct gtgaagatac g 21
<210> 98
<211> 21
<212> DNA
<213> Artificial
<220>
<223>Mankind A20 siRNA (human tnf-α inducible protein A20) sequence
<400> 98
acaaagccct catcgacaga a 21
<210> 99
<211> 21
<212> DNA
<213> Artificial
<220>
<223>Mankind A20 siRNA (human tnf-α inducible protein A20) sequence
<400> 99
atgccacttc tcagtacatg t 21
<210> 100
<211> 21
<212> DNA
<213> Artificial
<220>
<223>Mankind A20 siRNA (human tnf-α inducible protein A20) sequence
<400> 100
gtggacttca gtacaactca c 21
<210> 101
<211> 21
<212> DNA
<213> Artificial
<220>
<223>Mankind A20 siRNA (human tnf-α inducible protein A20) sequence
<400> 101
gtggaattta cttgcctctc c 21
<210> 102
<211> 21
<212> DNA
<213> Artificial
<220>
<223>Mankind A20 siRNA (human tnf-α inducible protein A20) sequence
<400> 102
gttggatgaa gctaacttac c 21
<210> 103
<211> 21
<212> DNA
<213> Artificial
<220>
<223>Mankind A20 siRNA (human tnf-α inducible protein A20) sequence
<400> 103
actgggaaga cgtgtaactc t 21
<210> 104
<211> 21
<212> DNA
<213> Artificial
<220>
<223>Mankind A20 siRNA (human tnf-α inducible protein A20) sequence
<400> 104
aaggaattgc atccaaggta t 21
<210> 105
<211> 21
<212> DNA
<213> Artificial
<220>
<223>Mankind A20 siRNA (human tnf-α inducible protein A20) sequence
<400> 105
ggaattgcat ccaaggtata c 21
<210> 106
<211> 21
<212> DNA
<213> Artificial
<220>
<223>Mankind A20 siRNA (human tnf-α inducible protein A20) sequence
<400> 106
ggatgagact ggcaatggtc a 21
<210> 107
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Mankind A20 siRNA (human tnf-α inducible protein A20) sequence
<400> 107
uccucaguuu cgggagauca ucc 23
<210> 108
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Mankind A20 siRNA (human tnf-α inducible protein A20) sequence
<400> 108
gagucucuca aaucucagga auu 23
<210> 109
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Mankind A20 siRNA (human tnf-α inducible protein A20) sequence
<400> 109
agcucuaguc cuuuuugugu aau 23
<210> 110
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Mankind A20 siRNA (human tnf-α inducible protein A20) sequence
<400> 110
cacuggaaau guucagaacu ugc 23
<210> 111
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Mankind A20 siRNA (human tnf-α inducible protein A20) sequence
<400> 111
augaugaaug ggacaaucuu auc 23
<210> 112
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Mankind A20 siRNA (human tnf-α inducible protein A20) sequence
<400> 112
cacacugugu uucaucgagu aca 23
<210> 113
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Mankind A20 siRNA (human tnf-α inducible protein A20) sequence
<400> 113
gcagaaccau ccauggacug uga 23
<210> 114
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Mankind A20 siRNA (human tnf-α inducible protein A20) sequence
<400> 114
aaagaugugg ccuuuuguga ugg 23
<210> 115
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Mankind A20 siRNA (human tnf-α inducible protein A20) sequence
<400> 115
uucagaacuu gccaguuuug ucc 23
<210> 116
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Mankind A20 siRNA (human tnf-α inducible protein A20) sequence
<400> 116
augagacugg caauggucac agg 23
<210> 117
<211> 21
<212> DNA
<213> Artificial
<220>
<223>Mankind CBL-B siRNA(E3 ubiquitin protein ligases CBL-B)Sequence
<400> 117
gtcaattcca gggagataac t 21
<210> 118
<211> 21
<212> DNA
<213> Artificial
<220>
<223>Mankind CBL-B siRNA(E3 ubiquitin protein ligases CBL-B)Sequence
<400> 118
gcctggaagc aatggctcta a 21
<210> 119
<211> 21
<212> DNA
<213> Artificial
<220>
<223>Mankind CBL-B siRNA(E3 ubiquitin protein ligases CBL-B)Sequence
<400> 119
gcaccaaacc cggaagctat a 21
<210> 120
<211> 21
<212> DNA
<213> Artificial
<220>
<223>Mankind CBL-B siRNA(E3 ubiquitin protein ligases CBL-B)Sequence
<400> 120
gttgcactcg attgggacag t 21
<210> 121
<211> 21
<212> DNA
<213> Artificial
<220>
<223>Mankind CBL-B siRNA(E3 ubiquitin protein ligases CBL-B)Sequence
<400> 121
ggattatgtg aacctacacc t 21
<210> 122
<211> 21
<212> DNA
<213> Artificial
<220>
<223>Mankind CBL-B siRNA(E3 ubiquitin protein ligases CBL-B)Sequence
<400> 122
ggaatcacag cgagttcaaa t 21
<210> 123
<211> 21
<212> DNA
<213> Artificial
<220>
<223>Mankind CBL-B siRNA(E3 ubiquitin protein ligases CBL-B)Sequence
<400> 123
gcaaggcata gtctcattga a 21
<210> 124
<211> 21
<212> DNA
<213> Artificial
<220>
<223>Mankind CBL-B siRNA(E3 ubiquitin protein ligases CBL-B)Sequence
<400> 124
ggtgaagaga gccttagaga t 21
<210> 125
<211> 21
<212> DNA
<213> Artificial
<220>
<223>Mankind CBL-B siRNA(E3 ubiquitin protein ligases CBL-B)Sequence
<400> 125
gtgaagagag ccttagagat a 21
<210> 126
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Mankind CBL-B siRNA(E3 ubiquitin protein ligases CBL-B)Sequence
<400> 126
aggagcuaag gucuuuucca aug 23
<210> 127
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Mankind CBL-B siRNA(E3 ubiquitin protein ligases CBL-B)Sequence
<400> 127
augucgaugc aaaaauugca aaa 23
<210> 128
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Mankind CBL-B siRNA(E3 ubiquitin protein ligases CBL-B)Sequence
<400> 128
gucacaugcu ggcagaaauc aaa 23
<210> 129
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Mankind CBL-B siRNA(E3 ubiquitin protein ligases CBL-B)Sequence
<400> 129
uccagguuac auggcauuuc uca 23
<210> 130
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Mankind CBL-B siRNA(E3 ubiquitin protein ligases CBL-B)Sequence
<400> 130
uugaacuuug aaccugugaa aug 23
<210> 131
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Mankind CBL-B siRNA(E3 ubiquitin protein ligases CBL-B)Sequence
<400> 131
uccacaucaa cagcuaaauc auu 23
<210> 132
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Mankind CBL-B siRNA(E3 ubiquitin protein ligases CBL-B)Sequence
<400> 132
augcuggcag aaaucaaagc aau 23
<210> 133
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Mankind CBL-B siRNA(E3 ubiquitin protein ligases CBL-B)Sequence
<400> 133
ugcagagaau gacaaagaug uca 23
<210> 134
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Mankind CBL-B siRNA(E3 ubiquitin protein ligases CBL-B)Sequence
<400> 134
ggcagaacuc accagucaca uca 23
<210> 135
<211> 23
<212> DNA
<213> Artificial
<220>
<223>Mankind CBL-B siRNA(E3 ubiquitin protein ligases CBL-B)Sequence
<400> 135
ucgguccugu gauaaugguc acu 23
<210> 136
<211> 2053
<212> DNA
<213> Artificial
<220>
<223>The nucleotide sequence of MSLN-CAR/iPD1
<400> 136
atggttctgc tggtgacatc tctcctgctc tgtgaactgc ctcatcccgc ttttctgctc 60
attcccgaca ttcaggctca agtccaactg gtccaaagtg gtgctgaagt caaacgcccg 120
ggtgcctccg tccaagtctc ctgccgtgcc tctggctact cgattaacac ctattacatg 180
cagtgggtcc gtcaagcacc gggtgcaggt ctggaatgga tgggtgtcat caatccgtcc 240
ggcgtgacct catatgcgca gaaatttcaa ggtcgcgtta ccctgacgaa cgataccagc 300
acgaataccg tctacatgca gctgaactct ctgacgagtg cagacaccgc ggtgtattac 360
tgcgcacgtt gggcactgtg gggcgatttc ggcatggatg tttggggcaa aggtacgctg 420
gtgaccgtta gctctggtgg tggtggttct ggtggtggtg gtagtggcgg tggcggttct 480
gatattcaga tgacgcaaag cccgtctacc ctgagtgcct ccattggtga ccgtgttacg 540
atcacctgtc gcgcatccga aggcatctat cattggctgg cttggtacca gcaaaaaccg 600
ggtaaagcgc cgaaactgct gatctataaa gcaagttccc tggcatcggg tgctccgagc 660
cgcttttcag gttcgggtag cggcaccgat ttcacgctga ccatctcatc gctgcagccg 720
gacgatttcg ctacctacta ctgccaacaa tactcaaact acccgctgac cttcggtgga 780
gggaccaagc tggagatcaa acgtgctagc accactaccc cagcaccgag gccacccacc 840
ccggctccta ccatcgcctc ccagcctctg tccctgcgtc cggaggcatg tagacccgca 900
gctggtgggg ccgtgcatac ccggggtctt gacttcgcct gcgatatcta catttgggcc 960
cctctggctg gtacttgcgg ggtcctgctg ctttcactcg tgatcactct ttactgtaag 1020
cgcggtcgga agaagctgct gtacatcttt aagcaaccct tcatgaggcc tgtgcagact 1080
actcaagagg aggacggctg ttcatgccgg ttcccagagg aggaggaagg cggctgcgaa 1140
ctgcgcgtga aattcagccg cagcgcagat gctccagcct accagcaggg gcagaaccag 1200
ctctacaacg aactcaatct tggtcggaga gaggagtacg acgtgctgga caagcggaga 1260
ggacgggacc cagaaatggg cgggaagccg cgcagaaaga atccccaaga gggcctgtac 1320
aacgagctcc aaaaggataa gatggcagaa gcctatagcg agattggtat gaaaggggaa 1380
cgcagaagag gcaaaggcca cgacggactg taccagggac tcagcaccgc caccaaggac 1440
acctatgacg ctcttcacat gcaggccctg ccgcctcggt aatcctactg cgtcgagcga 1500
ctgtgccttc tagttgccag ccatctgttg tttgcccctc ccccgtgcct tccttgaccc 1560
tggaaggtgc cactcccact gtcctttcct aataaaatga ggaaattgca tcgcattgtc 1620
tgagtaggtg tcattctatt ctggggggtg gggtggggca ggacagcaag ggggaggatt 1680
gggaagacaa tagcaggcat gctggggatg cggtgggctc tatgggtcga ccaaggtcgg 1740
gcaggaagag ggcctatttc ccatgattcc ttcatatttg catatacgat acaaggctgt 1800
tagagagata attagaatta atttgactgt aaacacaaag atattagtac aaaatacgtg 1860
acgtagaaag taataatttc ttgggtagtt tgcagtttta aaattatgtt ttaaaatgga 1920
ctatcatatg cttaccgtaa cttgaaagta tttcgatttc ttggctttat atatcttgtg 1980
gaaaggacga aacacctccc caggcgcaga tcaaagagag ttcaagagac tctctttgat 2040
ctgcgccttt ttt 2053
<210> 137
<211> 2057
<212> DNA
<213> Artificial
<220>
<223>The nucleotide sequence of MSLN-CAR/iCBL-B
<400> 137
atggttctgc tggtgacatc tctcctgctc tgtgaactgc ctcatcccgc ttttctgctc 60
attcccgaca ttcaggctca agtccaactg gtccaaagtg gtgctgaagt caaacgcccg 120
ggtgcctccg tccaagtctc ctgccgtgcc tctggctact cgattaacac ctattacatg 180
cagtgggtcc gtcaagcacc gggtgcaggt ctggaatgga tgggtgtcat caatccgtcc 240
ggcgtgacct catatgcgca gaaatttcaa ggtcgcgtta ccctgacgaa cgataccagc 300
acgaataccg tctacatgca gctgaactct ctgacgagtg cagacaccgc ggtgtattac 360
tgcgcacgtt gggcactgtg gggcgatttc ggcatggatg tttggggcaa aggtacgctg 420
gtgaccgtta gctctggtgg tggtggttct ggtggtggtg gtagtggcgg tggcggttct 480
gatattcaga tgacgcaaag cccgtctacc ctgagtgcct ccattggtga ccgtgttacg 540
atcacctgtc gcgcatccga aggcatctat cattggctgg cttggtacca gcaaaaaccg 600
ggtaaagcgc cgaaactgct gatctataaa gcaagttccc tggcatcggg tgctccgagc 660
cgcttttcag gttcgggtag cggcaccgat ttcacgctga ccatctcatc gctgcagccg 720
gacgatttcg ctacctacta ctgccaacaa tactcaaact acccgctgac cttcggtgga 780
gggaccaagc tggagatcaa acgtgctagc accactaccc cagcaccgag gccacccacc 840
ccggctccta ccatcgcctc ccagcctctg tccctgcgtc cggaggcatg tagacccgca 900
gctggtgggg ccgtgcatac ccggggtctt gacttcgcct gcgatatcta catttgggcc 960
cctctggctg gtacttgcgg ggtcctgctg ctttcactcg tgatcactct ttactgtaag 1020
cgcggtcgga agaagctgct gtacatcttt aagcaaccct tcatgaggcc tgtgcagact 1080
actcaagagg aggacggctg ttcatgccgg ttcccagagg aggaggaagg cggctgcgaa 1140
ctgcgcgtga aattcagccg cagcgcagat gctccagcct accagcaggg gcagaaccag 1200
ctctacaacg aactcaatct tggtcggaga gaggagtacg acgtgctgga caagcggaga 1260
ggacgggacc cagaaatggg cgggaagccg cgcagaaaga atccccaaga gggcctgtac 1320
aacgagctcc aaaaggataa gatggcagaa gcctatagcg agattggtat gaaaggggaa 1380
cgcagaagag gcaaaggcca cgacggactg taccagggac tcagcaccgc caccaaggac 1440
acctatgacg ctcttcacat gcaggccctg ccgcctcggt aatcctactg cgtcgagcga 1500
ctgtgccttc tagttgccag ccatctgttg tttgcccctc ccccgtgcct tccttgaccc 1560
tggaaggtgc cactcccact gtcctttcct aataaaatga ggaaattgca tcgcattgtc 1620
tgagtaggtg tcattctatt ctggggggtg gggtggggca ggacagcaag ggggaggatt 1680
gggaagacaa tagcaggcat gctggggatg cggtgggctc tatgggtcga ccaaggtcgg 1740
gcaggaagag ggcctatttc ccatgattcc ttcatatttg catatacgat acaaggctgt 1800
tagagagata attagaatta atttgactgt aaacacaaag atattagtac aaaatacgtg 1860
acgtagaaag taataatttc ttgggtagtt tgcagtttta aaattatgtt ttaaaatgga 1920
ctatcatatg cttaccgtaa cttgaaagta tttcgatttc ttggctttat atatcttgtg 1980
gaaaggacga aacacctccc caacacagac gccatgattt gcttcaagag agcaaatcat 2040
ggcgtctgtg ttttttt 2057
<210> 138
<211> 2053
<212> DNA
<213> Artificial
<220>
<223>The nucleotide sequence of MSLN-CAR/iCTLA4
<400> 138
atggttctgc tggtgacatc tctcctgctc tgtgaactgc ctcatcccgc ttttctgctc 60
attcccgaca ttcaggctca agtccaactg gtccaaagtg gtgctgaagt caaacgcccg 120
ggtgcctccg tccaagtctc ctgccgtgcc tctggctact cgattaacac ctattacatg 180
cagtgggtcc gtcaagcacc gggtgcaggt ctggaatgga tgggtgtcat caatccgtcc 240
ggcgtgacct catatgcgca gaaatttcaa ggtcgcgtta ccctgacgaa cgataccagc 300
acgaataccg tctacatgca gctgaactct ctgacgagtg cagacaccgc ggtgtattac 360
tgcgcacgtt gggcactgtg gggcgatttc ggcatggatg tttggggcaa aggtacgctg 420
gtgaccgtta gctctggtgg tggtggttct ggtggtggtg gtagtggcgg tggcggttct 480
gatattcaga tgacgcaaag cccgtctacc ctgagtgcct ccattggtga ccgtgttacg 540
atcacctgtc gcgcatccga aggcatctat cattggctgg cttggtacca gcaaaaaccg 600
ggtaaagcgc cgaaactgct gatctataaa gcaagttccc tggcatcggg tgctccgagc 660
cgcttttcag gttcgggtag cggcaccgat ttcacgctga ccatctcatc gctgcagccg 720
gacgatttcg ctacctacta ctgccaacaa tactcaaact acccgctgac cttcggtgga 780
gggaccaagc tggagatcaa acgtgctagc accactaccc cagcaccgag gccacccacc 840
ccggctccta ccatcgcctc ccagcctctg tccctgcgtc cggaggcatg tagacccgca 900
gctggtgggg ccgtgcatac ccggggtctt gacttcgcct gcgatatcta catttgggcc 960
cctctggctg gtacttgcgg ggtcctgctg ctttcactcg tgatcactct ttactgtaag 1020
cgcggtcgga agaagctgct gtacatcttt aagcaaccct tcatgaggcc tgtgcagact 1080
actcaagagg aggacggctg ttcatgccgg ttcccagagg aggaggaagg cggctgcgaa 1140
ctgcgcgtga aattcagccg cagcgcagat gctccagcct accagcaggg gcagaaccag 1200
ctctacaacg aactcaatct tggtcggaga gaggagtacg acgtgctgga caagcggaga 1260
ggacgggacc cagaaatggg cgggaagccg cgcagaaaga atccccaaga gggcctgtac 1320
aacgagctcc aaaaggataa gatggcagaa gcctatagcg agattggtat gaaaggggaa 1380
cgcagaagag gcaaaggcca cgacggactg taccagggac tcagcaccgc caccaaggac 1440
acctatgacg ctcttcacat gcaggccctg ccgcctcggt aatcctactg cgtcgagcga 1500
ctgtgccttc tagttgccag ccatctgttg tttgcccctc ccccgtgcct tccttgaccc 1560
tggaaggtgc cactcccact gtcctttcct aataaaatga ggaaattgca tcgcattgtc 1620
tgagtaggtg tcattctatt ctggggggtg gggtggggca ggacagcaag ggggaggatt 1680
gggaagacaa tagcaggcat gctggggatg cggtgggctc tatgggtcga ccaaggtcgg 1740
gcaggaagag ggcctatttc ccatgattcc ttcatatttg catatacgat acaaggctgt 1800
tagagagata attagaatta atttgactgt aaacacaaag atattagtac aaaatacgtg 1860
acgtagaaag taataatttc ttgggtagtt tgcagtttta aaattatgtt ttaaaatgga 1920
ctatcatatg cttaccgtaa cttgaaagta tttcgatttc ttggctttat atatcttgtg 1980
gaaaggacga aacacctccc cgcatcactt gggattaata ttcaagagat attaatccca 2040
agtgatgctt ttt 2053
<210> 139
<211> 2360
<212> DNA
<213> Artificial
<220>
<223>The nucleotide sequence of MSLN-CAR/iPD1- CBL-B
<400> 139
atggttctgc tggtgacatc tctcctgctc tgtgaactgc ctcatcccgc ttttctgctc 60
attcccgaca ttcaggctca agtccaactg gtccaaagtg gtgctgaagt caaacgcccg 120
ggtgcctccg tccaagtctc ctgccgtgcc tctggctact cgattaacac ctattacatg 180
cagtgggtcc gtcaagcacc gggtgcaggt ctggaatgga tgggtgtcat caatccgtcc 240
ggcgtgacct catatgcgca gaaatttcaa ggtcgcgtta ccctgacgaa cgataccagc 300
acgaataccg tctacatgca gctgaactct ctgacgagtg cagacaccgc ggtgtattac 360
tgcgcacgtt gggcactgtg gggcgatttc ggcatggatg tttggggcaa aggtacgctg 420
gtgaccgtta gctctggtgg tggtggttct ggtggtggtg gtagtggcgg tggcggttct 480
gatattcaga tgacgcaaag cccgtctacc ctgagtgcct ccattggtga ccgtgttacg 540
atcacctgtc gcgcatccga aggcatctat cattggctgg cttggtacca gcaaaaaccg 600
ggtaaagcgc cgaaactgct gatctataaa gcaagttccc tggcatcggg tgctccgagc 660
cgcttttcag gttcgggtag cggcaccgat ttcacgctga ccatctcatc gctgcagccg 720
gacgatttcg ctacctacta ctgccaacaa tactcaaact acccgctgac cttcggtgga 780
gggaccaagc tggagatcaa acgtgctagc accactaccc cagcaccgag gccacccacc 840
ccggctccta ccatcgcctc ccagcctctg tccctgcgtc cggaggcatg tagacccgca 900
gctggtgggg ccgtgcatac ccggggtctt gacttcgcct gcgatatcta catttgggcc 960
cctctggctg gtacttgcgg ggtcctgctg ctttcactcg tgatcactct ttactgtaag 1020
cgcggtcgga agaagctgct gtacatcttt aagcaaccct tcatgaggcc tgtgcagact 1080
actcaagagg aggacggctg ttcatgccgg ttcccagagg aggaggaagg cggctgcgaa 1140
ctgcgcgtga aattcagccg cagcgcagat gctccagcct accagcaggg gcagaaccag 1200
ctctacaacg aactcaatct tggtcggaga gaggagtacg acgtgctgga caagcggaga 1260
ggacgggacc cagaaatggg cgggaagccg cgcagaaaga atccccaaga gggcctgtac 1320
aacgagctcc aaaaggataa gatggcagaa gcctatagcg agattggtat gaaaggggaa 1380
cgcagaagag gcaaaggcca cgacggactg taccagggac tcagcaccgc caccaaggac 1440
acctatgacg ctcttcacat gcaggccctg ccgcctcggt aatcctactg cgtcgagcga 1500
ctgtgccttc tagttgccag ccatctgttg tttgcccctc ccccgtgcct tccttgaccc 1560
tggaaggtgc cactcccact gtcctttcct aataaaatga ggaaattgca tcgcattgtc 1620
tgagtaggtg tcattctatt ctggggggtg gggtggggca ggacagcaag ggggaggatt 1680
gggaagacaa tagcaggcat gctggggatg cggtgggctc tatgggtcga ccaaggtcgg 1740
gcaggaagag ggcctatttc ccatgattcc ttcatatttg catatacgat acaaggctgt 1800
tagagagata attagaatta atttgactgt aaacacaaag atattagtac aaaatacgtg 1860
acgtagaaag taataatttc ttgggtagtt tgcagtttta aaattatgtt ttaaaatgga 1920
ctatcatatg cttaccgtaa cttgaaagta tttcgatttc ttggctttat atatcttgtg 1980
gaaaggacga aacacctccc caggcgcaga tcaaagagag ttcaagagac tctctttgat 2040
ctgcgccttt tttagctatc gatagctaaa aaaacacaga cgccatgatt tgctctcttg 2100
aagcaaatca tggcgtctgt gttggggaag atctgtggtc tcatacagaa cttataagat 2160
tcccaaatcc aaagacattt cacgtttatg gtgatttccc agaacacata gcgacatgca 2220
aatattgcag ggcgccactc ccctgtccct cacagccatc ttcctgccag ggcgcacgcg 2280
cgctgggtgt tcccgcctag tgacactggg cccgcgattc cttggagcgg gttgatgacg 2340
tcagcgttcg aattgtcgac 2360
<210> 140
<211> 2356
<212> DNA
<213> Artificial
<220>
<223>The nucleotide sequence of MSLN-CAR/iPD1-CTLA4
<400> 140
atggttctgc tggtgacatc tctcctgctc tgtgaactgc ctcatcccgc ttttctgctc 60
attcccgaca ttcaggctca agtccaactg gtccaaagtg gtgctgaagt caaacgcccg 120
ggtgcctccg tccaagtctc ctgccgtgcc tctggctact cgattaacac ctattacatg 180
cagtgggtcc gtcaagcacc gggtgcaggt ctggaatgga tgggtgtcat caatccgtcc 240
ggcgtgacct catatgcgca gaaatttcaa ggtcgcgtta ccctgacgaa cgataccagc 300
acgaataccg tctacatgca gctgaactct ctgacgagtg cagacaccgc ggtgtattac 360
tgcgcacgtt gggcactgtg gggcgatttc ggcatggatg tttggggcaa aggtacgctg 420
gtgaccgtta gctctggtgg tggtggttct ggtggtggtg gtagtggcgg tggcggttct 480
gatattcaga tgacgcaaag cccgtctacc ctgagtgcct ccattggtga ccgtgttacg 540
atcacctgtc gcgcatccga aggcatctat cattggctgg cttggtacca gcaaaaaccg 600
ggtaaagcgc cgaaactgct gatctataaa gcaagttccc tggcatcggg tgctccgagc 660
cgcttttcag gttcgggtag cggcaccgat ttcacgctga ccatctcatc gctgcagccg 720
gacgatttcg ctacctacta ctgccaacaa tactcaaact acccgctgac cttcggtgga 780
gggaccaagc tggagatcaa acgtgctagc accactaccc cagcaccgag gccacccacc 840
ccggctccta ccatcgcctc ccagcctctg tccctgcgtc cggaggcatg tagacccgca 900
gctggtgggg ccgtgcatac ccggggtctt gacttcgcct gcgatatcta catttgggcc 960
cctctggctg gtacttgcgg ggtcctgctg ctttcactcg tgatcactct ttactgtaag 1020
cgcggtcgga agaagctgct gtacatcttt aagcaaccct tcatgaggcc tgtgcagact 1080
actcaagagg aggacggctg ttcatgccgg ttcccagagg aggaggaagg cggctgcgaa 1140
ctgcgcgtga aattcagccg cagcgcagat gctccagcct accagcaggg gcagaaccag 1200
ctctacaacg aactcaatct tggtcggaga gaggagtacg acgtgctgga caagcggaga 1260
ggacgggacc cagaaatggg cgggaagccg cgcagaaaga atccccaaga gggcctgtac 1320
aacgagctcc aaaaggataa gatggcagaa gcctatagcg agattggtat gaaaggggaa 1380
cgcagaagag gcaaaggcca cgacggactg taccagggac tcagcaccgc caccaaggac 1440
acctatgacg ctcttcacat gcaggccctg ccgcctcggt aatcctactg cgtcgagcga 1500
ctgtgccttc tagttgccag ccatctgttg tttgcccctc ccccgtgcct tccttgaccc 1560
tggaaggtgc cactcccact gtcctttcct aataaaatga ggaaattgca tcgcattgtc 1620
tgagtaggtg tcattctatt ctggggggtg gggtggggca ggacagcaag ggggaggatt 1680
gggaagacaa tagcaggcat gctggggatg cggtgggctc tatgggtcga ccaaggtcgg 1740
gcaggaagag ggcctatttc ccatgattcc ttcatatttg catatacgat acaaggctgt 1800
tagagagata attagaatta atttgactgt aaacacaaag atattagtac aaaatacgtg 1860
acgtagaaag taataatttc ttgggtagtt tgcagtttta aaattatgtt ttaaaatgga 1920
ctatcatatg cttaccgtaa cttgaaagta tttcgatttc ttggctttat atatcttgtg 1980
gaaaggacga aacacctccc caggcgcaga tcaaagagag ttcaagagac tctctttgat 2040
ctgcgccttt tttagctatc gatagctaaa aagcatcact tgggattaat atctcttgaa 2100
tattaatccc aagtgatgcg gggaagatct gtggtctcat acagaactta taagattccc 2160
aaatccaaag acatttcacg tttatggtga tttcccagaa cacatagcga catgcaaata 2220
ttgcagggcg ccactcccct gtccctcaca gccatcttcc tgccagggcg cacgcgcgct 2280
gggtgttccc gcctagtgac actgggcccg cgattccttg gagcgggttg atgacgtcag 2340
cgttcgaatt gtcgac 2356
<210> 141
<211> 2360
<212> DNA
<213> Artificial
<220>
<223>The nucleotide sequence of MSLN-CAR/iPD1- PD1
<400> 141
atggttctgc tggtgacatc tctcctgctc tgtgaactgc ctcatcccgc ttttctgctc 60
attcccgaca ttcaggctca agtccaactg gtccaaagtg gtgctgaagt caaacgcccg 120
ggtgcctccg tccaagtctc ctgccgtgcc tctggctact cgattaacac ctattacatg 180
cagtgggtcc gtcaagcacc gggtgcaggt ctggaatgga tgggtgtcat caatccgtcc 240
ggcgtgacct catatgcgca gaaatttcaa ggtcgcgtta ccctgacgaa cgataccagc 300
acgaataccg tctacatgca gctgaactct ctgacgagtg cagacaccgc ggtgtattac 360
tgcgcacgtt gggcactgtg gggcgatttc ggcatggatg tttggggcaa aggtacgctg 420
gtgaccgtta gctctggtgg tggtggttct ggtggtggtg gtagtggcgg tggcggttct 480
gatattcaga tgacgcaaag cccgtctacc ctgagtgcct ccattggtga ccgtgttacg 540
atcacctgtc gcgcatccga aggcatctat cattggctgg cttggtacca gcaaaaaccg 600
ggtaaagcgc cgaaactgct gatctataaa gcaagttccc tggcatcggg tgctccgagc 660
cgcttttcag gttcgggtag cggcaccgat ttcacgctga ccatctcatc gctgcagccg 720
gacgatttcg ctacctacta ctgccaacaa tactcaaact acccgctgac cttcggtgga 780
gggaccaagc tggagatcaa acgtgctagc accactaccc cagcaccgag gccacccacc 840
ccggctccta ccatcgcctc ccagcctctg tccctgcgtc cggaggcatg tagacccgca 900
gctggtgggg ccgtgcatac ccggggtctt gacttcgcct gcgatatcta catttgggcc 960
cctctggctg gtacttgcgg ggtcctgctg ctttcactcg tgatcactct ttactgtaag 1020
cgcggtcgga agaagctgct gtacatcttt aagcaaccct tcatgaggcc tgtgcagact 1080
actcaagagg aggacggctg ttcatgccgg ttcccagagg aggaggaagg cggctgcgaa 1140
ctgcgcgtga aattcagccg cagcgcagat gctccagcct accagcaggg gcagaaccag 1200
ctctacaacg aactcaatct tggtcggaga gaggagtacg acgtgctgga caagcggaga 1260
ggacgggacc cagaaatggg cgggaagccg cgcagaaaga atccccaaga gggcctgtac 1320
aacgagctcc aaaaggataa gatggcagaa gcctatagcg agattggtat gaaaggggaa 1380
cgcagaagag gcaaaggcca cgacggactg taccagggac tcagcaccgc caccaaggac 1440
acctatgacg ctcttcacat gcaggccctg ccgcctcggt aatcctactg cgtcgagcga 1500
ctgtgccttc tagttgccag ccatctgttg tttgcccctc ccccgtgcct tccttgaccc 1560
tggaaggtgc cactcccact gtcctttcct aataaaatga ggaaattgca tcgcattgtc 1620
tgagtaggtg tcattctatt ctggggggtg gggtggggca ggacagcaag ggggaggatt 1680
gggaagacaa tagcaggcat gctggggatg cggtgggctc tatgggtcga ccaaggtcgg 1740
gcaggaagag ggcctatttc ccatgattcc ttcatatttg catatacgat acaaggctgt 1800
tagagagata attagaatta atttgactgt aaacacaaag atattagtac aaaatacgtg 1860
acgtagaaag taataatttc ttgggtagtt tgcagtttta aaattatgtt ttaaaatgga 1920
ctatcatatg cttaccgtaa cttgaaagta tttcgatttc ttggctttat atatcttgtg 1980
gaaaggacga aacacctccc caggcgcaga tcaaagagag ttcaagagac tctctttgat 2040
ctgcgccttt tttagctatc gatagctaaa aagcctagag aagtttcagg gaatctcttg 2100
aattccctga aacttctcta ggcggggaag atctgtggtc tcatacagaa cttataagat 2160
tcccaaatcc aaagacattt cacgtttatg gtgatttccc agaacacata gcgacatgca 2220
aatattgcag ggcgccactc ccctgtccct cacagccatc ttcctgccag ggcgcacgcg 2280
cgctgggtgt tcccgcctag tgacactggg cccgcgattc cttggagcgg gttgatgacg 2340
tcagcgttcg aattgtcgac 2360
Claims (24)
1. a kind of T lymphocytes, which is characterized in that the cellular immunity checkpoint of the T lymphocytes is silenced;
And expression Chimeric antigen receptor, wherein
The Chimeric antigen receptor includes:
Extracellular region, the extracellular region include the heavy chain variable region and light chain variable region of single-chain antibody, the single-chain antibody specificity
Identify antigen MSLN;
Transmembrane region, the transmembrane region are connected with the extracellular region, and are embedded into the cell membrane of the T lymphocytes;
Intracellular region, the intracellular region are connected with the transmembrane region, and the intracellular region includes the intracellular section and CD3 ζ of CD28
Chain.
2. a kind of slow virus, which is characterized in that the slow virus carries following nucleic acid molecules:
The nucleic acid molecules of encoding chimeric antigen receptor, the Chimeric antigen receptor have SEQ ID NO:Amino acid sequence shown in 1
The nucleic acid molecules of row, the encoding chimeric antigen receptor have SEQ ID NO:Nucleotide sequence shown in 2;And
The nucleic acid molecules of silenced cell immunologic test point, the nucleotide sequence of the nucleic acid molecules of the silenced cell immunologic test point
To be selected from SEQ ID NO:At least one of 3~135.
3. a kind of slow virus, which is characterized in that the slow virus, which carries, contains SEQ ID NO:Nucleotide shown in 136~141
Sequence.
4. a kind of transgenosis lymphocyte, which is characterized in that the lymphocyte cell immunologic test point is silenced;And expression
Chimeric antigen receptor, the Chimeric antigen receptor include:
Extracellular region, the extracellular region include the heavy chain variable region and light chain variable region of antibody, and the antibody can be with tumour antigen
Specific binding;
Transmembrane region;And
Intracellular region, the intracellular region include co-stimulators intracellular section,
Wherein, the antibody is single-chain antibody, and the tumour antigen is MSLN.
5. transgenosis lymphocyte according to claim 4, which is characterized in that the lymphocyte cell immunologic test point
Independently selected from least one of CTLA4, PD1, TIM3, BTLA, LAG-3, IRAK-M, SOCS1, A20, CBL-B.
6. transgenosis lymphocyte according to claim 4, which is characterized in that the lymphocyte cell immunologic test point
Be silenced is realized by least one shRNA, antisense nucleic acid, ribozyme, dominant negative mutations, CRISPR and Zinc finger nuclease.
7. transgenosis lymphocyte according to claim 4, which is characterized in that the co-stimulators intracellular section is only
On the spot it is selected from 4-1BB, OX-40, CD40L, CD27, CD30, CD28 and at least one of their derivative.
8. transgenosis lymphocyte according to claim 5, which is characterized in that the lymphocyte cell immunologic test point
Independently selected from least one of CTLA4, PD1, CBL-B.
9. transgenosis lymphocyte according to claim 6, which is characterized in that the lymphocyte cell immunologic test point
Be silenced is realized by shRNA.
10. transgenosis lymphocyte according to claim 7, which is characterized in that the co-stimulators intracellular section
It is the intracellular section of 4-1BB or CD28.
11. transgenosis lymphocyte according to claim 4, which is characterized in that the lymphocyte is CD3+T lymphs are thin
Born of the same parents.
12. transgenosis lymphocyte according to claim 4, which is characterized in that the lymphocyte is that natural kill is thin
Born of the same parents.
13. transgenosis lymphocyte according to claim 4, which is characterized in that the lymphocyte is that natural killer T is thin
Born of the same parents.
14. a kind of construct, which is characterized in that the construct includes:
First nucleic acid molecules, the first nucleic acid molecule encoding Chimeric antigen receptor;And
Second nucleic acid molecules, the second nucleic acid molecules silenced cell immunologic test point, wherein the cellular immunity checkpoint,
The Chimeric antigen receptor is as defined in any one of claim 4~13.
15. construct according to claim 14, it is characterised in that first nucleic acid molecules and second nucleic acid point
Son is arranged on expresses the Chimeric antigen receptor and silenced cell is exempted from claim 4~13 any one of them lymphocyte
Epidemic disease checkpoint.
16. construct according to claim 14, which is characterized in that further comprise:
First promoter, first promoter are operably connected with first nucleic acid molecules;And
Second promoter, second promoter are operably connected with second nucleic acid molecules.
17. construct according to claim 16, which is characterized in that first promoter and second promoter point
Not independently selected from U6, H1, CMV, EF-1, LTR or RSV promoters.
18. construct according to claim 14, which is characterized in that the carrier of the construct is that non-pathogenic virus carries
Body.
19. construct according to claim 18, which is characterized in that the viral vectors includes being carried selected from retrovirus
At least one of body, slow virus carrier or adeno-associated virus (AAV) carrier.
20. a kind of preparing T lymphocytes described in claim 1 or the leaching of claim 4~13 any one of them transgenosis
The method of bar cell, which is characterized in that including:
Claim 14~19 any one of them construct or slow virus according to claim 2 or 3 are introduced into lymph
In cell or T lymphocytes.
21. a kind of therapeutic combination for treating cancer, which is characterized in that including:
It is claim 14~19 any one of them construct, slow virus according to claim 2 or 3, described in claim 1
T lymphocytes or claim 4~13 any one of them transgenosis lymphocyte.
22. therapeutic combination according to claim 21, which is characterized in that the cancer includes being selected from celiothelioma, pancreas
Cancer, oophoroma, cholangiocarcinoma, lung cancer, gastric cancer, intestinal cancer, at least one of the cancer of the esophagus and breast cancer.
23. a kind of method improving lymphocyte activity, the lymphocyte carry Chimeric antigen receptor, which is characterized in that make
The cellular immunity checkpoint of the lymphocyte is silenced,
Institute in the cellular immunity checkpoint, the lymphocyte, any one of the Chimeric antigen receptor such as claim 4~13
Definition,
The lymphocyte activity includes the proliferative capacity of the lymphocyte in vitro, the proliferation in tumour patient body and life
Deposit at least one of the orientation killing ability of ability and the lymphocyte in tumour patient body.
24. according to the method for claim 23, which is characterized in that the tumour includes being selected from celiothelioma, cancer of pancreas, ovary
Cancer, cholangiocarcinoma, lung cancer, gastric cancer, intestinal cancer, at least one of the cancer of the esophagus and breast cancer.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710056395.0A CN108342363B (en) | 2017-01-25 | 2017-01-25 | Transgenic lymphocytes co-expressing anti-MSLN chimeric antigen receptor and immune checkpoint inhibitory molecules and uses thereof |
PCT/CN2017/081274 WO2018137295A1 (en) | 2017-01-25 | 2017-04-20 | Transgenic lymphocyte co-expressing anti-msln chimeric antigen receptor and immune checkpoint inhibitor molecule and use thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710056395.0A CN108342363B (en) | 2017-01-25 | 2017-01-25 | Transgenic lymphocytes co-expressing anti-MSLN chimeric antigen receptor and immune checkpoint inhibitory molecules and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108342363A true CN108342363A (en) | 2018-07-31 |
CN108342363B CN108342363B (en) | 2021-02-12 |
Family
ID=62961795
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710056395.0A Active CN108342363B (en) | 2017-01-25 | 2017-01-25 | Transgenic lymphocytes co-expressing anti-MSLN chimeric antigen receptor and immune checkpoint inhibitory molecules and uses thereof |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN108342363B (en) |
WO (1) | WO2018137295A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111088231A (en) * | 2018-10-24 | 2020-05-01 | 艾生命序公司 | Anti-mesothelin CAR-T cell tumor immunotherapy secreted by PD-L1 antibody |
CN112969793A (en) * | 2018-09-17 | 2021-06-15 | 中国科学院动物研究所 | Modified T cells, methods of making and uses thereof |
WO2024120506A1 (en) * | 2022-12-09 | 2024-06-13 | 苏州沙砾生物科技有限公司 | Modified cell and use thereof |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11332713B2 (en) | 2016-11-16 | 2022-05-17 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
BR112020018658A2 (en) | 2018-03-15 | 2020-12-29 | KSQ Therapeutics, Inc. | GENE REGULATION COMPOSITIONS AND METHODS FOR IMPROVED IMU-NOTERAPY |
AU2019234926A1 (en) | 2018-03-15 | 2020-10-08 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
US20230065784A1 (en) * | 2019-03-21 | 2023-03-02 | City Of Hope | Composition and method for reducing expression of checkpoint inhibitors in t cells expressing a car or ctl |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2649086T3 (en) * | 2010-12-09 | 2017-09-18 | Univ Pennsylvania | USING CHEMICAL ANTIGEN RECEPTOR-MODIFIED T-CELLS TO TREAT CANCER |
KR20210115051A (en) * | 2013-06-10 | 2021-09-24 | 다나-파버 캔서 인스티튜트 인크. | Methods and compositions for reducing immunosupression by tumor cells |
CN105837692A (en) * | 2015-12-10 | 2016-08-10 | 苏州佰通生物科技有限公司 | Chimeric antigen receptor for blocking immunodetection point and use thereof |
-
2017
- 2017-01-25 CN CN201710056395.0A patent/CN108342363B/en active Active
- 2017-04-20 WO PCT/CN2017/081274 patent/WO2018137295A1/en active Application Filing
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112969793A (en) * | 2018-09-17 | 2021-06-15 | 中国科学院动物研究所 | Modified T cells, methods of making and uses thereof |
CN112969793B (en) * | 2018-09-17 | 2024-04-19 | 中国科学院动物研究所 | Modified T cells, methods of making and uses thereof |
CN111088231A (en) * | 2018-10-24 | 2020-05-01 | 艾生命序公司 | Anti-mesothelin CAR-T cell tumor immunotherapy secreted by PD-L1 antibody |
WO2024120506A1 (en) * | 2022-12-09 | 2024-06-13 | 苏州沙砾生物科技有限公司 | Modified cell and use thereof |
Also Published As
Publication number | Publication date |
---|---|
CN108342363B (en) | 2021-02-12 |
WO2018137295A1 (en) | 2018-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108342363A (en) | It co-expresses anti-MSLN Chimeric antigen receptors and immunologic test point inhibits the transgenosis lymphocyte and application thereof of molecule | |
CN106967685B (en) | Transgenic lymphocytes co-expressing anti-EGFRvIII chimeric antigen receptor and immune checkpoint inhibitory molecules and uses thereof | |
WO2017120998A1 (en) | Therapeutic composition for treating glioblastoma | |
US20210196756A1 (en) | Anti-cd19 car-t cell | |
WO2022007804A1 (en) | T lymphocyte and use thereof | |
CN108342361A (en) | The therapeutic combination of quality positive tumor between treatment | |
CN107531800A (en) | Slow virus carrier for the regulating and expressing of Chimeric antigen receptor molecule | |
WO2018006880A1 (en) | Co-expression of recombinant immune-checkpoint receptor and immune-checkpoint inhibitor and application | |
CN107034193B (en) | Therapeutic compositions for the treatment of B-cell leukemia and B-cell lymphoma | |
CN110462029A (en) | HIV immunotherapy without preimmunization step | |
WO2018006881A1 (en) | Recombinant immune-checkpoint receptor and application thereof | |
EP1824519A2 (en) | Inhibition of li expression in mammalian cells | |
CN106467906A (en) | Construct, transgenic lymphocyte and its production and use | |
CN108342360A (en) | Co-express anti-MSLN Chimeric antigen receptors and the transgenosis lymphocyte of nonfunctional EGFR and application thereof | |
WO2022012531A1 (en) | Method for preparing modified immune cell | |
ES2358187T3 (en) | PROCEDURES FOR THE GENETIC MODIFICATION OF HEMATOPOYETIC PROGENITING CELLS AND USES OF THE MODIFIED CELLS. | |
CN106967684A (en) | Transgenosis lymphocyte of the anti-EGFRvIII Chimeric antigen receptors that are co-expressed and nonfunctional EGFR acceptors and application thereof | |
JP6687246B2 (en) | Modified immune cell, method for producing modified immune cell, and use thereof | |
WO2024055339A1 (en) | Method for preparing and amplifying universal humanized anti-cd19 car-nk cell and use thereof | |
CN110042126A (en) | A kind of immunocyte drug comprising super-enhanced til cell | |
CN116670172A (en) | Cancer-specific trans-splicing ribozymes expressing immune checkpoint inhibitors and uses thereof | |
CN112048021A (en) | ROR 2-targeted chimeric antigen receptor, expression gene, expression vector, T cell and application thereof | |
CN111718957A (en) | Chimeric antigen receptor recombinant adeno-associated virus particle and application thereof | |
CN113549157B (en) | Double-targeting chimeric antigen receptor and application thereof | |
CN109750066A (en) | Secreting type anti-immunity checkpoint antibody, immunologic test intracellular point inhibit the coexpression and its application of molecule and tEGFR molecule |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |